#version: 0.2
t h
i n
t i
th e</w>
r e
a n
o n
e r
e n
o f</w>
e d</w>
o n</w>
a r
o r
a t
r o
i t
t o</w>
a l
an d</w>
o r</w>
i n</w>
in g</w>
o u
s t
a ti
e r</w>
i c
a c
e s</w>
e c
e s
i s
a l</w>
i s</w>
o m
s u
p ro
a s
s h
a t</w>
m en
e l
c on
ati on</w>
p l
s i
f or</w>
b e</w>
i l
a s</w>
o l
v e</w>
t s</w>
T h
d i
u s
w h
b l
m e
a p
it h</w>
a n</w>
w ith</w>
n o
r i
al l</w>
e m
u n
c l
e t
e n</w>
o s
a d
u r
u l
c om
t a
e d
ti on</w>
e v
i d
c e</w>
o u</w>
th at</w>
t r
e x
i m
q u
a g
on s</w>
p er
e re
f or
o w
a m
u c
sh all</w>
Th e</w>
b y</w>
s p
c h
m a
s ,</w>
at e</w>
no t</w>
in g
i r
l y</w>
men t</w>
ar e</w>
i g
h a
y ou</w>
s e
re c
e ,</w>
it y</w>
p ar
f f
er e</w>
ou l
e .</w>
i t</w>
s .</w>
n e
b e
th er</w>
t er
en t</w>
p re
ati on
oul d</w>
th e
l i
a bl
y ou
o c
o d
d uc
b er</w>
o p
th is</w>
t ed</w>
at ed</w>
a b
pro v
an ce</w>
ac c
u d
l e
ou n
f ro
fro m</w>
or d
ti on
wh ic
S t
st r
o v
f i
ou t</w>
whic h</w>
for m
m in
ti ve</w>
p o
' s</w>
ha ve</w>
sh ould</w>
re d</w>
o o
os e</w>
an d
e st
a f
A n
a u
y ,</w>
an t</w>
u m
ta k
em ber</w>
C om
su b
r e</w>
a v
pro duc
ti c
qu i
a r</w>
ma y</w>
sp ec
men t
y .</w>
h e
i r</w>
p or
un d
o ther</w>
d e
W h
es s
M ember</w>
t er</w>
l ow
s er
Com m
ig h
i c</w>
ti ons</w>
us t</w>
an c
com p
en ts</w>
us e</w>
e t</w>
abl e</w>
on e</w>
o g
si on</w>
es ,</w>
ap pl
ti cl
A r
w e
r a
en t
con t
e g
o t
you r</w>
w as</w>
i v
ti v
in e</w>
c h</w>
ic al</w>
d is
D i
Ar ticl
th or
m e</w>
u t
er s</w>
p e
men ts</w>
i ti
an y</w>
i d</w>
es s</w>
ar y</w>
p h
f ic
cl ud
re g
ati ons</w>
en ti
t re
is i
i th
s y
p ati
c er
o w</w>
ec tion</w>
re l
Di rec
at es</w>
re f
ac t
g h
Articl e</w>
it s</w>
) .</w>
as e</w>
an g
ed .</w>
al l
a y
au thor
w or
u t</w>
c ar
d ic
a y</w>
i f</w>
f ol
i al</w>
m on
as s
il l</w>
in t
p ri
u re
ser v
v er
' t</w>
es .</w>
pre s
p os
w ith
f in
o b
k e</w>
u m</w>
e p
m an
prov id
2 0
be en</w>
en d
al ly</w>
ur e</w>
c re
l e</w>
I n</w>
re qui
h as</w>
el l
in clud
a il
) ,</w>
es t</w>
s o</w>
m ar
si d
e ff
l a
w ill</w>
fol low
su re</w>
in form
ou r
su ch</w>
bl e</w>
pro c
h i
e ar
g o
ta in
acc ord
en c
the ir</w>
us ed</w>
r ap
the y</w>
f l
su l
j ec
h e</w>
tr an
Direc tive</w>
th an</w>
u p</w>
a in
spec i
I '
u p
v al
k no
t ing</w>
ere d</w>
re n
is sion</w>
m ust</w>
ow n</w>
s t</w>
oo d</w>
ed ,</w>
at ing</w>
ar d
Y ou</w>
r is
. .
s e</w>
su re
St ates</w>
e l</w>
c o
/ E
me a
or y</w>
ic e</w>
per i
pati ents</w>
c an</w>
com pl
pl ac
i st
ar d</w>
inform ation</w>
ag e</w>
o per
s ol
v e
g r
for e</w>
th er
ne x</w>
wh ere</w>
in to</w>
m or
An nex</w>
s ec
ap pro
ac h</w>
appl ic
k ing</w>
c i
p a
en ce</w>
d at
es e</w>
requi re
in ter
ou s</w>
t h</w>
u e</w>
m y</w>
is h
t .</w>
sy st
h y
w ere</w>
t y
eff ec
am e</w>
I f</w>
wh en</w>
su r
l l</w>
tre at
iti es</w>
f e
b as
t o
k s</w>
ation al</w>
igh t</w>
as t</w>
u s</w>
accord ance</w>
R eg
ev er
d es
d o
und er</w>
ul ation</w>
el y</w>
n i
v i
n o</w>
Th is</w>
fi ed</w>
n ec
p r
h is</w>
ere n
t ec
af ter</w>
e ment</w>
d ec
ev el
s ti
t ,</w>
ing ,</w>
d et
mar k
tak e</w>
f ir
th ere
t e
er red</w>
se e</w>
Comm ission</w>
el l</w>
g ro
follow ing</w>
p ur
d oc
I n
a st
con di
mor e</w>
th ose</w>
par tic
ag rap
al s</w>
r it
i es</w>
po in
men d
b et
s om
An d</w>
ou r</w>
con tain
d o</w>
re por
com m
me dic
il l
se t</w>
mea sure
u ro
ad min
en tr
par agrap
20 0
o d</w>
b o
f act
a d</w>
is ed</w>
in f
en er
ref erred</w>
s a
m at
appro pri
per s
a re
b ut</w>
ri b
sub st
.. .</w>
ad e</w>
ation ,</w>
d own</w>
ri gh
ov er
cont ro
su p
d ose</w>
dat a</w>
u tion</w>
h ic
' re</w>
me an
produc ts</w>
il ity</w>
o f
th ese</w>
re qu
ul ar</w>
t w
d ur
treat ment</w>
( 1
si g
in v
Comm un
nec ess
i str
sp on
ati ve</w>
con cer
includ ing</w>
n ational</w>
h ol
ing .</w>
prov isi
re s
i p
t y</w>
I t</w>
c ol
E uro
E C
I' m</w>
und er
me th
a ,</w>
with in</w>
pl e
proc ed
tran s
St ate</w>
oun t</w>
ve hic
al so</w>
ation .</w>
e m</w>
m o
ti me</w>
c or
si on
g et</w>
ff ic
est abl
ti c</w>
th ro
ac tiv
be fore</w>
ch ang
ta in</w>
t ri
concer n
s af
wh o</w>
ing s</w>
y s
h n
re spon
u al</w>
on 't</w>
u st
pl e</w>
or g
e qui
provid ed</w>
N o</w>
1 0
comp et
er i
on ly</w>
w at
u g
y ear
re sul
require ments</w>
f o
e ach</w>
u bl
st u
b r
ord er</w>
ac t</w>
g l
id e</w>
g u
or s</w>
w e</w>
ty p
st and
er .</w>
l o
kno w
c a
Euro pe
c ur
paragrap h</w>
F or</w>
l im
t est</w>
Europe an</w>
I I
li ke</w>
et y</w>
in al</w>
t est
in d
an im
y ing</w>
ex c
ap prov
ha d</w>
in cre
poin t</w>
en sure</w>
ar i
ac h
m g</w>
str uc
ab out</w>
we en</w>
s el
ac k
ar m
c ap
n um
Reg ulation</w>
bet ween</w>
compet ent</w>
an ti
d r
dur ing</w>
org an
fic ation</w>
b od
con tr
in ation</w>
on -
wh at</w>
serv ic
p en
t or</w>
c oun
pl an
si ble</w>
ad di
v ir
establ ish
4 .
m il
f ac
ov er</w>
rel ev
l ess</w>
s ection</w>
en g
ris k</w>
av ail
re e</w>
d ro
h ,</w>
c al
fi c</w>
s ;</w>
e f
isi on</w>
tec hn
b i
g iv
ac k</w>
condi tions</w>
ol og
1 9
im um</w>
in dic
appropri ate</w>
th ere</w>
tak ing</w>
tion ,</w>
Commun ity</w>
j ust</w>
sti t
necess ary</w>
su m
i z
o x
p ubl
c entr
b re
c as
enc y</w>
i l</w>
con sid
on g
le g
mean s</w>
( see</w>
tion al</w>
os t</w>
kno w</w>
ay s</w>
c an
produc t</w>
ev er</w>
measure s</w>
m ade</w>
syst em
f il
a ir
er ,</w>
rec e
fir st</w>
g e</w>
il d
y l
for m</w>
the m</w>
f un
in es</w>
ch ar
me .</w>
( 2
di es</w>
u fact
it e</w>
p ol
t ur
s o
anc es</w>
C h
provisi ons</w>
w ay</w>
car ri
sub jec
admin istr
P ar
id enti
tak en</w>
tw o</w>
relev ant</w>
i ve</w>
c ase</w>
e y</w>
ti es</w>
c r
ne w</w>
is e</w>
with out</w>
d os
mend ed</w>
me di
wor k</w>
s :</w>
d on't</w>
th ing</w>
ure s</w>
com b
g ener
it .</w>
th at
ere as</w>
f ul
as s</w>
ass ess
ta bl
syst em</w>
ti m
b el
is t</w>
saf ety</w>
s )</w>
cl in
C on
d evel
tion .</w>
ne ed</w>
t en
si st
E C</w>
er min
f a
man ufact
b ec
d .</w>
n 't</w>
h im
Wh at</w>
th in
hi m</w>
od s</w>
he al
c at
on g</w>
C oun
a ff
n on-
d er
p er</w>
l ev
t ly</w>
ard s</w>
ig n
s ame</w>
N o
di ff
cont in
e -
oun d</w>
e ther</w>
f u
el ec
D ec
e a
b en
re spec
fin anc
g re
num ber</w>
bod y</w>
St at
ab ility</w>
ad d
d el
som e</w>
p ec
th em
1 0</w>
is ation</w>
det ermin
bl ood</w>
pl o
eren ce</w>
equi p
st ar
c ri
di rec
e y
re com
ma ke</w>
us ing</w>
typ e</w>
cer ti
as ed</w>
giv en</w>
ou t
w ould</w>
qu al
le ast</w>
peri od</w>
1 .
d ,</w>
a z
de fin
ther ap
partic ular</w>
h ere
contro l</w>
ac tions</w>
la id</w>
ug h</w>
gr am
I t
b ro
e ts</w>
2 .
m g
ac tion</w>
author ities</w>
com e</w>
l l
we e
w a
r ul
b ot
e ar</w>
k in
con centr
l evel
p ow
go t</w>
u b
g o</w>
ati s
no ti
mark et</w>
( a
c ul
fun c
e qu
P ro
ci l</w>
appl y</w>
applic ation</w>
or m
Coun cil</w>
devel op
po si
h um
di st
ch em
is su
o ff
avail able</w>
financ ial</w>
lev el</w>
speci fic</w>
vi e
techn ical</w>
mon it
servic es</w>
m od
gh t</w>
v ing</w>
sid e</w>
it y,</w>
ple ment
provid e</w>
ag ain
li st
i ed</w>
v en
ex am
0 0</w>
c ould</w>
author ity</w>
ad op
clin ical</w>
sig n
( b
it ted</w>
d ev
k ed</w>
ment .</w>
t om
on ,</w>
a use</w>
n a</w>
p tion</w>
requi red</w>
al u
thro ugh</w>
d ate</w>
en d</w>
k .</w>
on .</w>
an al
H e</w>
doc tor</w>
par t</w>
me ,</w>
f y</w>
and /
is h</w>
st ud
Direc tiv
acc ount</w>
st at
l oc
do es</w>
po t
s am
and/ or</w>
at ory</w>
vir on
hol d
man ag
r ang
th ir
mon th
tic al</w>
H e
pro t
you .</w>
B ut</w>
il e</w>
tran sp
( 3
di v
ment ,</w>
e ments</w>
hy dro
It 's</w>
oc i
rece iv
per form
e ;</w>
ou s
h er</w>
bas ed</w>
t s,</w>
h el
d ra
W e</w>
b it
ma x
ac tive</w>
s w
reg ul
ob serv
year s</w>
a m</w>
doc u
re duc
a ir</w>
enti al</w>
Wh ere</w>
v is
n ing</w>
g on
c op
l es</w>
vehic le</w>
ut e</w>
at ely</w>
en viron
i a</w>
wat er</w>
oo k</w>
con sum
m ov
re ad
/E C</w>
ow n
diff eren
ch ild
a .</w>
l it
end ed</w>
me m
pe o
t le</w>
e .
d ri
effec ts</w>
f r
som e
tre ated</w>
re as
sol ution</w>
sub m
al ,</w>
cer tain</w>
l at
h ow</w>
ol d</w>
medic inal</w>
oper at
li f
l ab
er g
plo y
des ign
dis e
5 0</w>
Wh en</w>
be ing</w>
A c
D o</w>
l in
plac ed</w>
contain ing</w>
s ed</w>
mark et
m i
arm ac
sup pl
k ,</w>
rel ated</w>
Wh ereas</w>
righ t</w>
ne ed
n at
n orm
n ex
tic s</w>
proced ure</w>
fo re
ever ,</w>
i ther</w>
im por
m is
e p</w>
/E EC</w>
manufact ure
w ant</w>
ep t</w>
ist ered</w>
in i
max imum</w>
A T
v ari
thir d</w>
O R
and ,</w>
ex po
s it
e ed
eff ic
1 .</w>
d ay</w>
l ong
U ni
h igh
mg /
carri ed</w>
val ue</w>
0 .
prot ection</w>
contin u
it ed</w>
Th ey</w>
val u
t or
at e,</w>
ot al</w>
thin k</w>
k e
ma in
m l</w>
sec on
m ul
om e</w>
EC )</w>
(a )</w>
e )</w>
subjec t</w>
or t</w>
ch ec
t al
b u
im plement
em ploy
ver se</w>
div id
fl u
d u
v ol
ac ter
I N
ver y</w>
compl et
ti l</w>
f er
stu dies</w>
5 .
sa id</w>
cur ren
t em
chang e</w>
rul es</w>
ment al</w>
o l</w>
c rib
di d</w>
si ons</w>
ec t</w>
in j
h al
p end
Y ou
U n
an ts</w>
pres ent
ex peri
subst ances</w>
c y
serv ice</w>
pr in
( E
produc tion</w>
ob jec
s k
ni fic
t ure</w>
approv al</w>
pro gram
hum an</w>
ref erence</w>
plac e</w>
publ ic</w>
recom mended</w>
it y.</w>
ev alu
in iti
in st
ow ever,</w>
equip ment</w>
str u
w ell</w>
m p
n al</w>
ig h</w>
s or
s al
v er</w>
ass oci
A N
f ur
pos sible</w>
(b )</w>
t s.</w>
wh ether</w>
ben ef
at 's</w>
m ost</w>
g .</w>
er c
bas is</w>
di t</w>
resul ts</w>
assess ment</w>
ffic i
rit eri
t ro
sig nific
es ;</w>
stit u
certi fic
por t</w>
l or
s ev
3 .
r y</w>
go ing</w>
ec ted</w>
th en</w>
cat eg
vie w</w>
d s</w>
comp on
ph armac
gon na</w>
includ e</w>
p ut</w>
contain s</w>
effec t</w>
an y
speci fied</w>
re sid
1 ,</w>
subst ance</w>
ag re
st or
a x
as si
again st</w>
tr y</w>
un til</w>
th ree</w>
pur pos
g ive</w>
ell ,</w>
h ou
bec ause</w>
c riteri
s ing
s m
A d
20 1
p ose</w>
19 9
a k
Reg ul
heal th</w>
b ol
he ar
bot h</w>
l ar
Th ere</w>
partic ul
h and
ol e</w>
th ou
uc h</w>
rec og
(1 )</w>
sh e</w>
h ar
t otal</w>
on ic</w>
inv est
m s</w>
concern ing</w>
stud y</w>
comb ination</w>
af t</w>
er s,</w>
establish ed</w>
w ast
d em
in stru
int ere
A ll</w>
j o
o bl
c ov
' ll</w>
proc ess
col l
en s
consid ered</w>
in c
anim al</w>
d er</w>
d n't</w>
h our
to x
pur su
g en
al .</w>
administr ation</w>
a th
an other</w>
ro s
b ack</w>
se par
in spec
o p</w>
sur ance</w>
un ic
i f
e ither</w>
ta ble</w>
l os
accord ing</w>
defin ed</w>
ati c</w>
A l
r ing
olog ical</w>
s l
g ood</w>
2 0</w>
re at
proced ures</w>
activ ities</w>
te e</w>
level s</w>
is ,</w>
repor ted</w>
anal ys
compl i
ex ist
am ount</w>
E x
ad j
W e
) ;</w>
la w
elec tr
ing :</w>
c es</w>
int ended</w>
p i
e ed</w>
obl ig
un to</w>
e :</w>
rel ating</w>
2 .</w>
wor k
m an</w>
H ow</w>
tr ain
R E
il y</w>
pro tec
al low
st s</w>
anim als</w>
pos ed</w>
str ic
pro f
organ is
manag ement</w>
it 's</w>
ad verse</w>
pers on</w>
it ,</w>
pr ac
repor t</w>
reg ard</w>
v es</w>
an n
admin istered</w>
m ic
there fore</w>
re n</w>
in ,</w>
you 're</w>
is .</w>
list ed</w>
e. g.</w>
e th
( c
qual ity</w>
O n
id ence</w>
pl as
or ig
inj ection</w>
respec t</w>
l ast</w>
in divid
p ack
1 /
you ,</w>
differen t</w>
g n
t ell</w>
ever y</w>
expo sure</w>
b us
ic ity</w>
h igh</w>
Th ere
ad v
b ility</w>
tain ed</w>
( i
ic ally</w>
A p
od .</w>
er y</w>
ir e</w>
o m</w>
ent ly</w>
on om
re actions</w>
or ing</w>
ter s</w>
er ing</w>
crib ed</w>
c all
is l
particul ar
incre ased</w>
me ta
n ame</w>
3 0</w>
im medi
I I</w>
me n</w>
a ve</w>
w om
therap y</w>
applic able</w>
f ood</w>
1 2</w>
su ffici
es s,</w>
sam pl
od ,</w>
p ay
I' ll</w>
month s</w>
u sion</w>
a in</w>
ev en</w>
p ass
de pend
d ail
pos si
as es</w>
he ad
dra w
d om
l ist</w>
gro up</w>
pre gn
in hi
si ve</w>
( 4
enti ty</w>
t og
ed ;</w>
comm on</w>
le t</w>
l ow</w>
d ue</w>
mp tom
e ?</w>
acc oun
ch lor
th y</w>
n et
incre ase</w>
se qu
A s</w>
n ess</w>
char acter
Th ese</w>
0 0
v ent</w>
gro up
gener al</w>
Uni on</w>
under tak
Th at</w>
of f</w>
im pa
I S
a y.</w>
c ir
H owever,</w>
l ic
ur ity</w>
st e
sh ip
peo ple</w>
no w
v acc
cl ear
y ear</w>
pers on
j ud
mat eri
W ell,</w>
o ffic
associ ated</w>
su per
res s</w>
10 0</w>
r ic
u ri
R e
Dec ision</w>
prin ci
compli ance</w>
E n
approv ed</w>
ac hi
Comm it
adj ust
si mil
int en
t l
sh i
in jec
2 ,</w>
d ays</w>
s et
(2 )</w>
observ ed</w>
h o
addi tional</w>
A u
inv ol
sing le</w>
I F
I C
concern ed</w>
it y
gr an
ha ving</w>
ac y</w>
en ,</w>
m ot
con form
fi el
o ve</w>
re placed</w>
a w
ill ed</w>
or d</w>
leg isl
r ate</w>
cas es</w>
du ce</w>
tion s,</w>
cl os
g h</w>
3 .</w>
pre par
compl y</w>
acc ess</w>
chang es</w>
fur ther</w>
I O
ty pe
reg i
ac e</w>
a me
vehic les</w>
t an
contr act
child ren</w>
1 4
h ap
S o</w>
l oo
el s</w>
mi x
par t
ver i
E N
p rec
sy mptom
r .</w>
pot ential</w>
bus in
det ail
read y</w>
ener g
know n</w>
in e,</w>
pati ent
c our
pri or</w>
monit oring</w>
h ere</w>
li k
d ing</w>
/E C
sh e
cal cul
You 're</w>
u r</w>
Th en</w>
in ary</w>
c ell
f requ
lit tle</w>
criteri a</w>
at h</w>
em s</w>
im p
ac id</w>
ac ts</w>
ter rit
cre dit</w>
a red</w>
t ar
ig n</w>
as ,</w>
ell ing</w>
en .</w>
f am
rec ord
includ ed</w>
sion ,</w>
l y
in surance</w>
comm unic
ation s,</w>
tabl ets</w>
re present
T o</w>
sev ere</w>
f ail
at t
simil ar</w>
in .</w>
norm al</w>
w ays</w>
contro ll
I T
comp an
in ce</w>
air cr
ren al</w>
T reat
ap pe
di um</w>
signific ant</w>
i a,</w>
meta bol
mul ti
ex pec
l ight</w>
cov ered</w>
inf ec
E R
A g
mic ro
equi val
ra di
M ar
d e</w>
n ever</w>
in tr
l ine</w>
ex t
pursu ant</w>
meth od</w>
tion s.</w>
ex clud
wh ile</w>
id ,</w>
resul t</w>
pers ons</w>
o -
A R
cor rec
secon d</w>
can not</w>
qu es
ti s
y p
test s</w>
con duc
re stric
b ur
he pati
Y ea
min imum</w>
poin ts</w>
or ,</w>
i um</w>
t ed.</w>
author ised</w>
a mended</w>
Th at's</w>
I ,</w>
up on</w>
sy ring
o ther
leg al</w>
An nex
oc cur
mat er
develop ment</w>
ab il
m ach
b ack
C O
( EC)</w>
shi p</w>
ad equ
o id</w>
purpos es</w>
g as</w>
s atis
activ ity</w>
Y our</w>
we ight</w>
inst all
1 2
A C
follow ing:</w>
cl e
st atis
se ts</w>
type -
transp ort</w>
perform ance</w>
can 't</w>
f ree</w>
on ce</w>
pres ent</w>
fe ed
er s.</w>
tiv es</w>
per m
r u
s our
fac il
pro per
system s</w>
m a</w>
ic k
' ve</w>
reg ard
A n</w>
L OR
coun tri
fac e</w>
t en</w>
pl ant</w>
oc c
or al</w>
impor t
( e.g.</w>
meth ods</w>
x im
appl ied</w>
s ch
a mend
or ies</w>
sec urity</w>
w ar
m ight</w>
posi tion</w>
ag es</w>
ca use</w>
him .</w>
stand ard</w>
eg r
I s
/E EC
pur pose</w>
a y,</w>
me an</w>
e ti
mem b
car b
n ed</w>
1 5</w>
im m
pol ic
d own
ec onom
c oo
lim it</w>
ti g
here .</w>
environ mental</w>
Commit tee</w>
wast e</w>
l ong</w>
pres sure</w>
p ed</w>
m al
con f
m ary</w>
medic ine</w>
P ati
impa ir
con sist
E S
r an
c ame</w>
ar rang
w an
II I</w>
me d
pre -
are a</w>
i ous</w>
coun try</w>
dise ase</w>
on str
ur al</w>
2 /
ri c</w>
valu es</w>
qu anti
plac e
p op
b ra
cy cl
l am
t -
ment s,</w>
d am
s en
h an
A S</w>
recog n
ic es</w>
energ y</w>
n am
n a
cl assi
su red</w>
’ s</w>
manufacture r</w>
C Y
fu l</w>
sel f
dem onstr
le ase</w>
ma in</w>
lif e</w>
dail y</w>
h .</w>
op en
(c )</w>
sk in</w>
s ay</w>
un e</w>
ous ly</w>
pro bl
exist ing</w>
at or</w>
h er
trans f
adop ted</w>
dist rib
c are</w>
individ ual</w>
h or
implement ation</w>
necess ar
og rap
conform ity</w>
requ est
character is
c od
on e.</w>
Au thor
es sion
d ay
me et</w>
determin ed</w>
medic ines</w>
ex tr
ad ul
E ach</w>
o ,</w>
op ini
N e
et er
sit u
stand ards</w>
po st
li a
it al</w>
mater ial</w>
g e
No ,</w>
Comm is
I V
all ow</w>
l y.</w>
s ite</w>
u ary</w>
in struc
cl o
no w</w>
spec ial</w>
receiv ed</w>
me t
in stitu
cont rib
effic i
author isation</w>
he 's</w>
cir c
all ,</w>
ab ove</w>
os ph
hour s</w>
w rit
ure ,</w>
we igh
train ing</w>
requ ire</w>
ex pres
ad ing</w>
y -
p s</w>
inhi bit
I' ve</w>
6 /
cont ent</w>
em is
sti ll</w>
si z
ob tained</w>
9 /
1 7
pow er</w>
certific ate</w>
s ci
ation s.</w>
sh ow
pro g
tur al</w>
m uch</w>
th ,</w>
su g
pre vi
func tion</w>
aircr aft</w>
1 5
tim es</w>
r at
o re
un less</w>
en z
0 /
high er</w>
J o
them .</w>
3 ,</w>
entr y</w>
e ve</w>
su sp
sol u
s on</w>
b or
6 .
requ est</w>
( s)</w>
ish ed</w>
f ri
experi ence</w>
stu di
operat or</w>
y l</w>
concentr ation</w>
w as
b il
fic ations</w>
gre at
k g</w>
p ul
f uc
er ation</w>
un d</w>
di dn't</w>
l and</w>
lab or
del iv
respon sible</w>
cont act</w>
a ke</w>
(3 )</w>
for ce</w>
ter n
ne w
ful l</w>
s es</w>
P h
A L
ma j
Par lia
w ent</w>
ever y
wh ereas</w>
ut es</w>
x ed</w>
f ound</w>
comp ared</w>
con sul
aff ect</w>
hear t</w>
stu ff
p at
t ation</w>
curren t</w>
suffici ent</w>
pati ent</w>
y s</w>
vol um
sur ing</w>
in sul
ag ed</w>
In ter
equival ent</w>
es :</w>
g et
sh own</w>
pro te
partic ip
der iv
hou se
contro l
0 ,
acc ep
call ed</w>
abl e,</w>
cor respon
4 .</w>
k id
in form</w>
dec ision</w>
at ure</w>
O ther</w>
v ed</w>
subm itted</w>
T able</w>
symptom s</w>
en ter
des cribed</w>
CY P
us ,</w>
cri ption</w>
busin ess</w>
is ing</w>
tog ether</w>
Pati ents</w>
l y,</w>
al ready</w>
kin e
proc ess</w>
low er</w>
au gh
Articl es</w>
ke ep</w>
e ous</w>
o t</w>
market ing</w>
Par t</w>
trans m
bo dies</w>
ter m</w>
effec tive</w>
ed :</w>
og en
fore ,</w>
wh ere
A f
l igh
m any</w>
A S
con tain</w>
i m</w>
2 5</w>
gl y
achi ev
produc ed</w>
e di
direc t</w>
us .</w>
anc e,</w>
ha em
ma inten
ph ys
f re
receiv ing</w>
direc tly</w>
categ ory</w>
cl u
Directiv e.</w>
i ble</w>
il d</w>
respon se</w>
dev ice</w>
oper ation</w>
analys is</w>
pre vent</w>
possi bl
G od</w>
3 /
val id
p ain
an s</w>
re ally</w>
lim ited</w>
exc ept</w>
a em
expec ted</w>
so dium</w>
f illed</w>
dec re
t ?</w>
la w</w>
in ed</w>
y st
( d
ati v
es tim
prof ession
char g
inter nal</w>
av ir</w>
un it</w>
av ir
fin d</w>
S e
n er</w>
at e.</w>
le f
oper ating</w>
test ing</w>
mo di
wor king</w>
par ts</w>
stit ution</w>
contr act</w>
pl es</w>
1 8
a er
Dec ember</w>
econom ic</w>
controll ed</w>
there of
p ris
sm all</w>
inter national</w>
l et
M an
cap ac
wee ks</w>
to o</w>
No t</w>
ev idence</w>
wh ole</w>
se ar
ex t</w>
Af ter</w>
Is ra
es s.</w>
gro w
m ass</w>
prac tic
Wh ere
in s</w>
eed ing</w>
S ection</w>
effic acy</w>
O h,</w>
co sts</w>
reg ards</w>
invest ment</w>
es tig
g over
indic ated</w>
th ou</w>
cop e</w>
u su
s ing</w>
tion ed</w>
o red</w>
int ro
in e.</w>
se en</w>
inf usion</w>
hel p</w>
l ook</w>
separ ate</w>
ec han
chem ical</w>
st op
nat ural</w>
provisi on</w>
o kine
com par
Parlia ment</w>
im prov
ch o
ul y</w>
ren t</w>
er al</w>
volum e</w>
ann ual</w>
tem per
sy n
t on
ti l
him ,</w>
s c
fe ed</w>
L ord</w>
ent ,</w>
appropri ate,</w>
s ?</w>
hol d</w>
1 6
iz ed</w>
offic ial</w>
cl a
st er
4 /
S he</w>
Yea h,</w>
h om
as k</w>
li ver</w>
administr ative</w>
gu id
g en</w>
M y</w>
med ical</w>
de f
bel ow</w>
( C
st op</w>
immedi ately</w>
issu ed</w>
fiel d</w>
hy per
h s</w>
b ar
t el
legisl ation</w>
form ation</w>
1 8</w>
b er
J an
f ra
T H
sam ple</w>
t old</w>
co ated</w>
car ry</w>
in t</w>
inv estig
under taking</w>
en e</w>
ou t.</w>
tr ade</w>
sion .</w>
n it
mainten ance</w>
o id
4 ,</w>
design ed</w>
A s
us es</w>
reduc ed</w>
enti fic</w>
emis sions</w>
8 /
dos es</w>
ti me.</w>
program me</w>
los s</w>
l and
ment s.</w>
pol y
et h</w>
re pe
lik ely</w>
undertak ings</w>
m y
He 's</w>
re mov
star t</w>
sup port</w>
e u
al s,</w>
re d
pre jud
v ial</w>
import ant</w>
coo per
territ ory</w>
1 3
ex erc
al e</w>
ro w
t e</w>
sur ve
complet e</w>
R O
materi als</w>
ev ent</w>
fil m
eng ine</w>
mea sured</w>
Wh y</w>
that ,</w>
reas on
su it
b al
appro xim
ris ks</w>
el ,</w>
ser ious</w>
y e</w>
add ed</w>
ay ing</w>
u ally</w>
adequ ate</w>
us ti
plas ma</w>
as sets</w>
on al</w>
recom mend
sel f</w>
i a
o k
I s</w>
( 5
pro jec
ur ing</w>
) :</w>
v eter
go ods</w>
b ut
ure .</w>
m echan
th re
re duce</w>
opini on</w>
ter ms</w>
A t</w>
pl ic
d il
N ow</w>
7 /
be g
el y.</w>
concentr ations</w>
benef its</w>
r ing</w>
ha z
ent .</w>
av ing</w>
righ ts</w>
rang e</w>
mem ber</w>
f at
ed uc
li p
v ision</w>
identi fied</w>
al ways</w>
co -
c anc
gro und
mach in
abl y</w>
c ros
re s</w>
th ing.</w>
ed ge</w>
prejud ice</w>
pl e,</w>
hepati c</w>
ven tion</w>
U C
reg istr
3 1</w>
bet ter</w>
m ou
S T
' d</w>
B e
oc ial</w>
dr in
ation ;</w>
syring e</w>
contin ue</w>
pharmac okine
l ing</w>
em p
publ ic
wh ose</w>
har mon
s ever
olog y</w>
s ent</w>
countri es</w>
noti fied</w>
compon ents</w>
type- approval</w>
comp eti
reduc tion</w>
dec isi
s cre
inspec tion</w>
2 4</w>
re view</w>
at or
v it
th .</w>
1 ,
fin al</w>
I V</w>
re tur
a -
con nec
pro p
that 's</w>
oc k</w>
mo re
a k</w>
pec i
con fir
hou se</w>
iti es,</w>
rel ation</w>
av en
v isi
wa y.</w>
av i
un its</w>
O F</w>
an tly</w>
loc al</w>
ap ter</w>
wor ks</w>
exc eed</w>
c over</w>
recogn ised</w>
ograp h
an t
f ar</w>
E U
C l
intere st</w>
fu el</w>
ti s</w>
c all</w>
dise as
t ow
R es
op h
b est</w>
P l
s ince</w>
be l</w>
pa in</w>
c ell</w>
perform ed</w>
on e,</w>
Jan uary</w>
you r
m us
b ul
some thing</w>
br ing</w>
organ isation</w>
% )</w>
fil e</w>
defin i
c ou
typ es</w>
p et
a way</w>
s chem
impair ment</w>
consum ption</w>
con struc
adop t</w>
ne t</w>
l u
ag e,</w>
S h
pass eng
know l
su c
es )</w>
ar ound</w>
(E EC)</w>
qual i
u ght</w>
is m</w>
D on't</w>
oc k
ess ential</w>
2 ).</w>
. ”</w>
anc e.</w>
w ind
pro por
er s
film -
you n
le ad</w>
me work</w>
docu ment
calcul ated</w>
r un
t ook</w>
gran ted</w>
vehic l
in e
electr onic</w>
d est
that .</w>
c ust
ful ly</w>
fl ight</w>
t ed,</w>
r ying</w>
men tioned</w>
c ut
f und
evalu ation</w>
Regul ation.</w>
p ir
are as</w>
I m
bel i
you ?</w>
lo ve</w>
know ,</w>
h ome</w>
cl ose</w>
applic ant</w>
0 00</w>
wee k
av er
nat ure</w>
wh e
compl e
po int
wh ite</w>
g ir
t u
gre at</w>
( including</w>
film- coated</w>
5 .</w>
pl an</w>
he ad</w>
nex t</w>
Ag ency</w>
av oid</w>
sh ow</w>
p ic
appl i
pos al</w>
subm it</w>
tal k</w>
depend ent</w>
up .</w>
instru ments</w>
ar ing</w>
thou ght</w>
com it
em ission</w>
A D
re -
tran si
an k</w>
suppl y</w>
fri end
fa ir</w>
IO N</w>
y ;</w>
u ma
ar an
sh all,</w>
characteris tics</w>
struc ture</w>
fi ve</w>
m l
ph en
respon si
t a</w>
them ,</w>
intro duc
op en</w>
abl e.</w>
hap pen
vie w
num b
in d</w>
u gh
r onic</w>
con ver
un i
it ch
wor l
benef it</w>
establ ish</w>
pri v
wh y</w>
mod er
implement ing</w>
chec k</w>
ag e.</w>
pen di
expres sed</w>
B o
o .</w>
subjec ts</w>
ma king</w>
identi fication</w>
re di
dis continu
se e
.. ..
paragrap hs</w>
An y</w>
ing redi
int egr
oper ations</w>
stor age</w>
se .</w>
ph osph
lef t</w>
v iv
tox icity</w>
bec ome</w>
compon ent</w>
ing ?</w>
it ing</w>
st ate</w>
e as
sh are
determin e</w>
1 1</w>
w ord
addi tion</w>
memb ers</w>
p ing</w>
et .</w>
J ust</w>
fic i
hal f</w>
co ord
5 /
tis su
ad ap
f our</w>
1 4</w>
pl at
re ad</w>
in flu
L i
m es</w>
at ed.</w>
regul atory</w>
ol es
j usti
regard ing</w>
circ um
r as
fr on
en ta
pri mary</w>
Directiv e,</w>
tiv ity</w>
ev ents</w>
al co
follow s:</w>
E U</w>
gu aran
(1 ),</w>
sup por
par ti
al tern
D is
speci es</w>
sist ance</w>
1 )</w>
ter .</w>
sign s</w>
d ay.</w>
cl ear</w>
initi al</w>
fl am
correspon ding</w>
M E
operat ors</w>
erg ic</w>
d en
as set</w>
oul dn't</w>
ex ten
S uch</w>
tre at</w>
car di
exclud ing</w>
frequ ency</w>
d ang
LOR D</w>
b at
sci entific</w>
7 .
an .</w>
indic ate</w>
long er</w>
wee k</w>
s ).</w>
car rying</w>
pregn anc
We 're</w>
exc ep
m er
M r.</w>
hy po
cl ass</w>
2 -
y ?</w>
b it</w>
On e</w>
dur ation</w>
capac ity</w>
S ub
insul in</w>
tr act
ing s,</w>
O n</w>
(d )</w>
for c
an ,</w>
sh or
g ot
a qu
in stitution</w>
r s</w>
thou gh</w>
p ap
5 ,</w>
J une</w>
I .</w>
Ap pendi
ro ad</w>
per c
there .</w>
ati ves</w>
ad .</w>
ust ri
mo ve</w>
stand ing</w>
in ated</w>
measure ment</w>
l ov
p en</w>
th ings</w>
ist er</w>
detail ed</w>
st re
tabl et</w>
treat ment.</w>
sear ch</w>
pay ment</w>
d ou
re li
o il</w>
repor ts</w>
pro hi
AN D</w>
el .</w>
n igh
a id</w>
des cription</w>
sur face</w>
now .</w>
3 0
b ir
sure s</w>
fi xed</w>
c over
p ack</w>
hold ing</w>
t oo
ra z
t ol
provid es</w>
ex change</w>
cust om
m ag
s le
r and
lim its</w>
oblig ations</w>
acc id
J uly</w>
o di
ar r
or .</w>
at ric</w>
kin d</w>
h and</w>
profession al</w>
fra mework</w>
at ,</w>
t ures</w>
f ut
transf er</w>
oun d
4 ).</w>
ag g
b oo
ac compan
rece ive</w>
sp ace</w>
s cope</w>
veter inary</w>
Com e</w>
f ying</w>
at eg
bro ught</w>
st .</w>
n er
agre ement</w>
ox ide</w>
ffic ul
2 )</w>
w ise</w>
in -
6 0</w>
r ati
se ed</w>
la bel</w>
ren g
me et
si m
sul ph
am ong</w>
sub sequ
par ties</w>
arrang ements</w>
experi enc
effec tiv
con clud
categ ories</w>
meth od
des ign</w>
par ame
transp or
m ut
imp act</w>
Ch apter</w>
sa id,</w>
v o
Author ity</w>
sub paragraph</w>
b ri
(4 )</w>
d one</w>
respec tiv
particular ,</w>
represent ative</w>
comp any</w>
il i
great er</w>
susp en
em erg
process ing</w>
organ ic</w>
am oun
ow ,</w>
ric ul
fo od
recog ni
S af
ti n</w>
resul ting</w>
over all</w>
1 3</w>
suit able</w>
ag ing</w>
condi tion</w>
Stat es,</w>
( P
st reng
distrib ution</w>
iti es.</w>
necessar y,</w>
en ted</w>
der og
St and
al s.</w>
coll ec
There fore,</w>
repor ting</w>
add ress</w>
di fficul
A L</w>
ar ticl
in duc
con stitu
el ine</w>
on e
u ted</w>
ab sor
ag ricul
produc ts,</w>
I M
li ve</w>
m ol
Appendi x</w>
g /
A P
1 6</w>
s ay
ac id
H y
exam ination</w>
C ar
t on</w>
m id
tion ing</w>
sp eed</w>
pro posed</w>
circum st
h ard</w>
so on</w>
facil it
mil k</w>
h ni
doc tor
st and</w>
2 4
with draw
dev ices</w>
s ocial</w>
A I
hold er</w>
e z
vis ory</w>
men ted</w>
labor atory</w>
stuff s</w>
gl uc
fi l</w>
th i
c ost</w>
/EEC ,</w>
l og
net work</w>
gr ad
occ ur</w>
fl ow</w>
we 're</w>
establish ment</w>
all oc
R ec
ac et
docu ments</w>
siz e</w>
. "</w>
O r
E S</w>
us e.</w>
P re
bo ard</w>
W ith
pop ulation</w>
n ess,</w>
gro und</w>
ou gh</w>
Ac c
in ser
hel d</w>
dra w</w>
inf ection</w>
min im
fl o
B y</w>
pre- filled</w>
hy dr
wom en</w>
thro ugh
en ing</w>
E M
s -
s ),</w>
maj or</w>
previ ous</w>
por t
mat ter</w>
prepar ation</w>
par ty</w>
( S
ang u
re main
n or</w>
it ?</w>
sa w</w>
conduc ted</w>
r ating</w>
iz ation</w>
b a
sever al</w>
w ard</w>
si l
re ac
cell s</w>
pres ence</w>
e a</w>
W ith</w>
thereof ,</w>
k es</w>
employ e
b o</w>
O k
r o</w>
( 6
i es,</w>
B ec
un g
erc ial</w>
L ord
th is.</w>
allow ed</w>
A ,</w>
reg ular</w>
ter min
um ,</w>
he ard</w>
ach ed</w>
lo t</w>
6 ,</w>
pur ch
sec tions</w>
con comit
il ,</w>
z z
enz y
noti fication</w>
it es</w>
ar m</w>
O R</w>
r am
el im
6 .</w>
tec hni
si x</w>
id e,</w>
g rap
al ity</w>
thro m
it ation</w>
end ing</w>
instru ment</w>
oblig ation</w>
D e
enter pris
docu ment</w>
d ar
uma b</w>
fe el</w>
t as
institu tions</w>
dr y</w>
provid ing</w>
ta min
intr aven
s em
id es</w>
contr acts</w>
employ ed</w>
cooper ation</w>
(i i
orig in</w>
all y,</w>
p an
f low
con c
out side</w>
re action</w>
fail ure</w>
person al</w>
G et</w>
moder ate</w>
There 's</w>
d og
aver age</w>
edi atric</w>
N O
r up
bi o
star ting</w>
pr ice</w>
ro w</w>
do ing</w>
4 0</w>
He y,</w>
or ity</w>
pregn ant</w>
us ed.</w>
ad ,</w>
m ,</w>
lat er</w>
S ec
equ al</w>
c au
y :</w>
ext ent</w>
lo ad</w>
Stat e,</w>
cour se</w>
str a
u es</w>
temper ature</w>
hi st
U se</w>
c in
y et</w>
secon d
sampl es</w>
om et
N ov
fact or</w>
cap sul
approxim ately</w>
Pro duc
s we
pres ented</w>
youn g</w>
pol l
A re</w>
5 0
E L
consum er</w>
comm ercial</w>
fuc king</w>
di ag
bu ild
me at</w>
peri ods</w>
reas ons</w>
I' d</w>
ti me,</w>
princi ples</w>
adjust ment</w>
place bo</w>
tox ic
need s</w>
objec tives</w>
k ept</w>
IF R
ref l
n .</w>
l angu
si tivity</w>
environ ment</w>
u red</w>
techni qu
se ,</w>
Bec ause</w>
d y
Regul ation,</w>
dec lar
bre ast
wor d</w>
at ors</w>
w ell
c ulation</w>
vi a</w>
v ent
pre pa
e ph
M ay</w>
dri ve</w>
le ave</w>
ig ure</w>
ey e</w>
er ous</w>
(2 ),</w>
form ul
an t,</w>
dis ord
cl usion</w>
os is</w>
anti -
Q u
mea sure</w>
me ?</w>
rec over
w al
v ess
g i
complet ed</w>
et c
author is
the y
pow der</w>
8 ,</w>
am in
Saf ety</w>
sampl ing</w>
ini b</w>
tw ice</w>
righ t,</w>
wat er
tar get</w>
com ing</w>
require ment</w>
st ,</w>
m .</w>
d on
anal y
all ergic</w>
f itted</w>
sec uri
an sw
1 ).</w>
oc y
ne l</w>
au tom
hydro x
ex ter
char ge</w>
/EC ,</w>
group s</w>
pl ay</w>
post -
subst anc
or s,</w>
cod e</w>
contract ing</w>
ther .</w>
ne y</w>
ex ha
cl e</w>
ind u
stat us</w>
t ors</w>
ca ref
mon o
man .</w>
fam ily</w>
w ine</w>
E D</w>
on es</w>
ic k</w>
in flam
Th ey
col our
he at</w>
issu e</w>
ic i
I AS</w>
p um
instruc tions</w>
achiev ed</w>
pro ve</w>
gl ass</w>
car d</w>
contain ed</w>
si v
g ave</w>
fe w</w>
m ess
1 -
f all
enc e,</w>
ph ase</w>
invol ved</w>
ing s.</w>
ed g
t ;</w>
jo int</w>
need le</w>
knowl edge</w>
al i
e ).</w>
agricul tural</w>
li qu
at ten
re lease</w>
TH E</w>
cla im
design ated</w>
ac qui
t op
tem por
suppl i
bas ic</w>
k ey</w>
ic e.</w>
t end
u l</w>
e a,</w>
ter ,</w>
cle an
transm ission</w>
ed ul
al ised</w>
follow ed</w>
us e,</w>
20 0</w>
. e.</w>
pa id</w>
ingredi ents</w>
en able</w>
com mon
Annex es</w>
p ig
ent s,</w>
In formation</w>
addi tion,</w>
di g
1 7</w>
clear ly</w>
id al</w>
2 3
/EC .</w>
mod el</w>
suspen sion</w>
pain ,</w>
lar ge</w>
posi tive</w>
us ers</w>
incre as
he ar</w>
J es
CYP 3
s of
comm it
Commis sion,</w>
y n
E l
speci fic
5 %</w>
O c
ar s</w>
particular ly</w>
4 -
en ess</w>
fut ure</w>
at a</w>
regul ations</w>
H aving</w>
F in
cri min
veri fication</w>
detail s</w>
tri als</w>
p .</w>
f av
ab ov
4. 4).</w>
ther ,</w>
qui d</w>
pres cribed</w>
publ ished</w>
polic y</w>
cor por
u no
G re
dec ide</w>
3 ).</w>
monit ored</w>
pa th
v est
T ell</w>
up ,</w>
bl o
tr av
g ast
inf ra
sign ed</w>
M on
em ed</w>
T R
mar k</w>
sp ir
P lease</w>
re search</w>
c ro
pa ediatric</w>
chec ks</w>
statis tical</w>
k ill</w>
M ed
rit on
l ed</w>
g al
year s.</w>
Where as,</w>
st ep
ca used</w>
addi tive</w>
S ol
mg/ kg</w>
ch ild</w>
ell ed</w>
d en</w>
A b
f oo
exter nal</w>
m ob
deriv ed</w>
ou t,</w>
b order</w>
el y,</w>
II ,</w>
s /
ros s</w>
fact ors</w>
a h</w>
wh at
vacc ine</w>
place bo
eu tic</w>
sh are</w>
gir l
probl ems</w>
pa rent</w>
yp e</w>
self -
or r
mot or</w>
fe el
beli eve</w>
li abil
appl ying</w>
need ed</w>
Stat es.</w>
u g</w>
L et</w>
mon th</w>
clear ance</w>
vari ous</w>
includ es</w>
ship s</w>
ay ?</w>
a c</w>
LOR D
bal ance</w>
patient s.</w>
l eng
en s</w>
tabl et
ing ;</w>
No .</w>
usu ally</w>
en ter</w>
c am
sch edul
comb in
fir e</w>
enc es</w>
c ular</w>
amoun ts</w>
r ac
a ud
prog res
ard .</w>
sol id
get ting</w>
es sion</w>
IN G</w>
G ener
go od
bas eline</w>
saf e</w>
reg istered</w>
sub si
on s,</w>
m m</w>
6 0
min ut
ind ustri
identi fi
contr ac
n ,</w>
es peci
organis ations</w>
Con t
m ation</w>
cri p
( N
centr al</w>
4 0
diag no
res our
act ing</w>
M R
t ub
ri g
document ation</w>
U N
t um
st ain
adul t</w>
tr ad
h owever,</w>
therap eutic</w>
cap ital</w>
C ol
speci fications</w>
in dependent</w>
ex per
ar t
9 1/
fr u
st er</w>
7 5</w>
especi ally</w>
ac qu
P C
Y es,</w>
cont ents</w>
A .
n ur
ere d.</w>
no v
hydro chlor
en suring</w>
Treat y</w>
mea suring</w>
assess ed</w>
i es.</w>
prote in</w>
st ri
classi fied</w>
8 .
19 8
s cal
f ish</w>
P RO
require s</w>
n ation
devel op</w>
w id
inform ed</w>
oles c
anc ed</w>
main tain</w>
it ems</w>
C an</w>
surve ill
re st</w>
re v
exam in
peri od
ot ox
mean ing</w>
ag ents</w>
protec t</w>
intraven ous</w>
n ut
li quid</w>
ex pir
ser um</w>
suppl ied</w>
do es
ac ute</w>
ti me
a di
T ake</w>
quanti ty</w>
cal culation</w>
cl ass
1 9</w>
con tamin
ati c
at ed,</w>
tr aff
traff ic</w>
suc c
A B
through out</w>
objec tive</w>
l act
un c
effici ency</w>
f f</w>
ox y
ad olesc
wh om</w>
con stit
R ep
sour ce</w>
sp ea
an ta
f em
subsequ ent</w>
re al</w>
li fe
bl eeding</w>
wa y,</w>
G od,</w>
any thing</w>
T ev
ass ess</w>
w r
he av
ca em
pro mot
( 9
(i )</w>
A IF
sp ac
i b</w>
al t</w>
D av
appl ies</w>
int est
writ ten</w>
L e
ar ly</w>
4 6
3 -
registr ation</w>
C I
p ay</w>
proced ure
p ut
evalu ated</w>
e !</w>
add res
re new
ou gh
a ren
inc idence</w>
h er.</w>
aff ec
ti ll
. ;</w>
m oun
decre ase</w>
conclud ed</w>
L et
H C
C o
- up</w>
ro om
plac ing</w>
ol s</w>
h on
L oo
st ay</w>
acc ur
P o
E R</w>
th es
rand om
clin ically</w>
ro ll
ru n</w>
cut an
exam ple,</w>
dang erous</w>
ent s.</w>
Th ose</w>
consid eration</w>
pers en
meth yl
E X
ity ;</w>
un it
perc enta
T ran
f ish
ex plo
w if
on d</w>
fron t</w>
abl es</w>
dec la
sur g
clos ed</w>
sel ected</w>
dos e.</w>
ov ine</w>
IO N
facilit ate</w>
possi bility</w>
k s,</w>
G u
tri c</w>
ab s
form s</w>
b one</w>
M a
p y
( for</w>
ques tion</w>
multi ple</w>
exc eed
demonstr ated</w>
r ates</w>
long -
righ t?</w>
monit or</w>
az ol
p ra
Un ited</w>
M ay
y cl
grow th</w>
altern ative</w>
Di d</w>
phys ical</w>
A M
decre ased</w>
guid el
indic ation</w>
cas h</w>
os p
val id</w>
prepa red</w>
establish ing</w>
st age</w>
control s</w>
carb on</w>
D es
( T
enti ties</w>
as pec
9 0</w>
test ed</w>
perm it</w>
el ements</w>
exerc ise</w>
l ay</w>
col um
On ly</w>
w on't</w>
plan e</w>
loo king</w>
y )</w>
ed ing</w>
system ic</w>
mil li
A .</w>
y 's</w>
f ill
U R
ge ograph
2 5
bel ong
ra m</w>
communic ation</w>
enc ies</w>
signific antly</w>
r on
gover n
en ough</w>
s kin
an t.</w>
man ner</w>
s '</w>
other wise</w>
ex pl
here ,</w>
consid er</w>
h op
sol v
wan na</w>
ser ve</w>
re main</w>
S er
8 0</w>
ne g
2 1</w>
respec tive</w>
Wh o</w>
ple ase</w>
le ar
7 ,</w>
draw n</w>
system ,</w>
pro b
tl ed</w>
fa ther</w>
does n't</w>
ear ly</w>
comb ined</w>
bi g</w>
F ol
accoun ting</w>
super vision</w>
2 8</w>
previ ously</w>
tion ;</w>
bre ak
wan ted</w>
ow .</w>
dr ug</w>
del et
v om
ex cre
subsi di
h ath</w>
comp ati
con sequ
pl i
ell ow</w>
no thing</w>
ur b
ol ,</w>
back .</w>
t ext</w>
F e
fa ul
dis posal</w>
ag ent</w>
sur viv
( f
declar ation</w>
system .</w>
set ting</w>
ep t
coun tr
e f</w>
W or
1 1
n ight</w>
Stat e.</w>
feed ing</w>
accompan ied</w>
Mar ch</w>
m om
S C
p il
o s</w>
tic ally</w>
Ad min
er r
cycl e</w>
d re
al ed</w>
ou ght</w>
ig ible</w>
dos ing</w>
Directiv es</w>
sug g
mean ,</w>
com es</w>
me t</w>
pregnanc y</w>
t le
norm ally</w>
fer til
et ,</w>
again .</w>
decisi ons</w>
at s</w>
re view
el e
i br
concern ed.</w>
statis tics</w>
consist ent</w>
T S</w>
ma y,</w>
em bl
an e</w>
g as
ex emp
s oci
gener ally</w>
th ers</w>
ma kes</w>
pro long
7 .</w>
n ection</w>
it em</w>
heal thy</w>
probl em
plan ts</w>
ex clu
dis c
i red</w>
S ome</w>
priv ate</w>
el f
de b
P er
A )</w>
do m</w>
identi fy</w>
im pl
concomit ant</w>
comp ris
S P
stat ement</w>
parame ters</w>
construc tion</w>
agre ements</w>
( e)</w>
bre a
act ual</w>
id .</w>
hist ory</w>
N um
sol vent</w>
ation :</w>
Let 's</w>
subst anti
ut ro
there 's</w>
resid ue</w>
o il
iz e</w>
imm uno
de emed</w>
Ch ar
diff erence</w>
AT ION</w>
. ,</w>
tol er
produc ts.</w>
pet ro
noti ce</w>
cros s-
cas es,</w>
2 ,
ro und
e /
sour ces</w>
F ood</w>
surveill ance</w>
hold ers</w>
pop ul
in ter</w>
got ta</w>
us ed,</w>
rel ation
prac ti
stand ard
mil d</w>
a uc
t al</w>
reas on</w>
in ning</w>
correc t</w>
b ud
min utes</w>
breast -
aff ected</w>
plac ement</w>
stor e</w>
av oid
regul ated</w>
sl augh
f arm
el ev
us er</w>
princi ple</w>
9 .
ci um</w>
J er
work ers</w>
gr ant</w>
CYP3 A
8 ).</w>
it ary</w>
dist ance</w>
(1 )
employ ment</w>
N ow,</w>
sh oul
pot enti
exha ust</w>
estim ated</w>
classi fication</w>
pl us</w>
emerg ency</w>
as ked</w>
m ed</w>
at .</w>
B l
super visory</w>
o z
li ability</w>
oper ational</w>
eth yl
am .</w>
mon ey</w>
S ince</w>
pro pos
intere st
az ole</w>
abs ence</w>
( H
effici ent</w>
O P
s ound</w>
righ t.</w>
influ ence</w>
determin ation</w>
rati o</w>
lim it
enc our
est er
Be fore</w>
, ”</w>
mov ement</w>
achi eve</w>
n s</w>
S om
ar .</w>
con sign
record ed</w>
loo ks</w>
g ets</w>
ment ;</w>
Tev a</w>
derog ation</w>
dam age</w>
B i
h ost</w>
in hal
chem ic
( 7
appro ach</w>
R em
prog ress</w>
pi ec
con nection</w>
lar g
all .</w>
S w
5 -
wat er.</w>
F OR</w>
ys is</w>
Th or
Inter national</w>
t ure
feed ing
ch es</w>
A G
pri l</w>
pharmacokine tics</w>
p ip
ar ising</w>
per man
canc er</w>
low ing</w>
orig in
8 .</w>
3 )</w>
indu str
( excluding</w>
equip ped</w>
ch ol
de fici
aem ia</w>
co st
c e
concern ed,</w>
meet ing</w>
ed -
P ol
thre sh
9 ,</w>
syn dro
oun ds</w>
k s.</w>
nut ri
or i
f all</w>
d augh
ben z
I R
coll ection</w>
( or</w>
tur n</w>
n om
af f</w>
S he's</w>
F ro
ro om</w>
comm and
acc um
a b</w>
ar ies</w>
st ated</w>
im prove</w>
f ast
I L
A U
av ig
law s</w>
ac ks</w>
occ up
d ay,</w>
harmon ised</w>
th is
to ber</w>
certific ates</w>
Oc tober</w>
Admin istr
certi fication</w>
c ent
th us</w>
sal e</w>
od e</w>
ass embl
share s</w>
ch ro
passeng er</w>
b an
am ing</w>
sh ort</w>
possibl e,</w>
cre at
ar ,</w>
as h
Treat ment</w>
N ot
st aff</w>
pack age</w>
sug ar</w>
ed em
Wh at's</w>
ob tain</w>
F ur
t od
si mul
ic e,</w>
d ed</w>
D et
t y,</w>
request ed</w>
T w
capsul es</w>
servic es,</w>
m and
schem e</w>
certi fied</w>
st om
exc eeding</w>
ac ross</w>
in corpor
del eg
ch ronic</w>
pl ay
gly caem
Ne w</w>
19 7
up per</w>
amend ing</w>
4 )</w>
3 00</w>
( M
recogni tion</w>
manufacture r
applic ations</w>
t ac
en h
circumst ances</w>
curren tly</w>
Dec isi
bro k
sec tor
pro m
b ab
May be</w>
program mes</w>
pre t
ch ed</w>
peri od.</w>
vit ro</w>
noti fy</w>
k et
T O</w>
install ation</w>
h ur
alu min
siv ely</w>
securi ties</w>
occur red</w>
arr ho
in come</w>
intere sts</w>
r in
industri al</w>
dri ving</w>
ch e
C an
l ines</w>
resid ues</w>
gast ro
wor k.</w>
percenta ge</w>
amend ments</w>
A pril</w>
w ard
pa ren
S yst
F or
tr ying</w>
chang ed</w>
cas e,</w>
caref ul
D uring</w>
machin ery</w>
G er
m al</w>
ch ing</w>
produc t.</w>
child ren
giv ing</w>
de ath
They 're</w>
re move</w>
contrac ep
ab et
inform ation,</w>
develop ed</w>
that ?</w>
restric tions</w>
sec tor</w>
u sh
leng th</w>
l ying</w>
feel ing</w>
them sel
sup plement
( *
tain ing</w>
ey es</w>
process es</w>
articl es</w>
ud e</w>
tas ks</w>
ph ot
am ,</w>
g a
defini tion</w>
fol low</w>
ol .</w>
. .</w>
i on
experienc ed</w>
P L
Se e</w>
orig inal</w>
now ,</w>
Ok ay,</w>
(5 )</w>
su ff
iv il</w>
applic able,</w>
5 00</w>
a il</w>
second ary</w>
man ,</w>
1 50</w>
h ol</w>
b ed</w>
E E
str ain
k new</w>
b ind
D ata</w>
pharmacokine tic</w>
func tioning</w>
e tic</w>
et al</w>
dis crimin
C er
to ,</w>
ed )</w>
in es,</w>
persen sitivity</w>
peri od,</w>
addi tives</w>
C E</w>
vol un
rece ip
therap y.</w>
down .</w>
tog e
re t
hal f
intest inal</w>
With out</w>
i b
k ing
lo ad
6 -
sure ,</w>
situ ation</w>
s end</w>
plas tic</w>
expir y</w>
le as
i x
competi tion</w>
throm b
retur n</w>
r ub
tri al</w>
geograph ical</w>
O ffic
it ting</w>
infec tions</w>
bi ological</w>
sub cutan
fam il
J ud
H um
responsi bility</w>
protec ted</w>
tak es</w>
clo sure</w>
per form</w>
2 2</w>
usu al</w>
inhibit ors</w>
ir ing</w>
reason able</w>
ri v
prepar ations</w>
l aying</w>
su stain
res h</w>
exam ple</w>
bi tion</w>
M in
L ev
S o,</w>
de pres
guaran te
day s.</w>
immedi at
eg et
ch i
wat er,</w>
or s.</w>
su s</w>
manufact uring</w>
facil ities</w>
ad ver
perm itted</w>
carri er</w>
Annex .</w>
loc ated</w>
to p</w>
( F
re pa
i on</w>
do or</w>
t ex
w ay
m uc
di abet
C ap
o edem
ne uro
( as</w>
ol d
for ward</w>
be y
protec tive</w>
do .</w>
pharmac ist</w>
accoun ts</w>
% ,</w>
p oul
lab elling</w>
medi an</w>
neg ative</w>
they 're</w>
ple as
f at</w>
coll ected</w>
up d
equ ity</w>
pack aging</w>
T ec
hand s</w>
ri d
pro per</w>
appe ar</w>
pot assi
guidel ines</w>
g )</w>
be ha
E T
fin d
no t
ne ither</w>
c y</w>
k ill
cau tion</w>
re sist
8 )</w>
b on
alco hol</w>
aer o
stat ements</w>
heal th
Nov ember</w>
3 9
more ,</w>
con solid
recover y</w>
pro duce</w>
min e</w>
m ad
e ment,</w>
c ut</w>
V I
tr ac
m unic
inter val
al one</w>
ple mented</w>
m ys
adolesc ents</w>
t ered</w>
enti re</w>
adul ts</w>
satis fy</w>
a im
He al
ch .</w>
differen ces</w>
U L
n es
e at</w>
avail ability</w>
U S
ent al</w>
enc e.</w>
om ide</w>
he at
ra w</w>
p al
J e
w on
tic o
cap able</w>
UC IT
IFR S</w>
inf u
met form
cre w</w>
mou th</w>
saf et
dest ro
end s</w>
long- term</w>
gal ax
demonstr ate</w>
produc t
dri v
str ateg
A ir</w>
na us
ir on</w>
accep table</w>
trans fer
sure .</w>
produc t,</w>
sen si
igh t.</w>
tal king</w>
electr ical</w>
ubl ic</w>
bi oc
vess els</w>
inf ected</w>
gu ys</w>
n on
C H
p on
bot tle</w>
hepati tis</w>
practic es</w>
al ong</w>
ground s</w>
P e
t ou
su m</w>
there of</w>
ov ir</w>
oper ated</w>
al k
2 2
c ere
alco hol
A T</w>
h ?</w>
au dit</w>
word s</w>
hand ling</w>
O L
studi es,</w>
5 ).</w>
h our</w>
every thing</w>
Pro gram
s mo
n avig
restric ted</w>
nit ro
di zz
condi tion
comp ens
Commun ity,</w>
kid ney</w>
tr ic
lif e.</w>
agre ed</w>
st ored</w>
oc ks</w>
inter fer
di arrho
adop tion</w>
bor n</w>
Num ber</w>
E m
/EEC .</w>
jud g
Isra el</w>
pl e.</w>
er y
sel ec
mix ed</w>
men d</w>
individ u
g one</w>
charg es</w>
ap h
Or g
hyper ten
techn olog
haz ard
ma x</w>
pos s
pap er</w>
e ),</w>
R ev
(3 ),</w>
ag ain</w>
su spec
remov ed</w>
es tic
to -
cl i
as sistance</w>
ta x
er 's</w>
Jes us</w>
rec ord</w>
atten tion</w>
ati n</w>
v eget
ex posed</w>
dr aft</w>
avail able.</w>
ain 't</w>
th is,</w>
rec ep
O N
Fro m</w>
0 ,</w>
vir us</w>
fi es</w>
tissu e</w>
me tre
chlor ide</w>
beha vi
prof it</w>
tox ic</w>
territ or
fi re
si ght</w>
treat ment,</w>
know .</w>
drin k</w>
cal ibr
in side</w>
tow ards</w>
h arm
excep tion</w>
th en
h en
200 3/
g ra
p ass</w>
K ing
practi ce</w>
gl ob
beg inning</w>
Gener al</w>
pre serv
it ab
II I
ne utro
de ath</w>
ro r</w>
as cular</w>
I N</w>
im al</w>
- based</w>
star s</w>
veri fy</w>
to .</w>
in de
por ts</w>
es tic</w>
Med ic
(2 ).</w>
lic ence</w>
ke ep
E v
show ed</w>
micro gram
con ven
be aring</w>
riton avir</w>
k ey
carri ers</w>
t y.</w>
l ac
I D
go .</w>
ch ,</w>
continu ed</w>
s in
ma y
sup pres
Som e
S u
( D
tempor ary</w>
(ii )</w>
so il</w>
re m
as sum
b ase</w>
propor tion
is ol
c ab
8 /EC</w>
Jo hn
year s,</w>
adjust ed</w>
Commis sion.</w>
continu ous</w>
ar ter
sid e.</w>
food stuffs</w>
7 0/
mix ture</w>
. )</w>
ut ing</w>
k illed</w>
op ath
incre ases</w>
oper ate</w>
mus cle</w>
3 6
condi tions,</w>
es ?</w>
st atic</w>
om a</w>
det ec
chem o
wom an</w>
objec t</w>
M ic
C R
9 .</w>
lin ked</w>
agg reg
ab dom
inform ation.</w>
determin ing</w>
com for
per for
men ,</w>
m el
con clu
vir al</w>
some one</w>
bey ond</w>
II I,</w>
indic ating</w>
fi x
et ary</w>
re sistance</w>
n u
comp u
r are</w>
process ed</w>
streng th</w>
elec tro
connec ted</w>
9 8/
ocy t
ir rit
bioc idal</w>
ad m
w ide</w>
gu y</w>
s ons</w>
ph as
le ading</w>
im age</w>
bl ack</w>
Pro t
s ac
level ,</w>
ept ember</w>
K e
H IV</w>
re member</w>
5. 2).</w>
th reat
author ized</w>
wor thin
S eptember</w>
ref er</w>
m ph
dri ver</w>
cat al
E g
A gre
f resh</w>
ref eren
necessar y.</w>
inspec tions</w>
% .</w>
G o</w>
trans actions</w>
run ning</w>
guaran tee</w>
ho t</w>
avi ation</w>
a )</w>
f la
cri be</w>
bec om
whic h,</w>
oo l</w>
h osp
ent ered</w>
dr ug
record s</w>
inter medi
id s</w>
m ac
h ard
for get</w>
CYP 2
year .</w>
sol id</w>
proper ties</w>
p are</w>
200 2/
there ,</w>
str ong</w>
in ate</w>
s ou
l ay
ex pen
ass et
s on
de g
coord ination</w>
re serv
k ind
cop y</w>
E F
pre vention</w>
ex ec
bod y.</w>
phys ici
electr icity</w>
B re
dis till
dat a,</w>
C P
withdraw al</w>
l un
conf identi
here ?</w>
analy tical</w>
suffici ently</w>
O per
V ery</w>
2 1
( such</w>
ar t</w>
of ,</w>
decla red</w>
conduc t</w>
tr u
O p
b and
al is
G r
car cin
cal cium</w>
you 've</w>
con st
st ood</w>
speci fy</w>
comple x</w>
ri es</w>
i a.</w>
bo x
aspec ts</w>
sy m
market ,</w>
ing u
a e</w>
w ill
sh alt</w>
re l</w>
We 'll</w>
worl d</w>
the e</w>
le -
l uc
Man ag
law s,</w>
S peci
M eth
bre ast</w>
ang e</w>
di men
be half</w>
or e</w>
M e
pro file</w>
en forc
condi tions.</w>
Tec hn
M os
I U
B ,</w>
he ating</w>
re constitu
off ice</w>
manufact ure</w>
enti tled</w>
doctor .</w>
H ave</w>
was h
is n't</w>
dom estic</w>
N or
sec re
repe ated</w>
inser ted</w>
R A
v in
tr ading</w>
re ver
compan ies</w>
T r
2 3</w>
micro -
i di
sa ve</w>
Bo ard</w>
radi o</w>
li ving</w>
R ef
le av
ar th
tr ail
b acter
accord ing
R o
patient s,</w>
op tion</w>
invol ving</w>
law ,</w>
sig n</w>
plac e.</w>
ic ,</w>
min d</w>
s ens
plan s</w>
petro le
main tained</w>
l ad
f our
e ment.</w>
h ous
j u
sub -
of ovir</w>
consum ers</w>
le af
dec id
as sist
re tro
m L</w>
w ouldn't</w>
w is
b .</w>
.... ....
person nel</w>
as h</w>
wor k,</w>
re produc
B en
temper at
mal e</w>
g es</w>
di al
sle ep
qu e</w>
ne um
consid er
compar able</w>
step s</w>
employe es</w>
adv ice</w>
Ad di
port un
n e</w>
house hold</w>
prec au
I C</w>
studi ed</w>
2 6</w>
responsi bil
le ad
of :</w>
ere d,</w>
re st
j ob
gr av
deliv ered</w>
ar di
2 8
receip t</w>
regi onal</w>
re placement</w>
am ide</w>
us h</w>
sub str
be h
enc y,</w>
ca p</w>
( B
y ellow</w>
loc ation</w>
improv ement</w>
bra king</w>
off er</w>
cou pl
pend it
acc es
measure s,</w>
ph y
dos e,</w>
a way.</w>
hydro gen</w>
w el
ro aming</w>
ri t</w>
T S
Loo k,</w>
inter f
d ens
4. 8).</w>
mon ary</w>
deg ree</w>
proper ty</w>
a h,</w>
W at
she 's</w>
s ex
resour ces</w>
quali fied</w>
projec ts</w>
S ta
f act</w>
E V
maj ority</w>
is s</w>
lo ading</w>
li v
( in</w>
se l</w>
rel ative</w>
aw ard</w>
more .</w>
educ ation</w>
S U
inter action</w>
aw ard
was n't</w>
op portun
br y
mis sible</w>
in ine</w>
sti c</w>
mark ed</w>
b ound</w>
s ent
liabil ities</w>
G ive</w>
z one</w>
us al
sour c
sev en</w>
transi tional</w>
ti le</w>
Con vention</w>
5 )</w>
pro posal</w>
f ig
O f</w>
ri ed</w>
numb ers</w>
establish ed.</w>
contrib ute</w>
C L
u tive</w>
too .</w>
ro ut
possibl e.</w>
oc curren
li c</w>
impl ement</w>
cle an</w>
centr e</w>
S am
elec om
O b
w o
public ation</w>
T A</w>
Fol lowing</w>
under stand</w>
s s</w>
rat s</w>
l es
bo di
y ro
worthin ess</w>
scal e</w>
n ess
clos ely</w>
Org an
Offic ial</w>
valid ity</w>
evalu ate</w>
disc us
a fil</w>
T al
0 1</w>
enc y.</w>
confir med</w>
tic s,</w>
consul tation</w>
claim s</w>
so ,</w>
ch am
P E
sur fac
el igible</w>
eg g
( 0.
di oxide</w>
di p
as signed</w>
are .</w>
a im</w>
self .</w>
ed ?</w>
she et</w>
s is</w>
CYP3A 4</w>
vari able</w>
pay ments</w>
o ffici
ab normal</w>
form at</w>
fl av
8 7
w ish</w>
b ad</w>
eng ines</w>
propor tion</w>
wh il
peo ple
market .</w>
particip ation</w>
be au
ach ing</w>
trans action</w>
com part
manufacture rs</w>
art an</w>
Jer usal
year ,</w>
prohi bit
ang i
an ts,</w>
haz ard</w>
elecom munic
main ly</w>
9 2/
vacc ination</w>
op id
gluc ose</w>
del ay</w>
b ovine</w>
Fe br
mechan is
elec tric</w>
discontinu ed</w>
ation )</w>
p ,</w>
of ten</w>
i ,</w>
G od
thou gh
potassi um</w>
e k</w>
v es
nur se</w>
l ost</w>
be ar</w>
er ;</w>
dat ab
D oc
2 7</w>
re ve
( A
se as
careful ly</w>
(f )</w>
re ly</w>
p sy
fil ter</w>
es /
c ivil</w>
Yea h.</w>
V al
ta x</w>
au di
re d,</w>
par at
relation ship</w>
inhibit or</w>
um .</w>
n or
con j
alumin ium</w>
ful fil</w>
bre ak</w>
v ul
s ...</w>
s !</w>
ro p
fru it</w>
ex pendit
T ype</w>
P r
ext ended</w>
require d.</w>
ish ing</w>
m other</w>
H ol
ra y</w>
ha ir</w>
ch os
as s,</w>
O N</w>
CO N
no t,</w>
out put</w>
l ess
es sive</w>
solu tions</w>
cont ext</w>
show s</w>
mg/ ml</w>
system s,</w>
s av
mg/ k
func tional</w>
dog s</w>
mod e</w>
comple tion</w>
di d
are ,</w>
you 'll</w>
t ure,</w>
E ver
4 00</w>
% 1</w>
l ation</w>
develop ing</w>
all y.</w>
4 9
re ach</w>
modi fied</w>
func tions</w>
cover ing</w>
N A</w>
us ef
objec tiv
2 7
l ack</w>
we b
em b
opid og
is on</w>
dos age</w>
reg ulation</w>
ic on
ear li
accep ted</w>
ud ine</w>
r a</w>
pum p</w>
vis ual</w>
integr ated</w>
fi ed.</w>
2. 1.
z ed</w>
th ing,</w>
ne ar</w>
2 9
act ually</w>
J our
ti t
G ro
u tions</w>
g ain
er t</w>
O B
re d.</w>
od y</w>
d -
princi p
(1 ).</w>
il .</w>
d in
UCIT S</w>
mar king</w>
est s</w>
v al</w>
men .</w>
langu age</w>
injec tion.</w>
S )</w>
open ing</w>
cre d
cor e</w>
II .</w>
see k</w>
orr h
hap p
V i
ur ine</w>
ur g
paragrap h,</w>
c ount</w>
j ection</w>
hazard ous</w>
Eg yp
A m
P -
re spir
complet ely</w>
Ph armac
o es</w>
in nov
( L
ti ll</w>
schem es</w>
lat ter</w>
e ...</w>
F r
oc ol</w>
det ection</w>
Wh at
z er
ly mph
con s
comm od
Lord ,</w>
fem ale</w>
dizz in
Uni on.</w>
There fore</w>
C y
star ted</w>
measure ments</w>
k ing,</w>
fund s</w>
Febr uary</w>
( the</w>
v ot
pen sion</w>
avir in</w>
v ic
re ta
find ings</w>
him self</w>
? ”</w>
provid ers</w>
net works</w>
inter rup
colum n</w>
ok ay?</w>
immedi ate</w>
cl ou
Coun c
co ol
att rib
say ing,</w>
r y,</w>
MR L
w i
solu ble</w>
polic ies</w>
l ob
u min
guid ance</w>
concentr ate</w>
od ro
high est</w>
high -
communic ate</w>
I S</w>
th al
respectiv ely.</w>
quanti ties</w>
b es
bl ist
re ,</w>
pl ate</w>
id e
over ,</w>
h u
bind ing</w>
pr ices</w>
off .</w>
c os
k y</w>
Euro p
ser ies</w>
absor ption</w>
ti fic
m ust
A ir
tur ned</w>
ti de</w>
d ys
bre ath
st ar</w>
recommend ed.</w>
f um
el der
effectiv eness</w>
cl im
sw elling</w>
gover ning</w>
prac tical</w>
sh ap
fre ed
depend ing</w>
subcutan eous</w>
d ust</w>
B ar
4 8</w>
inf ring
e 's</w>
de ad
G ood</w>
200 1/
author ity.</w>
N ational</w>
M A</w>
compati ble</w>
lip tin</w>
E D
imm une</w>
bo il
sw itch
Man ufact
- related</w>
e ments,</w>
uni form</w>
install ed</w>
s at
o dium</w>
Ever y
lam ps</w>
sel ection</w>
dev ic
Ap plic
interfer on</w>
9 0/
organis ms</w>
as surance</w>
You 've</w>
O C
C al
2. 5</w>
techniqu es</w>
str onom
sp ati
b y-
si r.</w>
dise ases</w>
e x</w>
avail able,</w>
H ar
sp i
re ar</w>
go od.</w>
S im
wa it</w>
ogen ic</w>
ris e</w>
pr o</w>
j our
acqu isi
F ir
par ticl
infra structure</w>
creat inine</w>
acqui red</w>
rap id</w>
o pro
k il
id e.</w>
hour s.</w>
M P
s qu
conver sion</w>
wif e</w>
fi bre
inflam mation</w>
enterpris es</w>
de ad</w>
car go</w>
ben e
ap parat
provid er</w>
promot e</w>
level .</w>
industr y</w>
ul es</w>
iti s</w>
he ight</w>
comb us
sh oo
i -
Cl ass</w>
5 7
(i .e.</w>
ti es,</w>
ir able</w>
equip ment,</w>
dom in
st ro
p estic
com position</w>
Dav id</w>
wh at's</w>
wast es</w>
(3 .
regul arly</w>
mon e
T est</w>
succ ess
imm un
author ities,</w>
spea k</w>
metform in</w>
Ex c
(6 )</w>
p neum
cardi ac</w>
al ing</w>
0. 5</w>
half -
al )</w>
ab sol
N on-
6 ).</w>
ou s.</w>
ou ter</w>
am ine</w>
spati al</w>
il t</w>
h us
er ?</w>
brok en</w>
tle ment</w>
in es.</w>
immediat ely.</w>
exclud ed</w>
comp os
3 7
i el
ha ir
T el
4. 2</w>
ma il</w>
ar dis
test .</w>
poin ted</w>
dec reas
A v
sa y,</w>
install ations</w>
plat el
mo tion</w>
hom e.</w>
s ays</w>
hy persensitivity</w>
er a</w>
anc es,</w>
Heal th</w>
mechan ism</w>
it !</w>
ver sus</w>
potenti ally</w>
af ra
5 4
no ise</w>
mix tures</w>
contr ain
P ri
F l
pul monary</w>
contain er</w>
t t
constit ute</w>
introduc tion</w>
contrain dic
b ,</w>
ti d
manufact ured</w>
L ook</w>
20 10
se a</w>
flu or
ap hy
pro spec
v ir</w>
se at</w>
ro ute</w>
ro c
re insurance</w>
pret ty</w>
enz a</w>
ou red</w>
benef it
ac u
Acc ord
jo b</w>
su le</w>
regard ed</w>
navig ation</w>
faul t</w>
appropri ate.</w>
T it
Ch ri
jec t</w>
vom it
peo ple.</w>
Ke ep</w>
themsel ves</w>
t elecommunic
re p
nam es</w>
justi fied</w>
acc red
8 9/
under lying</w>
o 's</w>
er -
requ iring</w>
im e</w>
servic es.</w>
ot .</w>
met al</w>
i .e.</w>
2 6
w ants</w>
passeng ers</w>
dil ution</w>
collec tive</w>
L ist
( a</w>
stra ight</w>
pl y</w>
c ast
recommend ations</w>
M EN
LORD ,</w>
V I</w>
remain ing</w>
diseas e,</w>
de pos
atic ally</w>
haem at
bo x</w>
(2 )
( G
% ),</w>
w ines</w>
phosph ate</w>
inter val</w>
(a ),</w>
ra ther</w>
mor n
ach es</w>
T A
it e,</w>
adv anced</w>
resid ence</w>
pri mar
admin ist
H is</w>
exten sion</w>
beh ind</w>
u k
solu tion.</w>
nigh t.</w>
k ing.</w>
bod y,</w>
proc eed
ation s;</w>
off ered</w>
f it
bl ock
respir atory</w>
n ice</w>
inc id
fi b
b its</w>
Fur ther
un n
consist s</w>
author ity,</w>
your self</w>
this ?</w>
fore ign</w>
AR T
ti s,</w>
ph eral</w>
mar g
in depend
there fore,</w>
hop e</w>
inde x</w>
consum p
common ly</w>
2 50</w>
st ep</w>
fav our
re ached</w>
a ther</w>
a mend</w>
stud y,</w>
dat a.</w>
cal end
ax el</w>
projec t</w>
lat est</w>
lam p</w>
ag e
S pec
IS O</w>
to :</w>
discontinu ation</w>
em bry
di ox
consolid ated</w>
M ea
pat ch</w>
introduc ed</w>
elim ination</w>
cla im</w>
b all
as .</w>
aer odro
E X</w>
br an
ut ory</w>
ill s</w>
ION S</w>
pre pare</w>
f el
add ed:</w>
surviv al</w>
k i
cho ice</w>
B as
adv ised</w>
month s.</w>
gro ss</w>
b ig
ster oid
mat ory</w>
initi ation</w>
hydro carb
ha ven
Th ank</w>
eas ily</w>
Isra el
we 'll</w>
no ,</w>
g ,</w>
el se</w>
ad d</w>
) -
in e-
down ,</w>
B ased</w>
remov al</w>
p s,</w>
in k</w>
5. 1).</w>
pen al
flu id</w>
ell a</w>
dist urb
deleg ated</w>
fe at
ec ts</w>
as s.</w>
g ri
dou bl
bel ow.</w>
al f
air port</w>
show ing</w>
res c
fall ing</w>
cell ul
rec ycl
k ?</w>
g er</w>
diabet es</w>
att ached</w>
T ur
G e
primar ily</w>
at es,</w>
adequ ately</w>
poll ution</w>
est ,</w>
combus tion</w>
alloc ation</w>
abdom inal</w>
- 1</w>
require ments.</w>
( n
th an
r ab
p ast</w>
enti ty
cre ate</w>
chec ked</w>
pow ers</w>
haem orrh
war ning</w>
initi ated</w>
contrib ution</w>
ste ad
ex act
ef for
concern s</w>
v ar
t ell
excre ted</w>
bar ri
author ization</w>
we ak
ro ad
appe ars</w>
allow ances</w>
Rep ublic</w>
under taken</w>
techn ology</w>
on s.</w>
c ar</w>
al most</w>
C ateg
0 )</w>
nam ic</w>
mark ets</w>
fo od.</w>
(4 ),</w>
regi on</w>
inst e
expo sures</w>
th ing
im plemented</w>
diseas e.</w>
4 5</w>
r ine</w>
ep ti
class es</w>
resist ant</w>
represent atives</w>
fin ished</w>
af ter
f en
disord ers</w>
am mon
ful fill
2 9</w>
sum mary</w>
mer ic
health care</w>
I P
ser i
harm ful</w>
suppor ting</w>
proper ly</w>
b ook</w>
transp aren
reg ist
eth an
tri d
may be</w>
al -
per sist
m /
j e
Ser v
produc ing</w>
feeding stuffs</w>
S ,</w>
M A
2 /EEC</w>
ref rig
th el
plac es</w>
deliv ery</w>
ten ofovir</w>
regi ons</w>
c ot
Pro c
en ever</w>
H ow
tr act</w>
poll ut
per missible</w>
build ing</w>
A meric
ml /
fl igh
el f</w>
H el
multi -
ind ent</w>
Tw o</w>
metabol ism</w>
rec ent</w>
bat ter
( 4.
metabol ites</w>
ro le</w>
hol d,</w>
S .</w>
E N</w>
specific ally</w>
h un
U p
go es</w>
G od.</w>
Fin anc
Commun ity.</w>
200 9/
mob ile</w>
inter pre
transf erred</w>
g ent
enzy me</w>
week s.</w>
w ood</w>
perman ent</w>
lit az
compl ies</w>
administr ation.</w>
L -
B r
200 4/
th ous
n ess.</w>
head ing</w>
ur ation</w>
m igh
Li ke</w>
AU C</w>
um -
milli on</w>
hi stor
as :</w>
prob ably</w>
peo ple,</w>
m u
on ly.</w>
allow ing</w>
O s</w>
th r
b and</w>
anim als,</w>
Commit te
C a
op a
c ity</w>
usef ul</w>
increas ing</w>
t )</w>
pow ered</w>
fi er</w>
y ed</w>
hum ans</w>
h and,</w>
t in
st ock</w>
bl e.</w>
aud it
h ell</w>
d ers</w>
ras h</w>
fol d</w>
a king</w>
su n
m 2</w>
sit es</w>
reduc ing</w>
ow s</w>
off er
odi c</w>
conclu sions</w>
prop yl
oc cas
ex tre
cr yst
su d
dis sem
su sc
neutro pen
ed s</w>
cor d</w>
as i
s tic
aircr af
m ig
7 6/
satis fact
r y.</w>
fac ility</w>
the e,</w>
ne go
f igure</w>
t ary</w>
record ing</w>
k -
fic ation,</w>
under stand
fri end</w>
em ption</w>
C or
l e.</w>
tract or</w>
heal th,</w>
happen ed</w>
fa ther
en ed</w>
be fore
ver tical</w>
gran ting</w>
a :</w>
valid ation</w>
haven 't</w>
expendit ure</w>
col d</w>
c e.</w>
gastro intestinal</w>
defini tions</w>
alloc ated</w>
S up
Financ ial</w>
E G
posi tions</w>
el s,</w>
any one</w>
Further more,</w>
it self</w>
g ases</w>
dam n</w>
I G
M ake</w>
st abil
are :</w>
y !</w>
pos t</w>
pig s</w>
( R
min or</w>
ap pointed</w>
adv anta
Produc t</w>
ton n
mechan ical</w>
is es</w>
difficul ty</w>
r ation</w>
n ings</w>
coun ter
cap sule</w>
O D
nego ti
er :</w>
M ax
9 0
3 3
ic ation</w>
chos en</w>
calend ar</w>
tr a
k e,</w>
communic ations</w>
st able</w>
consid ers</w>
wat ch</w>
medi um</w>
Manag ement</w>
refl ect</w>
issu es</w>
inj ur
( h
machin es.</w>
dil uted</w>
Techn ical</w>
tu be</w>
opidog rel</w>
comp ounds</w>
al though</w>
R ap
(E 17
upd ated</w>
issu ing</w>
ar c
6 7
ti es.</w>
ot h</w>
fun g
in cur
i x</w>
dos si
M at
(b ),</w>
thereof .</w>
eg u
ag ency</w>
King dom</w>
( if</w>
t own
oun d.</w>
nes ium</w>
mach ines</w>
in clusion</w>
ti m</w>
contract ual</w>
me ets</w>
har m</w>
en em
E ff
sp ar
Tal k</w>
M il
w ell,</w>
other .</w>
m ir
est .</w>
b ag
acc ess
Par agrap
separ ately</w>
reconstitu ted</w>
hum an
deliv er</w>
c ouldn't</w>
Stand ard</w>
200 0/
199 9/
with draw</w>
h und
exclu sively</w>
I X</w>
on d
gener ation</w>
fuc k</w>
freed om</w>
St ud
n er.</w>
ro lim
observ ations</w>
n ame
telecommunic ations</w>
car trid
ul e</w>
itab ine</w>
i )</w>
bro ad
F OR
develop ments</w>
h er,</w>
de al</w>
4. 5).</w>
pil ot</w>
ox id
hy th
af en
n ers</w>
er s;</w>
comp ound</w>
S ci
sa ith</w>
AC E</w>
you 'd</w>
interest ed</w>
f ing
award ed</w>
T ri
vo ice</w>
purch as
appl y.</w>
Syst em</w>
beau ti
9 6/
or ation</w>
bl ister</w>
S y
ver ,</w>
rub ber</w>
e k
MRL s</w>
Ch ec
re ven
ro und</w>
os e,</w>
knowl edg
house .</w>
divid ed</w>
al ities</w>
vehicl e,</w>
fertil ity</w>
f le
establish ments</w>
ari an</w>
( p
require ments,</w>
pre f
correc tive</w>
ar ity</w>
F igure</w>
ver sion</w>
exten d</w>
contain ers</w>
7 0</w>
p acks</w>
gu ess</w>
S ch
Con tro
parti al</w>
in ing</w>
high ly</w>
f ar
E EC</w>
A V
t ing,</w>
st ability</w>
peri pheral</w>
ex emption</w>
con g
co- administered</w>
B .</w>
visi ble</w>
te am</w>
exam ine</w>
end -
a wa
On ce</w>
stom ach</w>
fir st
exc ess</w>
whe el</w>
sl igh
pre dic
placebo -
im posed</w>
giv es</w>
en abl
struc tures</w>
ri de</w>
m m
autom atic</w>
ar ch
t :</w>
hypo ten
exact ly</w>
Jour nal</w>
H IV
6 5</w>
ves sel</w>
tissu es</w>
form ed</w>
cho ose</w>
air worthiness</w>
il e
fi ed,</w>
b id
E r
3 5</w>
iv ers
cycl es</w>
R equi
C C
ativ ely</w>
sing le-
ni tion</w>
N et
ta int
sm all
om ic</w>
occurren ce</w>
ment s;</w>
ard ,</w>
ang ible</w>
M y
M L
P V
we ar</w>
cons ist</w>
y tic</w>
prec i
op tim
gir l</w>
estim ate</w>
6 8
4. 4</w>
wh ol
thi az
sup posed</w>
re sol
therap y,</w>
reta il</w>
pre mi
particular s</w>
E very</w>
B el
pres ents</w>
m s,</w>
form al</w>
compl ying</w>
3 8
subm ission</w>
some thing.</w>
prec eding</w>
mov ing</w>
that :</w>
inf ants</w>
uc k</w>
no te</w>
es '</w>
al one.</w>
ag liptin</w>
y s.</w>
Isra el,</w>
6 )</w>
hypo glycaem
f ell</w>
here in
bat ch</w>
saf egu
C lin
wr ong</w>
tion :</w>
substanc es,</w>
qu in
publ ish</w>
cl ari
P or
life -
identi ty</w>
decid ed</w>
N S
k e.</w>
our s</w>
dat e.</w>
concer n</w>
ac commod
Stand ing</w>
.. .
beli ev
sch o
present ation</w>
ol der</w>
frequ ently</w>
9 3/
sp e
B et
tain s</w>
oph il
flow s</w>
Q U
ment s:</w>
g un
fl ic
e ously</w>
ass es</w>
r ated</w>
proc ure
foo t
fil es</w>
dis pos
col our</w>
bl eed
belong ing</w>
activ ities,</w>
( V
f ight</w>
accum ul
B .
tem p
com pres
aqu atic</w>
allow s</w>
adjust ments</w>
An imal</w>
9 5/
tom or
ta m
prin ted</w>
r an</w>
ap ine</w>
um ),</w>
re al
off ering</w>
ner v
cri tical</w>
qu ick
na me,</w>
fi f
extr act</w>
cul tural</w>
out come</w>
ativ e,</w>
anti bodies</w>
3 ,
( g)</w>
cer taint
calibr ation</w>
a ;</w>
situ ated</w>
microgram s</w>
com men
ter s,</w>
tel eph
studi es.</w>
stre am</w>
mut ual</w>
ma ster</w>
Program me</w>
particip ating</w>
h es
c el
200 6/
supplement ary</w>
pre fer
modi fication</w>
go ,</w>
categ or
E P
9 5</w>
le ased</w>
exerc ised</w>
dou ble</w>
arth ri
acces sible</w>
You 'll</w>
tablet s.</w>
ra il
pass ed</w>
occur s</w>
contrib utions</w>
pe ak</w>
g ol
assess ing</w>
ab norm
D ose</w>
where as,</w>
pr int
ment ation</w>
issu er</w>
a stronom
EU /
d enti
l and,</w>
impair ment.</w>
doctor ,</w>
S E</w>
O r</w>
ver .</w>
termin al</w>
r ,</w>
for th</w>
C ould</w>
200 3</w>
stand ardis
program m
medic ine.</w>
f ab
sti mul
org an</w>
me d.</w>
i or</w>
hydrocarb ons</w>
h ow
ep id
de grad
affec ting</w>
Ch ild
6 /EEC</w>
transm itted</w>
n one</w>
addi tiv
si t</w>
los ses</w>
hor iz
e (s)</w>
a ul
% ).</w>
what ever</w>
susc epti
em bol
avir ,</w>
El ec
3 4
stu ff</w>
pl ung
e ties</w>
ac id,</w>
F il
up date</w>
qu ar
observ ed.</w>
mil k.</w>
T otal</w>
EU R</w>
E ar
Categ ory</w>
wom en.</w>
iv er
consist ing</w>
and s</w>
activ ated</w>
S elec
5 5
3 6</w>
tr ation</w>
sol d</w>
p u
becom es</w>
az ep
a es
k er</w>
ic s</w>
herein after</w>
f igh
d ex
P et
(* )</w>
pr ic
let 's</w>
intr a-
hold s</w>
A ug
sp read</w>
law .</w>
compet ence</w>
wal k</w>
th yro
sal es</w>
f ever</w>
di e</w>
S k
investig ation</w>
C A
1 %</w>
to ols</w>
p anc
elder ly</w>
- to-
mat ters</w>
bet a-
end ,</w>
det ected</w>
purch ase</w>
over dose</w>
mot or
G o
C entr
struc tural</w>
f oc
substanti al</w>
s pl
propos als</w>
provid ed.</w>
cir cul
Al though</w>
lat eral</w>
carri age</w>
t ap
lun g</w>
is ed,</w>
fo ods</w>
apparat us</w>
a be
my el
fe e</w>
es ti
compens ation</w>
1 ),</w>
- 2
peri odic</w>
ou s,</w>
ing ent</w>
avi ren
p iv
individu als</w>
import ance</w>
ar y,</w>
approxim ation</w>
Annex ,</w>
sul f
some times</w>
de part
AC T
ing )</w>
fe es</w>
Ad verse</w>
u tr
pro of</w>
enforc ement</w>
91/ 4
simul tan
scre en</w>
chemic als</w>
C D
Wh ile</w>
Des cription</w>
s on,</w>
re .</w>
princip al</w>
lic en
clean ing</w>
b y
Directiv e;</w>
200 4</w>
repor ted.</w>
pack ag
( ‘
re solution</w>
gly cer
func tion.</w>
cross- border</w>
comp ul
vehicl e.</w>
iti me</w>
T y
c raz
bl e,</w>
trav el</w>
dest ination</w>
M od
L a
remain s</w>
probl em</w>
mor ning</w>
it ch</w>
i ons</w>
him ?</w>
nitro gen</w>
know s</w>
S m
C )</w>
over sight</w>
fir m</w>
P RE
7 7/
the tic</w>
on :</w>
es ).</w>
por tion</w>
po or</w>
oles ale</w>
dis play</w>
day s,</w>
anta gon
am in</w>
aero plan
pre ven
enzy mes</w>
an aphy
ste el</w>
sligh tly</w>
se iz
O K
Comm on</w>
st a
ric h
f it</w>
chemo therapy</w>
absol ute</w>
S yn
Requi re
D el
A F
tion )</w>
o si
ear th</w>
a rent</w>
L u
hold ings</w>
govern ment</w>
Produc ts</w>
o g</w>
hydrox y
regi men</w>
ex plan
A ll
200 2</w>
pre mis
lac tic</w>
g ar
continu ing</w>
environ ment.</w>
design ation</w>
M o
wind ow</w>
car d
Agre ement</w>
loo ked</w>
( petrole
S tr
L ist</w>
L ab
L .</w>
ol ed
g ed</w>
ex p
consul t</w>
con clusion</w>
thresh old</w>
prohi bit</w>
per f
minut es.</w>
la x
g od
syndro me</w>
suspec ted</w>
resul ted</w>
piec e</w>
mol ec
s low
ques tions</w>
fiel ds</w>
f ,</w>
al g
P R
C ,</w>
10 0
deb t</w>
organ iz
heav y</w>
conf ig
E con
E L</w>
ust ed</w>
referen ces</w>
phen yl
m osph
coord in
amend ment</w>
y s,</w>
s on.</w>
rev ised</w>
refrig er
tr ue</w>
rec ip
le uk
repa ir</w>
mo ther
v el
group .</w>
eng ine
str ong
me tic</w>
inhi bition</w>
h ast</w>
c u
rap id
indic ator</w>
alf a</w>
ol ution</w>
keep ing</w>
fu sion</w>
f ine</w>
I )</w>
to m</w>
ord ers</w>
oled ronic</w>
es cap
m iti
h ot
dis closure</w>
d ut
bur n
bl ind
at ories</w>
P ut</w>
(3 ).</w>
jo int
gr ade</w>
bod y
al fa
act u
m am
acquisi tion</w>
Uni on,</w>
Stud y</w>
mess age</w>
activ ities.</w>
Com pet
iti z
direc tion</w>
cor tico
comm and</w>
C o-
t ings</w>
ay ed</w>
an hydro
C od
(petrole um),</w>
vol u
v ap
tr adi
measure s.</w>
exc essive</w>
ex por
encour age</w>
consid ered.</w>
ci pi
b ow
II I.</w>
pre domin
plan ning</w>
tw o-
righ te
pre hen
os is,</w>
li e</w>
conj unc
cr aft</w>
am bi
ul l</w>
associ ation</w>
s ick
re x
acc ept</w>
subst ance,</w>
sion s,</w>
no tic
man ual</w>
flav our
e e</w>
c it
c ast</w>
V ir
B u
sensi tive</w>
St u
i o</w>
dro p</w>
compl ied</w>
ch est</w>
ro b
particul ate</w>
Rec om
z ones</w>
ques tion.</w>
doubl e-
accid ent</w>
S M
radi ation</w>
fu els</w>
environ ment,</w>
W a
tro ubl
tar get
radi o
es ),</w>
10 .
inste ad</w>
T em
off -
know n.</w>
contraindic ated</w>
8 0
plan ned</w>
mar ine</w>
l en
effec ts.</w>
z om
rib avirin</w>
review ed</w>
over .</w>
bl ue</w>
V e
techn ological</w>
t ations</w>
mg )</w>
gr as
extr action</w>
effectiv ely</w>
charg ed</w>
vari ety</w>
list s</w>
gener ated</w>
fib re</w>
arm s</w>
ne tic</w>
EU/ 1/
wor ked</w>
vi ol
du ties</w>
compl ic
I r
sel ect</w>
se di
p eg
dev i
draw ing</w>
tum our</w>
tel es
ox et
m ill
f ill</w>
y el
quanti t
og litaz
injec t</w>
IC A
G M
4 7
t ot
con flic
Addi tional</w>
writ ing</w>
kid ne
des crib
contamin ation</w>
wr ong
si de
shoul d,</w>
rem un
ha bit
S A</w>
occur ring</w>
exam ined</w>
L E</w>
mis sed</w>
construc ted</w>
ca uses</w>
bas is.</w>
reg ister</w>
in direct</w>
valu ation</w>
v ast
statis tically</w>
oxy gen</w>
o thers</w>
my c
m er</w>
accompan ying</w>
0. 0
mand atory</w>
ent ly,</w>
V III</w>
Hy dro
8 5</w>
0. 00
self ,</w>
inter oper
f ast</w>
D )</w>
si x
request ,</w>
o ts</w>
coupl ing</w>
ba by</w>
sol ely</w>
reproduc tive</w>
at mosph
well .</w>
valid ated</w>
stop ped</w>
orm one</w>
interval s</w>
grow ing</w>
. e.
we ap
there ?</w>
hu h?</w>
d res
b os
acc el
sub s
speci al
possibl y</w>
impa ired</w>
ar g
B ut
m ell
i .</w>
g la
x il</w>
tr ust</w>
situ ations</w>
re present</w>
miti g
m ur
aw are</w>
s aying</w>
chec king</w>
toge ther.</w>
request s</w>
in put</w>
ia h</w>
dis opro
91/4 14
2 %</w>
proced ure.</w>
ne igh
meth yl</w>
inter actions</w>
ster ile</w>
m ist
proportion ate</w>
10 ,</w>
t ness</w>
stud y.</w>
sle ep</w>
ing -
chol ester
z e</w>
under standing</w>
sec tors</w>
ra ised</w>
afra id</w>
Treat y,</w>
C max</w>
t ari
sem i-
prolong ed</w>
plac e,</w>
mys elf
h it</w>
form ing</w>
ag li
lin k</w>
hol der
d ol
bl ock</w>
Ch em
0, 1</w>
im ag
anc y</w>
al ;</w>
M r</w>
H ere
suppor ted</w>
rel ate</w>
bel ow
S ocial</w>
C .</w>
2 /EC</w>
with standing</w>
here by</w>
car ton</w>
tic ip
techn ically</w>
ri x</w>
poul try</w>
horiz on
g am
er ship</w>
cod es</w>
br on
a h
U T
v oc
produc tion,</w>
nom inal</w>
anal og
og lob
authoris ations</w>
arrang ement</w>
2. 2.
k er
fum ar
We 've</w>
l ays</w>
f al
S -
E ur
let ter</w>
impor ted</w>
dou b
answ er</w>
W H
Ve hic
injec tions</w>
bas is,</w>
vari eties</w>
throm bo
exper ts</w>
' t.</w>
ti al</w>
liqu id
back ground</w>
and .</w>
an ch
C AS</w>
transp arent</w>
ta st
m erg
autom atically</w>
2 ),</w>
t un
skin ,</w>
metabol ite</w>
ful l
ever thel
ne gl
excep tional</w>
clo th
c itiz
V .</w>
ne utr
disopro xil</w>
C au
impor t</w>
compu ter</w>
W ould</w>
renew able</w>
on e-
flo z
Decisi on.</w>
infec tion,</w>
in take</w>
hosp it
expl ain
anim als.</w>
agli floz
lik e,</w>
i e</w>
compar ison</w>
T )</w>
Speci fic</w>
R is
sugg est</w>
recip i
om er
min eral</w>
de ad.</w>
writ e</w>
test ,</w>
no t.</w>
dis sol
Tran s
c um
O l
5. 3).</w>
200 0</w>
se x</w>
schedul ed</w>
ful fil
anti bio
With in</w>
precau tions</w>
e. g
dis pen
We ek</w>
provisi onal</w>
o thiaz
mono therapy</w>
mg ,</w>
iti s,</w>
al ia,</w>
M yl
An y
vomit ing,</w>
indic ations</w>
bu ilt</w>
V ,</w>
C re
responsibil ities</w>
o st
mono hydr
follow -up</w>
Gro up</w>
6 00</w>
raz ole</w>
l e,</w>
earli er</w>
an z
abil ity,</w>
9 9
su me</w>
self- employed</w>
plung er</w>
nam ed</w>
mod els</w>
in a</w>
colour less</w>
St atis
Europ e</w>
ul ti
rec ur
ot ype</w>
mom ent</w>
diagno stic</w>
dens ity</w>
com prehen
chec k
bir th</w>
Econ omic</w>
tic s.</w>
sal ts</w>
re place</w>
proc ess.</w>
har vest
h ormone</w>
S ur
iv udine</w>
id en
fi br
de fault</w>
cov ers</w>
(7 )</w>
struc tion</w>
s cr
are st</w>
air space</w>
Ph il
Aug ust</w>
4. 2).</w>
sub paragraph,</w>
adap t</w>
CYP2 C
veter in
t ure.</w>
j ust
produc er</w>
it or</w>
ev en
dar k</w>
ch ance</w>
but ton</w>
breast- feeding</w>
an k
activ ation</w>
accum ulation</w>
resid ent</w>
re memb
pri ority</w>
intro duce</w>
di ver
custom er</w>
vehicl es,</w>
thin king</w>
effec ts,</w>
c ed</w>
O ver
y lic</w>
ref use</w>
countri es,</w>
mone y.</w>
incur red</w>
hal er</w>
h id
grap e</w>
B AT</w>
sh ar
ph one</w>
log ical</w>
loc k</w>
bra ke</w>
6 5
sor ry</w>
retur ned</w>
random ised</w>
procure ment</w>
p s
op tions</w>
le aving</w>
ic h</w>
fat al</w>
dem and</w>
auc tion</w>
Rem ove</w>
ta r</w>
dis ci
g ain</w>
fl ex
do ,</w>
b ar</w>
V II</w>
Ap pro
wh enever</w>
th s</w>
th ing?</w>
ity )</w>
end or
) )</w>
us al</w>
stit ute</w>
s ess
ev id
bri d
break down</w>
Ev en</w>
od y
me tal
c ent</w>
acqui re
W ill</w>
x i
vehic le
mus cl
mag netic</w>
m it
C ode</w>
C -
th ine</w>
oul d
naus ea,</w>
n ic
invest ments</w>
h ex
frequ ent</w>
shor t-
n aph
ml )</w>
according ly.</w>
P A
B ab
satis fied</w>
s ell</w>
platel et</w>
pl aying</w>
in s,</w>
fur n
const ant</w>
bro w
Con ven
volun tary</w>
reli able</w>
house ,</w>
feat ures</w>
bro ther</w>
ail ed</w>
Un der</w>
Counc il,</w>
procedure s,</w>
ov ascular</w>
minim ise</w>
includ e:</w>
daugh ter</w>
vacc in
si lic
recogn ise</w>
lab elled</w>
indic ates</w>
h ate</w>
c yl
S al
worl d.</w>
medi a</w>
mag nesium</w>
f arm</w>
M ore
Compet ent</w>
n ar
AIF M</w>
sent ence</w>
sch ool</w>
manag ed</w>
l od
assembl y</w>
Bre ez
particip ate</w>
di ame
comp il
aim ed</w>
accep t
Sci entific</w>
3 5
no ted</w>
nigh t,</w>
m in</w>
e ments.</w>
back ,</w>
Mos es</w>
200 7/
bu y</w>
L ar
Clin ical</w>
vi als</w>
is ual</w>
Spec ial</w>
Administr ative</w>
w av
tou ch</w>
on set</w>
cl ust
Th e
Ac cord</w>
surg ery</w>
sof tw
se ment</w>
otox ic</w>
me !</w>
market ed</w>
financ ing</w>
exceed s</w>
communic ated</w>
I X
H B
vis it</w>
exist ence</w>
ethyl ene</w>
R om
In cre
B ri
ex port</w>
C our
y iel
sulph ur</w>
guarante es</w>
func tion,</w>
em ,</w>
def ine</w>
ass ist</w>
aerodro me</w>
R u
Chec k</w>
8 -
” .</w>
ri fic
istr y</w>
impor ts</w>
cou ple</w>
Commis sion
Administr ation</w>
Ac t</w>
ro t
behavi our</w>
b e,</w>
appe ar
U )</w>
quali fications</w>
leaf let</w>
ir ,</w>
hund red</w>
ent y</w>
con form</w>
all eng
Hum an</w>
ord inary</w>
ocyt open
me al</w>
A -
y ea
suppli er</w>
post- marketing</w>
ot e</w>
mechanis ms</w>
er y,</w>
em .</w>
bene fici
ba g</w>
author ities.</w>
R A</w>
tl e.</w>
oil s</w>
er ror</w>
k ling</w>
head .</w>
again ,</w>
Ob serv
IU /
Gr ade</w>
Cau tion</w>
dist inc
G en
mar ri
ev il</w>
aem ia,</w>
P ow
Max imum</w>
I rel
A N</w>
4 50</w>
op o
il eg
appropri at
surve y</w>
subsequ ently</w>
so di
recep tor</w>
le ts</w>
et axel</w>
bra in</w>
ac ted</w>
w all
ste ering</w>
pre vent
offici ally</w>
en jo
O T
EC T
Char acter
wa iting</w>
t elling</w>
qu ite</w>
1 :</w>
viv o</w>
produc ers</w>
pro ph
me ;</w>
b e.</w>
D ue</w>
open -
it es,</w>
ter s.</w>
refl ec
micro- organis
lif e,</w>
le y</w>
invol v
M iss</w>
4. 3).</w>
week ly</w>
ta ge</w>
play ed</w>
open ed</w>
low -
am s</w>
Co- administration</w>
tion ally</w>
put ting</w>
en vis
P D
um s</w>
sh it</w>
EE A</w>
pre v
non- discrimin
brea thing</w>
accur acy</w>
gre en
EN T
tis ing</w>
t s;</w>
sh ot</w>
la un
ist s</w>
d le</w>
M ost</w>
3. 1.
fibre s</w>
d ;</w>
pres s</w>
manufacture r.</w>
lo g</w>
alcohol ic</w>
w ild
ri ver</w>
mys elf</w>
it ud
En gl
require d,</w>
ic op
cryst all
ac tion.</w>
if t</w>
compl ain
ch ain</w>
w it
sw ine</w>
sustain able</w>
mar ks</w>
gre en</w>
ac tion,</w>
] .</w>
7 0
spi rit</w>
ent h</w>
egg s</w>
author iz
S odium</w>
Ne ther
tak en.</w>
p in
other ,</w>
ind er</w>
deriv ative</w>
A tt
4 5
volun te
st ages</w>
read ing</w>
ong ue</w>
mil itary</w>
eas y</w>
Ad d</w>
sur round
reac tions,</w>
perform ing</w>
improv ed</w>
fl un
appli ances</w>
acet ate</w>
B er
9 7/
ot yp
hor mon
ef aviren
dist ingu
S um
veri fied</w>
tel ev
fa ec
M i
whic h
scre ening</w>
key s</w>
integr ity</w>
il s</w>
dis close</w>
st air
na me.</w>
m L
au l</w>
se ems</w>
repor t.</w>
metabol ised</w>
favour able</w>
ex ist</w>
dri ed</w>
T ra
th ank</w>
satisfact ory</w>
on ;</w>
iz umab</w>
head ach
N ame</w>
E ,</w>
tl y,</w>
reason ably</w>
rapid ly</w>
physici an</w>
out ?</w>
man age</w>
in sufficient</w>
dig ital</w>
sign al</w>
ligh ting</w>
ch ick
3 %</w>
sec ur
me d,</w>
low est</w>
d uly</w>
accoun t.</w>
enterpris e</w>
bl oc
technolog ies</w>
st ore
spec tr
pres crib
hy gi
de par
datab ase</w>
cre ated</w>
as one</w>
alk al
ag ree</w>
relev ant,</w>
fla g</w>
de ep</w>
azol e,</w>
adap ted</w>
Nether land
Contro l</w>
se aled</w>
rec ov
ras h,</w>
inc in
hear t
benz o
S ev
tu red</w>
trans plan
improv ing</w>
examin ations</w>
e.g .,</w>
b uc
Selec t</w>
pro mp
det eri
ar ri
ar om
with .</w>
sl ud
i an</w>
children .</w>
P har
ti ous</w>
tak e-
spac es</w>
sp or
qu e
B e</w>
s ory</w>
method ology</w>
dis charge</w>
O S
regard less</w>
indic ators</w>
friend .</w>
four th</w>
cy to
carb on
O ur</w>
tri ed</w>
separ ated</w>
on to</w>
mal ign
E d
As sess
won der
re plic
gl ass
ec h</w>
at inib</w>
acid s</w>
subjec ted</w>
rolim us</w>
pneum on
dat e,</w>
certaint y</w>
bre eding</w>
b ound
Medic ines</w>
G al
C /
system s.</w>
metre xed</w>
me ter</w>
er cul
employe e</w>
7 5
ur inary</w>
induc tion</w>
fr act
ex chang
Stu dies</w>
M et
tre ating</w>
s ick</w>
l us
estim ates</w>
c .</w>
bor ne</w>
applic abl
Commun ity
int angible</w>
en ough
confir m</w>
Gu id
t ing.</w>
invol ve</w>
comm un
her it
ack .</w>
In dic
I A</w>
stop per</w>
sac rific
bu ild</w>
al isation</w>
sulph on
strateg y</w>
ra ise</w>
labor atories</w>
induc ed</w>
id omide</w>
em ic</w>
e ight</w>
Wh ite</w>
H ere</w>
subsidi ary</w>
se g
p ac
o con
month s,</w>
mis s</w>
wat ers</w>
par al
incorpor ated</w>
eng aged</w>
des crip
ch alleng
speci ally</w>
ne arest</w>
n y</w>
f ati
ep is
d er.</w>
at es.</w>
ap point
4 4
2. 1</w>
set tlement</w>
inflam matory</w>
sim ple</w>
schedul e</w>
man u
ligh t.</w>
im pose</w>
difficul t</w>
c ation</w>
S O
19 6
- P
u til
an ts.</w>
- off</w>
tex tile</w>
public ly</w>
on ly
intermedi ate</w>
id ea</w>
fertil is
ag ul
S pi
l ose</w>
death .</w>
coun ts</w>
addres sed</w>
Paragrap h</w>
Articl e,</w>
ure a</w>
now ?</w>
form er</w>
el ement</w>
control .</w>
Pre par
st ing</w>
rec ently</w>
long itud
dis cre
Myl an</w>
200 8</w>
z on
stat utory</w>
sm oo
lab our</w>
half- life</w>
friend s</w>
ell ing,</w>
d ates</w>
co ff
P ur
In t
un likely</w>
sim pli
posi tion.</w>
ot ec
mac ro
le ak
ang er</w>
Jo int</w>
70/ 15
un known</w>
tion s;</w>
sec ure</w>
room .</w>
h is
well -
solv ency</w>
id one</w>
ep il
cool ing</w>
co- administration</w>
ad just</w>
R et
weigh ted</w>
prohibit ed</w>
oc ardi
hap pen</w>
calcul ate</w>
200 5</w>
ha v
calcul ating</w>
3 /EC</w>
(n =
what ?</w>
safet y,</w>
etc .</w>
approv al,</w>
Ph ase</w>
correc tion</w>
F ren
1. 5</w>
weigh ing</w>
ti gh
quantit ative</w>
mor tal
fe et</w>
ent ries</w>
el i
difficul ties</w>
conf idence</w>
bl u
Treat y.</w>
v or
fem al
d educ
In f
you !</w>
curren cy</w>
con sent</w>
con sec
commit tee</w>
anti body</w>
S ME
h at
S ha
w et</w>
servic e,</w>
priv ileg
g ing</w>
exemp ted</w>
eren t</w>
2003/ 87
inc en
ig nition</w>
cardi ovascular</w>
accred itation</w>
u v
r h
oun d,</w>
ol ate</w>
ligh t-
igh t,</w>
caref ul</w>
mol lus
li able</w>
erg y</w>
equip ment.</w>
epil ep
di abe
on ?</w>
l ate</w>
grad u
c row
c on</w>
200 6</w>
w ild</w>
restric tion</w>
infec tion.</w>
er y.</w>
do ors</w>
competi tive</w>
ari a</w>
Cont ents</w>
t les</w>
sever ity</w>
mov ed</w>
invest ors</w>
for th
est ed</w>
ery thro
ers '</w>
enter ing</w>
ax le</w>
att ach
Stat es;</w>
In tr
3 2</w>
(ii i)</w>
month ly</w>
if ying</w>
ic al,</w>
her b
c og
aglifloz in</w>
Sw ed
P res
Mic ha
(a )
where by</w>
tempor ar
relev ance</w>
at temp
ass ay</w>
Lord .</w>
I denti
I cel
ti tle</w>
promot ing</w>
was h</w>
ograp h</w>
iti es;</w>
pri ate</w>
li z
li ves</w>
imp act
hom ogen
OB D</w>
0 .</w>
in ess</w>
an s,</w>
slaugh ter
7 )</w>
vir t
prefer ably</w>
im bur
happ y</w>
gly co
bec ame</w>
reduc tions</w>
r ad
manufacturer ,</w>
c are
blo od
a ?</w>
T ime</w>
S how</w>
sp ot</w>
program me,</w>
n al
bab y.</w>
flo or</w>
20 10</w>
t ory</w>
t ing
dail y.</w>
d s,</w>
conven tional</w>
compos ed</w>
transparen cy</w>
t ask</w>
m b
ad vis
L y
Breez haler</w>
tan k</w>
aero plane</w>
R en
no ver</w>
f ever,</w>
drin king</w>
com e.</w>
c is
belong s</w>
W om
O EC
transi ent</w>
str ain</w>
prom ised</w>
pic k</w>
iv er</w>
i bility</w>
custom ers</w>
circ ulation</w>
author ise</w>
oedem a</w>
injur y</w>
deriv atives</w>
correc ted</w>
activ ity.</w>
Pati ent</w>
sen sitivity</w>
lin e.</w>
level s.</w>
es tive</w>
Net work</w>
- time</w>
pres sure,</w>
gover ned</w>
Pe o
N -
syring es</w>
suppl ies</w>
respectiv ely,</w>
predomin antly</w>
own er</w>
ov ere
l .</w>
inter im</w>
hand .</w>
g el
dut y</w>
J ac
! ”</w>
ul ture</w>
sor i
person s,</w>
oglitaz one</w>
lic ens
in suffici
hur t</w>
form ulation</w>
et s,</w>
ery them
ch ain
200 1</w>
th en,</w>
pass ing</w>
bud get
Fir st</w>
Con comit
7 7
thre e-
re sear
plat form</w>
o ke</w>
ic .</w>
di ed</w>
bl y</w>
9 4/
sal t</w>
ea .</w>
dy sp
amin o
Concomit ant</w>
tub ercul
establish es</w>
er b
concomit antly</w>
before .</w>
assi ve</w>
N a
1 /EEC</w>
“ I</w>
oxet ine</w>
longitud inal</w>
lact ose</w>
6 9
ter n</w>
sl ow</w>
si gh
s );</w>
read ily</w>
placebo .</w>
in ner</w>
for ward
C ro
AI D
suppli ers</w>
ship ,</w>
resid ual</w>
m s.</w>
legisl ation,</w>
iv es</w>
hy p
horizon tal</w>
form ,</w>
fl ask</w>
AI F</w>
test s,</w>
sh op
proced ure,</w>
fic ation.</w>
defici ency</w>
Meth od</w>
tomor row
speci fication</w>
re leased</w>
injec ted</w>
est ro
de al
ag o.</w>
I D</w>
y c
re imbur
l ys
every one</w>
countr y.</w>
contracep tion</w>
be at</w>
there by</w>
sh all
respon d</w>
countr y,</w>
coun ting</w>
whe el
ol er
fro z
en sures</w>
em tric
effec t.</w>
ec o-
net work
j ur
fa ith
el se
ec h
com e,</w>
S he
/E U</w>
w /
u ble</w>
t own</w>
st up
otox icity</w>
is e,</w>
invest or</w>
fam ili
fail ure,</w>
bi om
A bra
tod ay.</w>
pur ity</w>
origin ating</w>
fund ing</w>
ambi ent</w>
R T
Ch ang
A vi
8 5
y ).</w>
vom iting</w>
abov e,</w>
Pro v
(5 ),</w>
some body</w>
re ten
eph al
anc es.</w>
xim ab</w>
we 've</w>
thresh ol
i tion</w>
hydrox ide</w>
dis comfor
b ed
a meth
L im
Character is
treat ment
sta ke
see ing</w>
p un
ogen icity</w>
glob al</w>
circ u
1. 1</w>
ur it
low ering</w>
l es,</w>
1 A
time -
e at
bo y</w>
st ear
sor ry,</w>
mis sing</w>
me tr
fi x</w>
diarrho ea,</w>
bur den</w>
t ed:</w>
il li
ex cipi
ess ed</w>
do ?</w>
analys es</w>
P reg
1 20</w>
st on
pow er
Stat e;</w>
Ma j
D NA</w>
4 %</w>
ol l
m ate</w>
know ?</w>
g ame</w>
ever .</w>
D ,</w>
Articl e.</w>
shoo t</w>
restric t</w>
oglob in</w>
list en</w>
dossi er</w>
achiev ing</w>
M om
I T</w>
( hereinafter</w>
v enti
typ e,</w>
sch e
ICA O</w>
D E</w>
Al ways</w>
A ar
fl es
ex hi
call s</w>
Jud ah</w>
D oes</w>
war far
tow ard</w>
represent ing</w>
k ers</w>
fin ding</w>
cum ul
Ref erence</w>
8 /EEC</w>
und es
tr ack</w>
tabl e.</w>
modi fications</w>
m )</w>
docu mented</w>
D en
veget able</w>
tre n
ru min
r s.</w>
premis es</w>
e ith
destro y</w>
b is
anhydro us</w>
P ers
s n
rul e</w>
pul l</w>
im ages</w>
dis p
compul sory</w>
bl ind</w>
IV ,</w>
Ch ris
tl y.</w>
st ation</w>
s anc
prospec t
moun ted</w>
div ision</w>
distrib ut
busin ess
anti retro
alfa -2
t !</w>
st o
sion s.</w>
lay er</w>
ist .</w>
absor bed</w>
M ag
G over
200 9</w>
0 2</w>
/EEC ;</w>
hel icop
arm a</w>
ack ed</w>
abov e
EC E</w>
9 8</w>
' .</w>
whil st</w>
syring e.</w>
re mot
exclu sive</w>
c ob
ach ,</w>
Nov o
t et
iden tical</w>
do x
cy t
cros s</w>
ator .</w>
administr ation,</w>
accur ate</w>
K ing</w>
y er</w>
y a</w>
w all</w>
pe p
int ell
i er</w>
gen etic</w>
t on.</w>
sit e.</w>
ish ,</w>
formul a</w>
def erred</w>
d ust
comprehen sive</w>
aes thes
Cl opidogrel</w>
wor sen
so .</w>
monit or
enabl ing</w>
servic e.</w>
reac tions.</w>
p ha
constitu ents</w>
Jo h
IM O</w>
Chri st
( may</w>
ish es</w>
consign ment</w>
con sci
AT C</w>
x .</w>
ton ight.</w>
stop ping</w>
ograph ic</w>
main taining</w>
func tion
fir ms</w>
educ ational</w>
cro ps</w>
accept ance</w>
- free</w>
withdraw n</w>
thous and</w>
standard s.</w>
mov ements</w>
degrad ation</w>
Sh ould</w>
wee k.</w>
tiv ely</w>
penal ties</w>
objec ts</w>
langu ages</w>
in s.</w>
h ood</w>
cos metic</w>
Tit le</w>
Assess ment</w>
- on</w>
st ocks</w>
ref ers</w>
ec t
custom s</w>
compart ment</w>
Tel es
sti p
spar kling</w>
pri or
pay able</w>
occup ational</w>
det ect</w>
c ad
Fl av
p p
mou th,</w>
in '</w>
ill us</w>
des cribe</w>
An ti
w ards</w>
particl es</w>
c oc
al iv
S E
P leas
M ac
De fin
susp ended</w>
marg in</w>
fo od,</w>
egr ad
as is</w>
Sum mary</w>
It al
ra in</w>
is )</w>
di d.</w>
cul ture</w>
bir ds</w>
L oc
D ate</w>
3 9</w>
v is</w>
ship .</w>
pro mis
placebo- controlled</w>
S p
Mon it
M al
influ enza</w>
consid ering</w>
combin ations</w>
co h
Sec urity</w>
K y
mar itime</w>
n as
li vest
compar ative</w>
any thing.</w>
under stood</w>
one 's</w>
lo dip
activ ity,</w>
a p</w>
un able</w>
termin ation</w>
s mar
es !</w>
R us
sp ring</w>
ric h</w>
remun eration</w>
procedure s.</w>
is o
es tion</w>
em i
AT E</w>
* ,</w>
vacc ines</w>
sur pris
renew al</w>
off ,</w>
oc ular</w>
no .</w>
metabol ic</w>
hand le</w>
g old</w>
car .</w>
al in</w>
Not withstanding</w>
IN G
ver te
progres sion</w>
diff er</w>
b um
(h )</w>
w ing</w>
o ste
mol /
dimen sions</w>
call ing</w>
C F
vari ation</w>
end point</w>
astronom ers</w>
ast ,</w>
C ER
(9 5%</w>
( k
t ed;</w>
s y</w>
common :</w>
as king</w>
applic ation.</w>
C ur
u z
thromb ocytopen
repor t,</w>
prot ocol</w>
posi tion,</w>
indu ce</w>
fir st.</w>
extre m
excre tion</w>
dis order</w>
design ate</w>
Wh ich</w>
P ot
s es,</w>
hosp ital</w>
ful .</w>
d um
a mental</w>
. A.
vol ati
por te
histor ical</w>
condition s:</w>
cellul ose</w>
catal ytic</w>
ach .</w>
P en
Ok ay.</w>
O C</w>
vot ing</w>
uni que</w>
test s.</w>
mell it
l ap
compris e</w>
ar ise</w>
ab ol
P .</w>
Min imum</w>
A re
work er</w>
st ac
panc re
iv ed</w>
fr ic
enh anc
at s,</w>
L o
H old</w>
( with</w>
tl e,</w>
s core</w>
migh ty</w>
how ever</w>
diagno sis</w>
diabe tic</w>
ca using</w>
H or
3 /EEC</w>
wash ing</w>
standard s,</w>
neigh b
bacter ial</w>
FOR M
9 5
6 %</w>
( A</w>
w ro
ul cer
tri als,</w>
t ent</w>
prote ins</w>
po ol
m os
green house</w>
distrib uted</w>
criteri on</w>
control ,</w>
can di
ag es,</w>
se em</w>
opportun ity</w>
observ ation</w>
g e.</w>
IT Y</w>
IS T
valu e.</w>
re in
mi um</w>
f ly</w>
ap parent</w>
200 7</w>
tar gets</w>
improv ements</w>
consul ting</w>
b an</w>
ag o</w>
a x</w>
Prot ocol</w>
More over,</w>
y ...</w>
s in</w>
ris k.</w>
pleas e.</w>
pen d</w>
orig in,</w>
ol f</w>
land .</w>
k n
ir ub
confidenti al</w>
us ?</w>
sud den</w>
prom ise</w>
gener ating</w>
drug s</w>
diarrho ea</w>
des p
cortico steroid
blo od.</w>
above mentioned</w>
St e
S i
B ul
mig ration</w>
legisl ation.</w>
ev ent
de gre
consequ ences</w>
al ter
" .</w>
up take</w>
techniqu e</w>
super vis
program me.</w>
id es,</w>
M ulti
p uri
ml/ min
ment ary</w>
lif t</w>
immuno suppres
emp ty</w>
con stitution</w>
cli ent</w>
air ,</w>
8 6/
speci es,</w>
se eds</w>
l ot
infu sion.</w>
Ph arma</w>
them ;</w>
te zom
substanti ally</w>
recov ered</w>
pe ac
nation als</w>
ing ing</w>
flu sh
ear th
driv en</w>
compl ex
applic ation,</w>
( e.g.,</w>
threat ening</w>
dissem ination</w>
dev ice.</w>
crystall ine</w>
N ACE</w>
Ex am
8 %</w>
syn thetic</w>
sp eed
proceed ings</w>
ob tain
in s
h am
galax ies</w>
distill ation</w>
cre ation</w>
H os
F ran
D an
Con di
CO M
ti p</w>
sid e,</w>
purpos e,</w>
i xed</w>
fun d</w>
fo etal</w>
do g</w>
affec ts</w>
Commun ity;</w>
u el</w>
sh ut</w>
if ,</w>
for ,</w>
aqu eous</w>
0, 5</w>
od egrad
k et</w>
intra- Community</w>
head s</w>
fl as
depend s</w>
R el
(c ),</w>
prot oc
pregnanc y.</w>
on y
oc occ
me t.</w>
gu e,</w>
gras tim</w>
etc .)</w>
countri es.</w>
C V
6 4
200 5/
weigh t.</w>
train ed</w>
ocardi al</w>
l ung
glob ul
conjunc tion</w>
the ore
m ic</w>
hol y</w>
compris ing</w>
bur ning</w>
Medic inal</w>
Euro stat
s co
p sori
nerv ous</w>
ar y.</w>
Accord ing</w>
sp ray</w>
s la
fi bro
fe ar</w>
di e.</w>
co ast
beauti ful</w>
arr hyth
Joh n</w>
v acu
ther n</w>
are a.</w>
al ysis</w>
ack ,</w>
D ay</w>
201 3</w>
transpor t,</w>
sw ord
interoper ability</w>
individ ually</w>
In st
D u
AN N
A ustri
kid s</w>
headach e,</w>
fat ten
ey es,</w>
ethan ol</w>
elim inated</w>
assist ed</w>
N G
J os
I ES</w>
1 /EC</w>
weigh t,</w>
str y</w>
on going</w>
In di
Cour t</w>
x ili
uri c</w>
tract ing</w>
reven ue</w>
men s</w>
mar row</w>
d ab
ap ar
ac ter</w>
Require ments</w>
Par t-
, 5</w>
( 1</w>
re ti
prevent ing</w>
oedem a,</w>
identi fying</w>
h edg
aren 't</w>
accoun t,</w>
H er
8 00</w>
valu e,</w>
ther mal</w>
pres cribe</w>
des er
abov e.</w>
D UC
A ud
s ell
ris k,</w>
mo ist
meth od.</w>
l ,</w>
fl ying</w>
coll ect</w>
arthri tis</w>
an o
administ ering</w>
P eg
sex ual</w>
sat ell
rel ap
red ness</w>
popul ation.</w>
g end
aggreg ate</w>
w s</w>
tr ain</w>
tim es.</w>
shall :</w>
os ing</w>
oper ation.</w>
dos e-
des irable</w>
c ub
bron ch
S et</w>
(3 )
small er</w>
separ ation</w>
l s</w>
expl ain</w>
b all</w>
avir /
at e)</w>
V ol
Regul ations</w>
tabl es</w>
sh it.</w>
larg er</w>
bio availability</w>
avoid ed</w>
anc h</w>
T om
S S
O ff
F lu
D .</w>
0 3</w>
t ti
s elling</w>
perman ently</w>
clear ing</w>
an ticip
( used</w>
th ings.</w>
softw are</w>
nu cle
consist ency</w>
air .</w>
S hi
Proc ed
Cer tific
3 3</w>
undes irable</w>
tradi tional</w>
min ute</w>
every body</w>
d er,</w>
and -
IN T
vari ables</w>
th ick
t ...</w>
respon ses</w>
point .</w>
mg .</w>
effor ts</w>
cap rine</w>
as th
temporar ily</w>
sp ok
s car
ques tion
purpos es,</w>
pri est</w>
it s,</w>
fumar ate</w>
ammon ium</w>
B L
v ary</w>
re strain
r ate,</w>
li ke
ir respective</w>
for .</w>
expen ses</w>
etc .
assess ments</w>
al ign
Peo ple</w>
interf erence</w>
in land</w>
ig il
hydro gen
form .</w>
er ic</w>
b iv
appropri ately</w>
transf ers</w>
sp ort</w>
serv ant</w>
period ically</w>
ov isual</w>
answ ered</w>
undertak ing,</w>
thro w</w>
t ug
si c</w>
neutropen ia</w>
fligh ts</w>
e ast</w>
decisi on.</w>
d ered</w>
ag es.</w>
P os
3 2
z o
ul ts</w>
ic in</w>
St op</w>
Regul ation;</w>
w ind</w>
transi tion</w>
sal ic
ob taining</w>
hydrochlor ic</w>
eti n</w>
cer tain
ab out.</w>
0 5</w>
mid dle</w>
medic ines,</w>
int ens
chang ing</w>
ch ill
bot tom</w>
asset s,</w>
antiretro viral</w>
accommod ation</w>
I B
profession als</w>
proc ess,</w>
p ed
materi als,</w>
ca th
ad al
En viron
- type</w>
w in
v as
ti fied</w>
particip ants</w>
pack ages</w>
mach ine</w>
lo ts</w>
job .</w>
ic ular</w>
hel p.</w>
H igh</w>
train ing,</w>
teleph one</w>
it ;</w>
Where 's</w>
( listed</w>
where .</w>
visi on,</w>
sh aring</w>
rat ings</w>
af are
What ?</w>
Ex ec
ES Os</w>
1. 2</w>
quali fication</w>
muc h.</w>
le l</w>
hyperten sion</w>
cor ro
Avi ation</w>
z a</w>
sp ra
occur .</w>
instruc ted</w>
d ed
Serv ice</w>
I RE
2. 2</w>
thor ough
sid es</w>
recommend ation</w>
prohi bition</w>
pro motion</w>
plan .</w>
nam ely</w>
fr action</w>
dizzin ess,</w>
dis abl
criteri a,</w>
cl ar
ast er</w>
ap s</w>
V er
P E</w>
List en,</w>
(4 ).</w>
your self.</w>
toxic ological</w>
resc ue</w>
nutri tion</w>
interpre tation</w>
fin e.</w>
enh ance</w>
el s.</w>
dis posed</w>
c e,</w>
am i
Lar ge</w>
tis ation</w>
te ach
stead y</w>
re jec
fil m</w>
clos ing</w>
anim al
- treated</w>
tonn es</w>
symptom atic</w>
port fol
pat tern</w>
omet er</w>
children ,</w>
burn t</w>
bil irub
beg an</w>
Z oledronic</w>
A er
20 ,</w>
swe et
r y
prepar ing</w>
lit er
lim itation</w>
k m/
ic ial</w>
fail ed</w>
fac e,</w>
delet ed.</w>
circumst ances,</w>
bodi es,</w>
blist ers</w>
Organ isation</w>
Inter net</w>
ine /
end .</w>
der mal</w>
defici encies</w>
d one.</w>
am us
ME D
7 2</w>
s es.</w>
naus ea</w>
ingredi ent</w>
ic ked</w>
busin ess.</w>
assum ed</w>
ap preci
S ing
G unn
vit amin</w>
u table</w>
treat ments</w>
mad e.</w>
int oler
Th an
C le
199 9</w>
hap s</w>
elev ated</w>
dest in
comp any
U S</w>
Par ts</w>
Im m
3. 1</w>
s ation</w>
go od,</w>
bur n</w>
Res olution</w>
8 8
rever sible</w>
of -
ill ary</w>
di ure
dar k
co efficient</w>
se e,</w>
recogni zed</w>
propyl ene</w>
p ush
gu y.</w>
fre ez
breast- feed
I U</w>
( E</w>
p ure</w>
gas eous</w>
f .</w>
expo sure.</w>
est ing</w>
consec utive</w>
assess ment,</w>
analys is,</w>
al /
ac he</w>
S il
Recom mend
7 -
wid th</w>
se p
num ber
ml .</w>
l as
h -
ar -
an tico
J ap
9 )</w>
3. 2</w>
pl et
p -
not es</w>
al idomide</w>
S ou
PRO V
E .</w>
2 :</w>
, 000</w>
tim ely</w>
re constitution</w>
op tion
og ue</w>
k ne
group s.</w>
di pl
awa ren
accid ents</w>
I f,</w>
AS A</w>
vi al.</w>
vast atin</w>
sum mar
she ep</w>
inv ited</w>
g ath
accel er
L D
H igh
0 -
under take</w>
tro uble</w>
paral lel</w>
mi x</w>
mg/k g/
in c</w>
cop ies</w>
pul sion</w>
numb er,</w>
inhi bit</w>
group ,</w>
by- products</w>
bo y.</w>
bi odegrad
as tig
analys ed</w>
T aking</w>
te m</w>
siz ed</w>
recycl ing</w>
labor ator
hydrochlor othiaz
fung al</w>
de pend</w>
bro ther
at om
5 2</w>
transi t</w>
toge ther,</w>
s or</w>
ob stac
method olog
inf arc
icon azole</w>
5 6</w>
ter ri
telev ision</w>
sulphon yl
fr ag
cooper ate</w>
bot tles</w>
behavi our
B oth</w>
ur tic
sof t</w>
sev ere
satis fies</w>
in u
f ed</w>
cent res</w>
cartrid ge</w>
beg in</w>
b ub
OEC D</w>
N ever</w>
Monit oring</w>
In sul
v ascular</w>
v ag
t our
super v
struc ture,</w>
sp ent</w>
mg/ m2</w>
innov ation</w>
controll ing</w>
characteris tic</w>
br u
anc e)</w>
R as
worl d
servic es;</w>
ro de</w>
opath y</w>
naph th
n ing,</w>
it ted.</w>
infec tious</w>
hydrochlor ide</w>
fall s</w>
cr uc
blo od,</w>
ast er
ag encies</w>
AIF M
9 %</w>
(E U)</w>
p H</w>
gen ic</w>
extr a</w>
ear ch</w>
dis continue</w>
at ing,</w>
appro ve</w>
appli ed.</w>
with ,</w>
registr y</w>
phosph or
nec k</w>
mer cur
lev od
indic ative</w>
exec ution</w>
c m</w>
be am</w>
Manufact ure</w>
provid ed,</w>
lin ear</w>
k ings</w>
ic k.</w>
ess enti
au t
201 1</w>
- -</w>
un ivers
tell s</w>
per sible</w>
inv ent
gl omer
eri ous</w>
b s</w>
N B
In jection</w>
HC V</w>
roll ed</w>
pol ice</w>
lear n</w>
haem oglobin</w>
group :</w>
ec ological</w>
cl ot
am es</w>
adv ance</w>
X -
1, 000</w>
ure ly</w>
t s:</w>
n .e.
mollus c
lov ed</w>
famil y.</w>
b y:</w>
al :</w>
ad hes
The ir</w>
wh o's</w>
un it.</w>
transpor ted</w>
tax es</w>
secon ds</w>
ment :</w>
lic ences</w>
he t</w>
harmon isation</w>
egr avir</w>
dex ameth
applic ants</w>
Th us</w>
Th ro
Gre tti
C S
w ere
initi ating</w>
em powered</w>
ear s</w>
des c
S and
K ar
AN CE</w>
tiv e.</w>
ot ens
n er,</w>
in )</w>
exclud e</w>
epis od
ent an</w>
bo l</w>
UN ECE</w>
Su per
Det ermin
B SE</w>
ti tan
ia )</w>
f os
compati bility</w>
b y,</w>
R )</w>
In struc
(1 .
uri ties</w>
re s,</w>
os e.</w>
my ocardial</w>
ed- release</w>
a h.</w>
T ,</w>
Au dit</w>
purpos es.</w>
pestic ide</w>
materi al,</w>
im plan
fig ures</w>
chi ef</w>
aeroplan es</w>
admin ister</w>
ac e
R ob
thyro id</w>
theore tical</w>
stro ke</w>
sol e</w>
re production</w>
identifi able</w>
ativ e.</w>
an avir</w>
Y or
Wor l
ES MA</w>
web site</w>
stric t</w>
pers on,</w>
ang le</w>
N ob
( not</w>
ur on
s can
cat ch</w>
P )</w>
M S</w>
D r.</w>
Al tern
under going</w>
sw itch</w>
own ership</w>
j um
fir m
Por tug
Manufact ure
An n
verte br
shi el
s at</w>
myself .</w>
hom e,</w>
e w</w>
L ea
C I</w>
provisi on
pro pi
lam ivudine</w>
e able</w>
cab in</w>
articl e</w>
Z en
U sing</w>
S ap
P F
worsen ing</w>
re tained</w>
method s,</w>
meta static</w>
concentr ated</w>
cell s.</w>
tur nover</w>
t ach
subst ance.</w>
ris k
k al
en ant</w>
audi ovisual</w>
afen ib</w>
adver tising</w>
B or
( 8)</w>
organ ization</w>
li es</w>
is tic</w>
gla d</w>
fab ric
cau ght</w>
arm .</w>
adul ts.</w>
M rs.</w>
w ar</w>
ro se</w>
overe ign</w>
omet ric</w>
o ever</w>
fat ty</w>
diame ter</w>
ch an
bre th
T -
Prepar ation</w>
Ch ange</w>
7 %</w>
sc rap
part ners</w>
offic er</w>
m ission</w>
14 ,</w>
threshol ds</w>
struc ture
seas onal</w>
r or
derog ations</w>
cumul ative</w>
constit utes</w>
con stip
col oured</w>
bet ter.</w>
af for
Un less</w>
T Y
the -
swe et</w>
pollut ants</w>
parti ally</w>
m m.</w>
l )</w>
cro p</w>
approv al.</w>
al t
Prot ection</w>
Jerusal em</w>
C op
1 ;</w>
zer o</w>
reve al</w>
mar ried</w>
manag er</w>
det ail</w>
comp ound
barri er</w>
administr ator</w>
PC B
H z</w>
st one</w>
rul es,</w>
re combin
ra p</w>
py ro
pol ys
op e</w>
gath ered</w>
flun omide</w>
enzy m
decreas es</w>
coord inated</w>
br anch</w>
bel t</w>
[ 1
R a
MEN TS</w>
M L</w>
Doc u
Bl ood</w>
A /
( O
smo ke</w>
incin eration</w>
hypoglycaem ia</w>
gr and
fer ti
c ris
b ate</w>
as sign
al ter</w>
S ig
we aring</w>
w ip
titan ium</w>
tific ial</w>
themsel v
siz es</w>
respectiv ely</w>
resid u
in sured</w>
cour t</w>
cap it
Flav is</w>
suff ering</w>
land ing</w>
int ends</w>
instruc tion</w>
harmon ized</w>
undertak ings,</w>
toxic ity,</w>
suscepti ble</w>
l um
injec tion,</w>
haz ards</w>
design ,</w>
cou gh
P eri
round ed</w>
livest ock</w>
limit ations</w>
impair ment,</w>
fif th</w>
experi mental</w>
cas e.</w>
ag on
accoun ted</w>
W ast
Res pon
(b )
where ,</w>
ve in</w>
t ob
sav ed</w>
head ,</w>
envis aged</w>
consul ted</w>
comm er
at e
are a,</w>
tic ul
pic ture</w>
p s.</w>
kill ing</w>
dis closed</w>
develop ment,</w>
c ess
E qui
3 7</w>
tor .</w>
territ ories</w>
sp ake</w>
sc en
pregn ant,</w>
investig ations</w>
hus band
eth yl</w>
employ er</w>
continu ously</w>
ar k</w>
adm itted</w>
C r
ANN EX</w>
- like</w>
st ory</w>
re presents</w>
per s</w>
patient ’s</w>
irrit ation</w>
forth with</w>
cour se,</w>
cor ne
Th ou</w>
M ab
HIV -1</w>
Exec utive</w>
Chem ical</w>
w ound</w>
tezom ib</w>
me tric</w>
impor ter</w>
gu n</w>
d i</w>
be t</w>
Ger many</w>
4. 3</w>
serv ants</w>
retur ns</w>
epid emi
cur ve</w>
bud get</w>
ail s</w>
F R</w>
w ,</w>
ure s,</w>
tiv e,</w>
reve aled</w>
pr ud
porte ur</w>
p it
ody namic</w>
liqu e
he um
ati tis</w>
as k
ab ac
Wat er</w>
P an
M ore</w>
sp are</w>
nutri tional</w>
negl igible</w>
correspon d</w>
cop per</w>
confir mation</w>
au xili
T er
P i
P a
tri g
sym bol</w>
it em
fe asi
elf are</w>
am lodip
Pri or</w>
Elec tr
A UC
territor y.</w>
persist ent</w>
pend ing</w>
list .</w>
lax is</w>
injec tions.</w>
exclud ed.</w>
c av
b agg
Sim il
S H
L O
/EC ;</w>
s ely</w>
part ner
p ill
multi pl
invol ve
g ear</w>
ex ac
Un der
Pl ace</w>
HC T</w>
Centr al</w>
2 ;</w>
st ances</w>
sk ills</w>
rout ine</w>
re leas
pursu e</w>
ous ness</w>
nat ur
inhal ation</w>
fulfil s</w>
fac e.</w>
et y,</w>
dizzin ess</w>
dec k</w>
an aemia</w>
accid ental</w>
Re por
M c
ut h</w>
ro -
resour c
rail way</w>
op i
non-discrimin atory</w>
n ol
ex act</w>
conduc ting</w>
co al</w>
att ack</w>
Po si
L eg
F a
Chang es</w>
wis e,</w>
medic ation</w>
is dic
d es</w>
ag ulation</w>
ug e</w>
system atic</w>
smoo th</w>
sh ak
roll ing</w>
pot ent</w>
o es
inter net</w>
ill umin
got ten</w>
entr icular</w>
en sured</w>
aqu e</w>
Reg u</w>
Po int</w>
PRO DUC
under go</w>
un it,</w>
resul ts.</w>
cham ber</w>
acet yl
Pol y
w .</w>
tor ,</w>
ro ph
ok ay.</w>
in sure
fol der</w>
fo et
d ul
abil ity.</w>
Un iver
T AI
P S</w>
Isra el.</w>
A R</w>
3. 2.
199 8</w>
........ ........
veri fier</w>
tract ors</w>
ram s</w>
quick ly</w>
ob vi
J on
. '</w>
tw el
ro g
r il
ov en</w>
load ed</w>
girl .</w>
discus s</w>
ch ur
adv ise</w>
Zen tiv
I -
76/ 7
slow ly</w>
ot rex
intens ity</w>
bl ow</w>
al ity,</w>
Hy persensitivity</w>
.. ..</w>
t ons</w>
recombin ant</w>
heal th.</w>
exper ti
concern ed;</w>
co ating</w>
bel ong</w>
anz apine</w>
ag ents,</w>
adap tation</w>
D ev
D ep
( Eurostat
you ...</w>
sti m
slaugh ter</w>
sedi ment</w>
li ved</w>
fel t</w>
er )</w>
chro mat
build ings</w>
al arm</w>
P O
L am
E )</w>
Ac tiv
thir d-
sequ ently,</w>
nat ure,</w>
ity :</w>
ith ro
gener al,</w>
evalu ating</w>
dang er</w>
be hold,</w>
vacc inated</w>
pre lim
op tical</w>
fre sh
di go
carb am
ar bit
pa st
or ally</w>
must ,</w>
medi ated</w>
at eral</w>
W IT
C ases</w>
ter ol</w>
separ at
s word</w>
s per
ri al</w>
re verse</w>
own .</w>
organ s</w>
non- compliance</w>
jur isdic
b un
M er
F )</w>
C am
voc ational</w>
p age</w>
n ine</w>
institu tions,</w>
ex plic
el etal</w>
dil u
bir th
approv als</w>
ac tion
Th ree</w>
Rus si
In vest
F er
B on
x y
prec ise</w>
olog ic</w>
mu ta
min er
me :</w>
market ;</w>
b ought</w>
’ t</w>
sil ver</w>
prote ase</w>
p ush</w>
or 's</w>
dist or
digo x
child bearing</w>
all ing</w>
Up on</w>
Un til</w>
D S
Bab yl
transm it</w>
leg ally</w>
col leg
a way,</w>
M AR
9 6</w>
ul tr
s ort</w>
op tional</w>
in sur
C all</w>
14 0
veterin arian</w>
prog ram</w>
print ing</w>
olog ically</w>
min e.</w>
interf ere</w>
integr ation</w>
food stuff
exper t</w>
di et</w>
config uration</w>
Sev ere</w>
Con tracting</w>
Com b
Characteris tics</w>
ter at
ta g
sup plemented</w>
se ats</w>
re medi
ma st
legisl ative</w>
in ts</w>
correspon ds</w>
confidenti ality</w>
ar riv
any more.</w>
Worl d</w>
typ ically</w>
too l</w>
sa id.</w>
prelim inary</w>
lin ed</w>
l augh
inform ation:</w>
attrib utable</w>
angi otens
S lov
10 .</w>
vacu um</w>
substr ate</w>
st aff
sel ves</w>
on y</w>
del ayed</w>
c ement</w>
W as</w>
Gover n
2001/ 8
vari ations</w>
us age</w>
unit s,</w>
simultan eously</w>
selec tive</w>
provisi ons,</w>
phen y
pat tern
oc ar
morn ing.</w>
lin e,</w>
hor se</w>
exist s</w>
eu tical</w>
consign ments</w>
astig mine</w>
adj uv
ac tions,</w>
T re
IFR S
un usual</w>
um b
sustain ed</w>
ment )</w>
manag ing</w>
galax y</w>
eg g</w>
command ed</w>
L ow</w>
plan ets</w>
mob ility</w>
in :</w>
happen s</w>
great est</w>
consequ ence</w>
ce il
V I,</w>
In clud
I g
Ger man
trans plant</w>
ti fication</w>
premi ums</w>
ph r
low ,</w>
instru ments,</w>
ing ly,</w>
elim inate</w>
Y es.</w>
LORD .</w>
Insul in</w>
EM EN
tow ed</w>
substanc es.</w>
se afare
request .</w>
regul ar
mix ing</w>
meth an
licens ing</w>
inspec ted</w>
h ell
de p
compli ant</w>
an xi
6 6
4 8
ul ph
rul es.</w>
g ently</w>
cour ses</w>
contract .</w>
assess ment.</w>
P- g
youn ger</w>
ty res</w>
te en</w>
sen se</w>
protec tion,</w>
privileg es</w>
pr urit
point ,</w>
jud icial</w>
foo t</w>
fl at</w>
Im plement
Direc tor</w>
CI :</w>
y et.</w>
top ic</w>
skin .</w>
reason ed</w>
plan ,</w>
o therapeutic</w>
les ions</w>
every thing.</w>
et r
coo l</w>
remot e</w>
r at</w>
on e?</w>
ic ated</w>
gent le
ere c
dr un
bu ff
7 1</w>
success ful</w>
reten tion</w>
pra y</w>
id ine</w>
h ad
com ments</w>
bor row
ap p
antico agul
V E
A ut
random ised,</w>
it e.</w>
hour s,</w>
fix ing</w>
cod e:</w>
D on
wo od
tim ing</w>
medi um-
hy dra
e ing</w>
adm ission</w>
W in
Exc ept</w>
B al
Applic ation</w>
t rib
includ ing,</w>
dro w
assum p
wh olesale</w>
trail er</w>
sit ting</w>
s er</w>
product s;</w>
pre clud
ket ocon
here !</w>
ex ,</w>
dy namic</w>
an nex
Q T
( except</w>
( e
under gone</w>
speci alised</w>
materi al.</w>
lad en</w>
hy bri
en 's</w>
distrib u
disci pl
contract ,</w>
Q T</w>
( 8
tan eous</w>
oper ation,</w>
ol s,</w>
f i</w>
br inging</w>
Pharmac otherapeutic</w>
Not e</w>
F o
E -
tr ace</w>
subjec ts.</w>
sor ry.</w>
s mil
re agent</w>
p as
l op
comm itted</w>
charg ing</w>
bre ath</w>
Sol om
P op
O pen</w>
F und
wor th</w>
se al</w>
o tic</w>
ne bul
lear ning</w>
equival ence</w>
V alu
Mea sure
A P</w>
200 8/
star ch</w>
rel ates</w>
perfor med.</w>
p ath</w>
opini ons</w>
of .</w>
n on</w>
morn ing,</w>
main tain
inter vention</w>
ia h,</w>
ear nings</w>
dis played</w>
clear ,</w>
avail abl
S OL
R NA</w>
M ad
G iv
199 6</w>
x ,</w>
vo y
ti er</w>
st am
room s</w>
problem s.</w>
pro pulsion</w>
mitig ation</w>
meth otrex
me mor
if :</w>
fin ance</w>
contamin ated</w>
certific ate,</w>
aff ixed</w>
whe els</w>
ri fam
prec ip
dev ice,</w>
des ired</w>
den om
child .</w>
boil ing</w>
T F
6 1
o ?</w>
isol ated</w>
includ e,</w>
in directly</w>
ful filled</w>
explo sive</w>
exemp t</w>
be st
appl y,</w>
aircraf t,</w>
But ,</w>
then tic
spectr um</w>
psy cho
parti es,</w>
o il,</w>
inf ant</w>
ec tive</w>
an s.</w>
Wom en</w>
Ris k</w>
IV E</w>
AC C
, "</w>
tion ary</w>
thro at</w>
switch ed</w>
substr ates</w>
speci es.</w>
repe at</w>
char acter</w>
al pha
Committe e,</w>
s ed
repe aled</w>
pip e</w>
ben ch
au th
appe ared</w>
an a</w>
Eff ects</w>
( and</w>
s ed.</w>
ref er
n ing.</w>
m ing</w>
level s,</w>
hygi ene</w>
fund amental</w>
f ound
div isi
deteri oration</w>
decla res</w>
d ental</w>
bo ys</w>
avir .</w>
Oper ator</w>
NO T</w>
E ffic
1. 1.
un certainty</w>
ty re</w>
pursu it</w>
independ ence</w>
ic ist
b a</w>
at e;</w>
arter ial</w>
F ra
46 /EC</w>
war ran
or th
mortal ity</w>
l ing,</w>
hor ses</w>
er s:</w>
entity 's</w>
dre am
ar ound.</w>
acet am</w>
H O
Ch in
/ her</w>
( j
” ,</w>
salic ylic</w>
safegu ard</w>
l id
ex pi
at az
R ight</w>
A fric
transfer ase</w>
tiv eness</w>
thrombo embol
pol i
de aling</w>
chro me</w>
broad cast
ac af
S et
Re pe
NO x</w>
( Article</w>
ul i
sum ed</w>
stop p
piec es</w>
oblig ed</w>
n.e. c.</w>
cl er
at -
R ed</w>
tak en,</w>
surg ical</w>
stra igh
mo st
em bar
cor relation</w>
U /
G L
Effic acy</w>
As soci
4 2</w>
los s,</w>
l ess,</w>
d s.</w>
compon ents,</w>
ac ept</w>
Z e
sol vent
sit e,</w>
ml ,</w>
me ant</w>
fa ther.</w>
err ors</w>
contrib uting</w>
analys is.</w>
M em
Ch ap
9 2</w>
we ak</w>
ut in
produc t-
molec ular</w>
modi fy</w>
justi fication</w>
intr amus
certific ate.</w>
achiev ement</w>
W ar
B R
w are</w>
p ped</w>
id ov
fin ds</w>
cut ting</w>
Hy per
H IC
G EN
91/414 /EEC</w>
satell ite</w>
pe ace</w>
num er
medic ines.</w>
g ram</w>
fore see
en -
driv ers</w>
dis h
abil ities</w>
Fren ch</w>
199 7</w>
we igh</w>
t ongue</w>
susp end</w>
stic k</w>
metabol is
mean s,</w>
low .</w>
l es.</w>
fin ally</w>
ar tificial</w>
Rom an
IV .</w>
tend er</w>
tem ple</w>
ov igil
met als</w>
leg iti
ir d</w>
increas ed,</w>
in ic</w>
girl s</w>
cath et
V eter
T ar
RE QU
Instruc tions</w>
C .
B ro
201 2</w>
surfac es</w>
short- term</w>
oper ations,</w>
meth od,</w>
know n
joint ly</w>
ic k,</w>
ey es.</w>
ativ es,</w>
am az
ad en
accid ent
access ories</w>
Off ice</w>
K al
Ag enc
201 4</w>
12 5</w>
w arm
sh ouldn't</w>
noti fying</w>
l ysis</w>
fil e.</w>
Condi tions</w>
tast e</w>
suff er</w>
mat ure</w>
l ens
hous es</w>
gen e
enjo y</w>
d n
col labor
blind ,</w>
b ank</w>
In surance</w>
C ha
typ e.</w>
sol di
ra il</w>
p up
ol ab
m assive</w>
jo in</w>
grow n</w>
fish ery</w>
enc ephal
effic ac
class ical</w>
cat ch
ari a,</w>
al ia</w>
st ed</w>
depres sion</w>
cr ush
ator s,</w>
ad ata</w>
V ic
read y.</w>
organiz ations</w>
o to</w>
k id</w>
in e)</w>
for :</w>
efaviren z</w>
di etary</w>
al tered</w>
Fr ance</w>
/E U
sub stitu
sequ ence</w>
particular :</w>
lim iting</w>
king dom</w>
it ative</w>
ing !</w>
immuno globul
he aven
conver ted</w>
can .</w>
applic able.</w>
Teles cope</w>
S Y
No thing</w>
HB V</w>
CO 2</w>
- resistant</w>
( s),</w>
which ever</w>
un authorised</w>
prospect us</w>
leaf let
ish .</w>
he pat
cont ingent</w>
commit ment</w>
bo ard
bl ur
ation ).</w>
anaphy lactic</w>
Res ults</w>
R adi
Di st
v ide
up ?</w>
tiv ir
ti tr
su ic
rop in</w>
pu ts</w>
perc ent</w>
is :</w>
ic ity,</w>
fr ame</w>
eren ces</w>
en ic</w>
cholester ol</w>
a o
' cause</w>
respectiv el
ques tion,</w>
pres sure.</w>
it ors</w>
inv o
initi ative</w>
hyperten sive</w>
T o
R ud
Pl as
For m</w>
9 1</w>
12 -
virt ue</w>
vi ro
th ings,</w>
tabl y</w>
re tain</w>
hear ing</w>
crimin al</w>
bran ches</w>
ation s:</w>
F -
Con f
4 3
y ),</w>
rifam pic
purpos e.</w>
non- target</w>
mod ule</w>
lead s</w>
lat er.</w>
f er</w>
de hydr
consum ed</w>
bo at</w>
appli ed,</w>
anc e;</w>
M ix
Jo sh
wif e.</w>
we ather</w>
us e;</w>
teles cop
stre t
standardis ation</w>
mist ak
in ity</w>
fac tion</w>
exac erb
dial ysis</w>
any body</w>
( EC
sil den
op a</w>
mem ory</w>
ithro myc
is ch
hol e</w>
h ang
P ublic</w>
B )</w>
( 2</w>
wom an.</w>
un acceptable</w>
tot ally</w>
ti a</w>
medic ine,</w>
ic ul
eti r
du plic
au th</w>
ab alin</w>
W el
9 3</w>
y r
tre e</w>
ster il
s oul
no thing.</w>
investig ated</w>
gen otype</w>
del i
cost s,</w>
Sub ject</w>
R educ
Con sequently,</w>
war m</w>
speci fying</w>
hy s
explan ation</w>
expec t</w>
ea m</w>
clo sures</w>
at er
al de
ac char
ab at
V IC
Netherland s</w>
F ed
3 4</w>
23 77/
v an
u str
request ing</w>
qu ot
k P
hel ps</w>
flavour ing</w>
do ing?</w>
correc tly</w>
chlor ide,</w>
associ ations</w>
a ur
Phil ist
Me an</w>
E s
1 1.
undertak ing
tr ap
take- off</w>
ste in</w>
protec tion.</w>
leav es</w>
k !</w>
h one
ground .</w>
ch air
b righ
H S</w>
Gretti r</w>
Ac tion</w>
typ ical</w>
too ,</w>
surve ys</w>
poss ession</w>
poly ethylene</w>
pl ays</w>
her ?</w>
b id</w>
appear ance</w>
alis ki
add ing</w>
acquire r</w>
S at
30 ,</w>
201 1/
' ;</w>
sym bol
pers on.</w>
ish ed.</w>
gast ric</w>
ext ingu
dy nam
co at
Veter inary</w>
Val ue</w>
G l
D evel
D -
B a
6 7/
was .</w>
vul ner
parame ter</w>
numb er.</w>
et s.</w>
effec t,</w>
dis patch</w>
de ploy
aim s</w>
abnorm alities</w>
V U</w>
T i
RE S
J ord
Ge org
C oo
ART IC
tran s</w>
the e.</w>
ta il
sti pul
par tly</w>
ous ly.</w>
mix ture
kin son
it inib</w>
ev ap
consump tion,</w>
ann oun
ac illus</w>
I sl
G R
1 2,</w>
w ick
v ec
su n</w>
sp ot
s ed,</w>
peg interferon</w>
par king</w>
gon e.</w>
god damn</w>
al ert</w>
7 8/
ti les</w>
pro pose</w>
pool ed</w>
paren ts</w>
new ly</w>
man ner.</w>
ma ble</w>
ir a</w>
im pos
gen e</w>
foresee able</w>
dys function</w>
do or.</w>
ap point</w>
an th
M -
E p
yc in</w>
un known.</w>
tan ks</w>
mean ing
int eg
initi ally</w>
h oo
gu ard</w>
es ...</w>
eren 't</w>
batter ies</w>
aud its</w>
S en
Phar ao
L at
Ag ency.</w>
AIF s</w>
trans -
ti ght</w>
re vision</w>
min d.</w>
gain ed</w>
budget ary</w>
bas el
W al
MEN T</w>
EU/1/ 0
Be hold,</w>
us es,</w>
territor y,</w>
mon etary</w>
mon ella</w>
ground water</w>
froz en</w>
d ?</w>
b ad
al an
H aem
Cont act</w>
An d,</w>
" ?</w>
surround ing</w>
hypoten sion</w>
fore stry</w>
forc ed</w>
doub t</w>
bul k</w>
P C</w>
M T
En ergy</w>
toxic ity.</w>
or ub
ograph y</w>
o on</w>
invol ves</w>
inten tion</w>
det erg
d y</w>
cell s,</w>
appli ance</w>
ag ents.</w>
ST R
O .
H ell
Child -P
them ?</w>
temperat ure,</w>
set .</w>
r heum
is ed.</w>
fat ,</w>
bl es</w>
absor b
Th org
5. 1</w>
ure s.</w>
un changed</w>
thorough ly</w>
t ed
remain ed</w>
problem .</w>
preven tive</w>
licen sed</w>
le a
in ?</w>
enough .</w>
dos es.</w>
cost -
chan nel</w>
ati de</w>
1 1,</w>
( A)</w>
tr uth</w>
success fully</w>
sh ut
ri d</w>
ren der</w>
rand om</w>
feeding stuff
exemp tions</w>
enti ty.</w>
S on</w>
(* *
wa ve</w>
prin t</w>
mou se</w>
im ,</w>
gu ys.</w>
good s,</w>
cat s</w>
appl y:</w>
ac i
Zentiv a</w>
O ut
Giv en</w>
Al so</w>
yiel d</w>
tri als.</w>
str ang
safet y.</w>
s ):</w>
rec i
pot at
pack ed</w>
mob il
m es
hous ing</w>
haem odi
friend s.</w>
everthel ess</w>
depar ture</w>
U D
Sing le</w>
Pleas e,</w>
P ap
6 6/
urb an</w>
tr uc
tari ff
red ness,</w>
micro-organis m</w>
mess ages</w>
giv en.</w>
g el</w>
fav our</w>
em ul
cycl e.</w>
conf erred</w>
agre ement,</w>
a head</w>
E y
Chris t</w>
tal ked</w>
re presented</w>
qual ity,</w>
present ing</w>
perf ec
micro b
involve ment</w>
fal se</w>
f as
erc ep
commit ments</w>
busin ess,</w>
all erg
S aul</w>
Fur ther</w>
A C</w>
5 5</w>
‘ the</w>
us ers,</w>
twel ve</w>
ro utes</w>
pi oglitazone</w>
os es</w>
me at,</w>
manag ement,</w>
leg s</w>
cover age</w>
chlor o
4 ),</w>
pri ests</w>
perm its</w>
nas al</w>
ju ice</w>
hus band</w>
electro magnetic</w>
doc etaxel</w>
dissol ved</w>
dipl om
delet ed;</w>
d :</w>
Wh o's</w>
T rich
Accord ingly,</w>
sat ur
s ought</w>
part y.</w>
par t,</w>
oph osph
minut e.</w>
infec tions,</w>
his /her</w>
famil ies</w>
exten sive</w>
batter y</w>
awaren ess</w>
Stand ards</w>
Mab Th
Lab or
In stru
ES A</w>
10 -
( I
w rap
st ation
si bility</w>
ra rely</w>
on- site</w>
metre s</w>
meet ings</w>
let ters</w>
inter ven
igh ts</w>
expres sion</w>
discrimin ation</w>
dec om
bod y's</w>
S orr
Parlia ment,</w>
L uc
C hic
' ,</w>
“ The</w>
venti lation</w>
studi ed.</w>
sou l</w>
ple ments</w>
pheny to
o ted</w>
la sting</w>
k en</w>
ap pro</w>
ab an</w>
Sec tions</w>
H er</w>
ES O</w>
weigh ts</w>
t on,</w>
solv ents</w>
solu tion,</w>
sh ake</w>
c ow
Vehic les</w>
R iv
7 4/
te ach</w>
re serve</w>
pro mo
og ram</w>
man if
farm s</w>
contrac ted</w>
commit te
col lateral</w>
c up
becom ing</w>
Tur n</w>
Child-P ugh</w>
B ring</w>
4 2
3 8</w>
ug g
symptom s.</w>
ro ot</w>
pestic ides</w>
per .</w>
pen dic
open- label</w>
ma .</w>
frequ encies</w>
exceed ed</w>
essenti ally</w>
F S
B M
suppres sion</w>
organis ations,</w>
mor ph
mat urity</w>
manufacturer 's</w>
enc ed</w>
car ds</w>
auxili ary</w>
EF SA</w>
w ed
se e.</w>
piv otal</w>
part ner</w>
oc k,</w>
judg ment</w>
fiel d.</w>
destro yed</w>
consump tion.</w>
R -
P 450</w>
4 9</w>
wh ite,</w>
ter ing</w>
sign ature</w>
man 's</w>
m erc
han g</w>
disord er,</w>
dam aged</w>
col or</w>
In spec
Ag ency,</w>
7 5/
tomorrow .</w>
reti re
pre- existing</w>
paragrap h.</w>
ol d.</w>
occur ,</w>
mis sions</w>
manufacture ,</w>
legiti mate</w>
jour ney</w>
is e.</w>
cyl ind
con vul
bro ke</w>
a u</w>
Wh olesale</w>
Can 't</w>
B an
( iv
veri fi
reason s,</w>
possi bil
petrole um</w>
lin ks</w>
hydra ul
escap e</w>
ep tic</w>
engine ering</w>
desp ite</w>
demonstr ating</w>
carri es</w>
c ord
b right</w>
acid .</w>
G ot</w>
2. 3</w>
z oo
tum ours</w>
sa y.</w>
ol e
need ed.</w>
n el
n ations</w>
hear t,</w>
grap es</w>
gen ital</w>
co m</w>
Equi p
Det ailed</w>
Ad visory</w>
week s,</w>
refer ring</w>
pan el</w>
pain .</w>
or ph
inst ance</w>
edi ble</w>
dis pat
death ,</w>
de ad,</w>
bodi es.</w>
act .</w>
ter ror
pursu ed</w>
pl atin</w>
ould 've</w>
new s</w>
mo l</w>
lef t.</w>
fici ency</w>
ex it</w>
commer ci
au thentic
ac tions.</w>
Where ,</w>
IC AL</w>
7. 5</w>
1 10
with :</w>
resul ts,</w>
re vo
os bu
no body</w>
ic los
ho st
eng en</w>
bl ank</w>
al tit
ag ent
C C</w>
An im
t es</w>
public .</w>
pro u
on ce.</w>
n ac
month .</w>
mL /
ligh t,</w>
infring ements</w>
iclos por
g au
fro m
elev ations</w>
el ing</w>
cat tle</w>
bal anced</w>
as e,</w>
M us
way s,</w>
w w
set tled</w>
proper ty,</w>
pre n
ous ly,</w>
mou th
mis artan</w>
lo ans</w>
herb al</w>
for ?</w>
ev ol
cul tiv
con serv
calcul ations</w>
M edi
(T ext</w>
reduc es</w>
ple a
parti es.</w>
ir s</w>
in sec
gra in</w>
fo rec
ey el
ec itabine</w>
disabl ed</w>
d ap
connec t</w>
as ive</w>
ar ti
aem ic</w>
Z i
C N
w eren't</w>
un used</w>
sulph ate</w>
figh ting</w>
enti tlement</w>
a ),</w>
V is
Stat es'</w>
Sch engen</w>
P ack</w>
9 %)</w>
4 ,
trail ers</w>
town .</w>
streng th
st ating</w>
soci ety</w>
om en
gu ide</w>
en afil</w>
ell ation</w>
arom atic</w>
RE S</w>
O S</w>
9 5%</w>
- 2-
wat ch
suppor tive</w>
sa id
resol ved</w>
od er
o be
jour ne
h em
great .</w>
coun ted</w>
contract s,</w>
cob icist
b us</w>
al tar</w>
W he
REQU IRE
H ou
Christ m
s ending</w>
microb ial</w>
list ing</w>
li on</w>
guarante ed</w>
g if
fire .</w>
expres s</w>
dec e
cham b
bre ach</w>
ar tan
ab b
Po st
MR L</w>
M el
En ter</w>
C ause</w>
Bul g
AD R
A 1
w icked</w>
there to</w>
sh ell
sci enti
s ail
remov ing</w>
pol lu
otec an</w>
group s,</w>
e ating</w>
dis rup
conc ep
character ised</w>
anticip ated</w>
R ic
Com p
( v
wast e,</w>
suit ability</w>
she ets</w>
sh op</w>
sector ,</w>
s aving</w>
neighb our
in herit
good will</w>
eco- label</w>
cop hen
contracep tive</w>
co agulation</w>
are as,</w>
al ph
T e
O )</w>
N at
CYP3 A</w>
wild er
vap our</w>
tabl e,</w>
t 's</w>
ris k-
problem s,</w>
po etin</w>
on !</w>
man ?</w>
estim ation</w>
epidemi ological</w>
concentr ations.</w>
adver sely</w>
U M
L in
Gre ec
F orm
C A</w>
(6 ),</w>
tr ust
tend ere
spl it</w>
sou th</w>
olog y,</w>
im plic
gl ory</w>
dead line</w>
St ev
P P
OP S</w>
H am
visi ons</w>
vis a</w>
toler ance</w>
sp oke</w>
slaugh tered</w>
reimbur sement</w>
present .</w>
or bate</w>
him ;</w>
clim ate</w>
biv al
barri ers</w>
ac r
IS TA</w>
Devel op
D r
2003/87 /EC</w>
univers al</w>
reg ener
pre dn
os is.</w>
oper ations.</w>
if ene</w>
facilit ating</w>
exam ples</w>
direc ted</w>
S or
Fra mework</w>
AN D
A gr
9 6
67/ 54
( n</w>
t ase</w>
satis faction</w>
s an
reserv ed</w>
phy si
ori ent
n y.</w>
mad e,</w>
gro w</w>
emtric itabine</w>
down stream</w>
cyto chrome</w>
consul t
con ve
am poul
RE F
Ger man</w>
(9 )</w>
rel atively</w>
qu arter
perf ect</w>
mam mal
leak age</w>
en :</w>
anch or
ac etic</w>
C hair
C W</w>
patient .</w>
fat s</w>
el se.</w>
characteris tics,</w>
abl es,</w>
S erious</w>
P AC
C riteri
199 5</w>
vol tage</w>
sol ar</w>
six th</w>
sist er</w>
reli ability</w>
propor tional</w>
prom ell
plan et</w>
organ ised</w>
no tably</w>
is ?</w>
im pres
ill ustr
fil grastim</w>
condi tioning</w>
con dens
amin o</w>
I ts</w>
Decisi ons</w>
tre a
tac rolimus</w>
r hyth
men tion</w>
kil omet
inter connection</w>
hear t.</w>
g ear
fac ts</w>
explain ed</w>
expen se</w>
ded icated</w>
b ever
H D
CYP2 D
t oc
qual itative</w>
le th
kno c
k g.</w>
fish ing</w>
bro ad</w>
w as,</w>
spok en</w>
sign als</w>
sal e,</w>
progres sive</w>
pap er
micro biological</w>
g as,</w>
dr ying</w>
OK ,</w>
Je ho
Here 's</w>
C z
B eth
5 24
(Eurostat )</w>
y- state</w>
ub ility</w>
u ter
shap e</w>
recur rent</w>
purch ased</w>
prop ag
p et</w>
life- threatening</w>
int ing</w>
inser ted:</w>
dri ver
d ere
cap ability</w>
anc illary</w>
air y</w>
Micha el</w>
F re
Acc ess</w>
tor que</w>
relev ance)</w>
os ,</w>
opath ic</w>
om y
loc ked</w>
li ve
et te</w>
U G
Con sid
Bl ack</w>
( 5.
wan t.</w>
v est</w>
tra ffic
thre at</w>
spec tro
scho ol.</w>
prop an
minim al</w>
log ic</w>
hand s.</w>
cre ating</w>
contr ast</w>
and ...</w>
all o
al ong
R ib
9 /EEC</w>
work s,</w>
we a
shor ter</w>
sh ad
set tle</w>
ros is</w>
iv es,</w>
interrup tion</w>
gl u
entr usted</w>
devic es,</w>
d wel
cot ton</w>
TAI L</w>
P AR
N orm
? "</w>
4. 5</w>
(2 .
tion ally,</w>
symptom s,</w>
od is
j ack
hel p
excipi ents</w>
ex changes</w>
environ ment
bul k
a 's</w>
T .</w>
I ...</w>
AL T</w>
6 4/
visi on.</w>
str ingent</w>
righ ts,</w>
receiv es</w>
on ly,</w>
ne ph
m ass
lat e.</w>
h ide</w>
fail ure.</w>
do or
an ib</w>
an ese</w>
ad y
C ivil</w>
( s).</w>
strain s</w>
reci proc
pay ing</w>
ox ic
ovigil ance</w>
on azole</w>
mo ther.</w>
inhibit ors,</w>
harvest ed</w>
conc ept</w>
air e</w>
S el
P rin
B ud
she ep
mercur y</w>
fl ox
end points</w>
aqu ac
Mar ket
L act
IF IC
C ART
(1 );</w>
y al</w>
un t</w>
t esti
signific ance</w>
restrain t</w>
per ,</w>
operat ors,</w>
nor th</w>
mellit us</w>
inter face</w>
femal es</w>
ev ir
demonstr ation</w>
consul tations</w>
attrib uted</w>
al tar
ain t</w>
N )</w>
F act
9 -
3 ),</w>
techn ic</w>
radi olab
offici als</w>
ma ,</w>
conj ug
cas es.</w>
air ports</w>
S cot
H )</w>
tur ning</w>
som nol
sim ply</w>
medium- sized</w>
impor tan
di r
citiz ens</w>
ast s</w>
ast .</w>
SP EC
I ;</w>
He 'll</w>
G -
B O
AL MA</w>
se ed,</w>
scr utin
ro d
ref r
prolong ed-release</w>
ow ing</w>
mal es</w>
li me
gener ate</w>
fin ish</w>
dox orub
assump tions</w>
ad a</w>
T or
8 5/
pack aged</w>
on line</w>
necessar ily</w>
li ber
itch ing</w>
infring ement</w>
in clu
haemat ological</w>
delet ed</w>
con fu
complic ations</w>
c and
ativ ely,</w>
an tivir
W o
Res earch</w>
Repor ting</w>
E li
199 1</w>
( which</w>
th en.</w>
popul ations</w>
mod es</w>
method s.</w>
me t,</w>
ly mp
lu br
lab el,</w>
itch ing,</w>
gen icity</w>
etir acetam</w>
en ;</w>
cont ent,</w>
cas e-
carbam azep
allow ance</w>
F ac
sti ll
sick ness</w>
sh o
osi tion</w>
fore seen</w>
e uro
cr ude</w>
cap .</w>
ap one</w>
P-g p</w>
Aar on</w>
201 5</w>
1, 5</w>
there af
suppl ement</w>
fra me
for ces</w>
eff lu
compos ite</w>
ation /
alkal ine</w>
M is
In iti
Ac counting</w>
8 /EC.</w>
‘ The</w>
wat ching</w>
kin '</w>
jud ge</w>
experti se</w>
ex clusion</w>
devi ation</w>
can did
an y,</w>
am une</w>
Sub stances</w>
Ac ta
A ri
1 2.
purchas ing</w>
pl ates</w>
o estro
li ver,</w>
de alt</w>
ac idi
O AT
Hol y</w>
H az
2010 /
2 8,</w>
standardis ed</w>
st ations</w>
rap porteur</w>
pres sure
prec ision</w>
practic e.</w>
pa thy</w>
p ist
or odis
orodis persible</w>
mat ter.</w>
la z
initi ate</w>
ill .</w>
heat er</w>
extr ap
episod es</w>
enti rely</w>
compan y.</w>
cl opidogrel</w>
a ).</w>
NB :
K DE</w>
H en
H ear
D C</w>
vari ability</w>
thin ks</w>
os sed</w>
l a</w>
it ate</w>
in oc
im possible</w>
g ard
d well
criteri a.</w>
collec ting</w>
E col
D ef
w est</w>
vin yl</w>
tablet s,</w>
ri f
r i</w>
poul tr
pharmac eutical</w>
p t</w>
p ass,</w>
no se</w>
h lor
everthel ess,</w>
de ep
cutan eous</w>
ch ron
c ities</w>
S un
S ar
C T
z inc</w>
y ar
warfar in</w>
they 'll</w>
ta ber
taber nac
sector al</w>
pro ficiency</w>
practic e,</w>
or n</w>
intere st,</w>
hydr ate</w>
grad ually</w>
fir st,</w>
extre me</w>
enti ty,</w>
continu ation</w>
ch ann
cam er
ax is</w>
am ed</w>
M P</w>
Com pli
" ,</w>
um )</w>
star ts</w>
sof osbu
si r,</w>
fact or
below :</w>
au tical</w>
at oid</w>
ac tic</w>
Re member</w>
4. 1</w>
year s)</w>
view s</w>
un treated</w>
switch ing</w>
s ity</w>
on c
lat est.</w>
ir regular</w>
int end</w>
heav en</w>
h as
flex ible</w>
expo sure
e ment
di es
contrib utes</w>
Statis tical</w>
Irel and</w>
Commun ities</w>
Americ an</w>
10 00</w>
wav el
se men</w>
roc k</w>
pe metrexed</w>
inter nation
fl ame</w>
cour se.</w>
chro mos
b ad.</w>
are as.</w>
Sy mptom
RE L
H P
Determin ation</w>
AD R</w>
8 4</w>
199 0</w>
sw elling,</w>
ship s,</w>
poss ess</w>
neutro ph
moun tain
en e,</w>
de struction</w>
d ad</w>
b ord
Pro f
Lev el</w>
w ool</w>
w elling</w>
situ ation.</w>
si r
s ”</w>
reac tion
preclud e</w>
out standing</w>
os is
m mol/
lu min
lov e.</w>
human s.</w>
at or,</w>
WIT H</w>
St ar
S us
M IN
C are</w>
C ali
Appro priate</w>
8 8/
19 ,</w>
z ation</w>
y es,</w>
ut yl</w>
test ing,</w>
st res
si a</w>
sens or</w>
retire ment</w>
produc tion.</w>
op pos
continu es</w>
condi tion.</w>
at test
Recommend ation</w>
Lu x
Al umin
will .</w>
wavel eng
transp osition</w>
shor tness</w>
ser ial</w>
reac tion,</w>
rat s,</w>
pir a</w>
ir .</w>
indic ated.</w>
imp acts</w>
heat ers</w>
forc e.</w>
fo ol
disp ute</w>
conflic t</w>
bl e
SME s</w>
P D</w>
Incre ased</w>
Identi fication</w>
where ver</w>
up !</w>
u pri
st ates</w>
proc eed</w>
princi pl
k is
integr al</w>
dwel t</w>
ch ass
arch it
ant ine</w>
Ma inten
L if
3 :</w>
0 4</w>
sa ke</w>
s ounds</w>
re ign
oid s</w>
mut ation</w>
k g/
ha m</w>
er ly</w>
docu ments,</w>
dec l
ag ed.</w>
Par kinson
O .</w>
8 0/
tre m
tod ay</w>
system ;</w>
sp end</w>
present ,</w>
l ord
l ess.</w>
fill ing</w>
encour aged</w>
elim in
bel ow,</w>
be :</w>
Wor k
Ty pe
T E
Serv ices</w>
Jud ah,</w>
year ly</w>
wom en,</w>
sud den
respon se.</w>
programm es,</w>
p el
optim al</w>
liqu ids</w>
inhal er</w>
foc us</w>
esti mat
er ies</w>
emb our
b )</w>
ay er</w>
as e.</w>
appl i</w>
adop ting</w>
140 8/
1 2.</w>
( to</w>
z idov
trans formation</w>
tr ast
pregnanc y,</w>
mone y,</w>
ed !</w>
ce ase</w>
candi date</w>
ari es,</w>
Rib avirin</w>
O ,</w>
MA H</w>
AIFM s</w>
sug ar
sor bit
rec ru
portfol io</w>
phys ic
pen .</w>
moist ure</w>
lo an</w>
know n,</w>
it es.</w>
en larg
coast al</w>
claim ed</w>
catch ment</w>
bleed ing.</w>
al one,</w>
agre ements,</w>
adal afil</w>
S ign
Loo ks</w>
Commun ication</w>
Commission 's</w>
Ac ute</w>
(iv )</w>
( Child-Pugh</w>
z ,</w>
y m
syn thes
ri es,</w>
offic ers</w>
occas ion
iz ing</w>
in fl
identifi er</w>
go ing.</w>
e ability</w>
cloth es</w>
c ity,</w>
ar ip
appe al</w>
Se e,</w>
70/15 6/EEC</w>
15 ,</w>
wrong .</w>
us ers.</w>
tri glycer
tach ograph</w>
sampl e.</w>
re s.</w>
re jo
pres crip
o b</w>
m ice</w>
induc ers</w>
i onal</w>
h !</w>
gr ants</w>
fo il</w>
fa ith</w>
ed ).</w>
cov enant</w>
an es
abac avir</w>
Market ing</w>
H ung
H an
Gre at</w>
Defin ition</w>
7 9/
wind ows</w>
w ed</w>
veget ables</w>
v ill
und ue</w>
sum an</w>
reg ime</w>
pregn ant.</w>
mg/ day</w>
lab els</w>
id ea.</w>
f t</w>
est ab</w>
dre w</w>
cad mium</w>
b ade</w>
arip ip
an om
Win thro
S pain</w>
RE G
Pur su
Equip ment</w>
3 ;</w>
0 8</w>
0 %</w>
syndro me,</w>
ster oid</w>
s ound
pro phy
p ale</w>
on ed</w>
o z</w>
nucle o
most ly</w>
m ap
insul in.</w>
inhibit or
ing ...</w>
er ad
ed ed</w>
dexameth asone</w>
authoris ation,</w>
Spi ro
Mea sures</w>
Lux embour
In suman</w>
Com plet
' Cause</w>
wal king</w>
w ine-
w elfare</w>
mon ey
lop in
f itting</w>
dail y,</w>
corpor ate</w>
be fore,</w>
Att rib
50 ,</w>
199 3</w>
( 3</w>
y ing,</w>
wor se</w>
teles cope</w>
stric tly</w>
silden afil</w>
share holders</w>
sec ured</w>
intere st.</w>
inser t</w>
ini on</w>
he 'll</w>
de preci
cre am</w>
cont ex
ast ro
ap art
alde hy
Than ks</w>
D ul
C E
B ody</w>
Ann ual</w>
A t
1. 3</w>
wif e,</w>
v s</w>
upd ating</w>
predic ted</w>
persen si
oz ol
on 's</w>
mg/ m
larg est</w>
ess ing</w>
enc oun
clean ed</w>
ca red</w>
but ...</w>
alfa-2 b</w>
REQUIRE MENTS</w>
O -
K in
D am
weigh ed</w>
volum es</w>
v il
trast uz
tim es,</w>
tic ular</w>
simpli fied</w>
ref in
protec ting</w>
oper ative</w>
max im
infec tion
in- like</w>
g er
ex o
] ,</w>
S n
Ren al</w>
Nob ody</w>
I .
En g
Author ity,</w>
199 2</w>
whol ly</w>
vor iconazole</w>
tw enty</w>
stake holders</w>
sk y</w>
set tings</w>
se emed</w>
re stri
j a
hand led</w>
grap h
gene tically</w>
farm ing</w>
fa ther,</w>
describ es</w>
clou d</w>
clari fy</w>
angiotens in</w>
V R
Some thing</w>
Re ad</w>
Author isation</w>
wor ry</w>
will ing</w>
us e).</w>
raz ol
rab bits</w>
period ;</w>
pen et
p es</w>
now !</w>
mil k,</w>
fiel d,</w>
et ?</w>
d ance</w>
breast-feed ing.</w>
V acc
L AB
He pati
Ac id</w>
tob acc
str ange</w>
pharmac ological</w>
met adata</w>
hydro lys
compon ent
bre ad</w>
asth ma</w>
appro aches</w>
al ized</w>
Trans fer</w>
Sand oz</w>
ST CW</w>
O ri
Israel ites</w>
ven ous</w>
them :</w>
rat e.</w>
piv ir
og en</w>
ob serve</w>
mut ations</w>
li p</w>
l ou
ic a</w>
glycaem ic</w>
fa il</w>
establish ed,</w>
d well</w>
c up</w>
c iclospor
S pe
MabTh era</w>
Josh u
EM AS</w>
D id
vehicl es.</w>
unit s/
u h,</w>
shor t
scen ari
sampl ed</w>
inspec tion,</w>
fac es</w>
enh anced</w>
ear th.</w>
cost s.</w>
conclud e</w>
bro ther.</w>
Z on
Rap id</w>
Is n't</w>
Ac tu
wro te</w>
psy ch
out !</w>
justi fy</w>
independ ently</w>
hydraul ic</w>
gu il
f air
cophen olate</w>
ati tis,</w>
V )</w>
Sur ve
Sta y</w>
F T
E ph
CYP 1A
70/ 524
3. 3</w>
' s.</w>
war nings</w>
wal ked</w>
scre w</w>
scre en
offic e.</w>
intramus cular</w>
ing -up</w>
he 'd</w>
g ue</w>
ey e,</w>
entity s</w>
electro ly
e- related</w>
cas h-
bes artan</w>
at ed;</w>
Rep ubl
P hys
Ex peri
As k</w>
4 :</w>
suscepti bility</w>
promp tly</w>
organis ational</w>
or ange</w>
ol ic</w>
h all
ev ening</w>
dom ,</w>
Reg istr
5 6
201 3.</w>
volunte ers</w>
troubl e.</w>
test ing.</w>
sign alling</w>
rheum atoid</w>
recipi ent</w>
own ers</w>
ity /
gran ul
fles h</w>
fic ial</w>
ev ents,</w>
d one,</w>
cr u
ad ren
Un able</w>
Sou th</w>
Egyp t</w>
z ing</w>
ten d</w>
sure ly</w>
sm ell</w>
opportun ities</w>
nat al</w>
mollusc s</w>
l ens</w>
gradu ated</w>
evap or
es om
decl are</w>
con current</w>
certi fying</w>
bul l
brea ks</w>
am b
V L
Tr ade</w>
J usti
F C
5 9
won der</w>
w/ w</w>
vacc ine.</w>
ud e,</w>
ti red</w>
se w
pyro technic</w>
psy chi
pr on
our ,</w>
kind s</w>
in habit
em itted</w>
double- blind,</w>
biom ass</w>
benefit s,</w>
audit ors</w>
ac king</w>
Winthro p</w>
V it
EC U</w>
Dis till
Author ity.</w>
4 4</w>
worl d,</w>
will ,</w>
sub sets</w>
strain ts</w>
pass es</w>
initi atives</w>
infu sion
in complete</w>
decisi on-
coff e
advanta ge</w>
Pursu ant</w>
H ,</w>
Child ren</w>
Ben j
y /
st ress</w>
slud ge</w>
see king</w>
le g</w>
k a</w>
inflam m
fol lic
etc .,</w>
es is</w>
compan y,</w>
colum ns</w>
brow n</w>
Wa it</w>
S ir,</w>
S C</w>
Reg istry</w>
Qu ality</w>
P al
wor ms</w>
wee k,</w>
water -
type- examination</w>
trans dermal</w>
stuff .</w>
rel ax
ov arian</w>
natur ally</w>
micro- organisms</w>
ligh ts</w>
ill ness</w>
g res
et ed</w>
craz y</w>
cor on
cop i
carbon ate</w>
b ones</w>
Prin ci
9 7</w>
2 /EEC,</w>
um e</w>
ti tration</w>
st ock
ro ll</w>
rib avir
re aching</w>
pref erred</w>
other s.</w>
o- 1,
mou th.</w>
for tun
f ear
energ y-
el ess</w>
dis pose</w>
chang ed.</w>
at in,</w>
and ed</w>
[ 2
T abl
Qu e
3. 5</w>
way s.</w>
volati le</w>
urg ent</w>
op or
lit re</w>
just ...</w>
en ?</w>
el ines</w>
drin ks</w>
dis c</w>
bil ateral</w>
at ul
ac in</w>
Un common:</w>
U r
M or
Decisi on,</w>
C la
AT IONS</w>
18 0</w>
trans amin
tend ers</w>
surfac e.</w>
se es</w>
naphth a</w>
kn itted</w>
haemorrh ag
colour ing</w>
bilirub in</w>
D add
Cha in</w>
you :</w>
wind screen</w>
t inib</w>
stor age,</w>
sl ight</w>
p ping</w>
ma k
gran ules</w>
fer mentation</w>
ercep tin</w>
coord inate</w>
c ,</w>
ation -
a i
Coo per
COM M
secre t</w>
restri al</w>
plan ts,</w>
part y,</w>
k itch
it s.</w>
ful ,</w>
ell ar</w>
effor t</w>
bloc king</w>
bl ocks</w>
adequ acy</w>
adap ting</w>
S ER
R i
Pe metrexed</w>
P ER
L )</w>
Col l
C CP
B oo
wor st</w>
vulner able</w>
s al</w>
require ments:</w>
repe at
men opa
law ful</w>
kid .</w>
hour .</w>
er mal</w>
ed e</w>
conform ing</w>
cess ation</w>
boo k
avoid ed.</w>
aquac ulture</w>
al og
Vehic le</w>
Un common</w>
Preg abalin</w>
M B
Jerusal em,</w>
F unc
F ri
v entricular</w>
subjec ts,</w>
serv ing</w>
s wee
refr act
re min
pollut ant</w>
pi g</w>
nu clear</w>
ing ly</w>
hormon al</w>
aer ob
F requ
F R
2 20
yea h,</w>
wi fe
tic ,</w>
superv ised</w>
sum mer</w>
spac e.</w>
petro l</w>
pa ir</w>
o ing</w>
neuro path
n evertheless</w>
mem br
ma p</w>
loc ations</w>
in h
him !</w>
har vest</w>
extrem ely</w>
e ur
conc e
cathet er</w>
avoid ing</w>
al og</w>
S IS</w>
Pet er</w>
H erceptin</w>
” ).</w>
tor s,</w>
there after</w>
reli ef</w>
pharmac odynamic</w>
li ps</w>
k in</w>
id ae</w>
fact ,</w>
chang e.</w>
add ed.</w>
Lea ve</w>
A Z
4 3</w>
third- country</w>
riton avir,</w>
pil ot
multipl ied</w>
il ly</w>
develop ment.</w>
der m
depos itary</w>
day )</w>
carcin ogenicity</w>
believ ed</w>
Certific ate</w>
C ell
Bi g</w>
- in-
w ine,</w>
u cle
mean s.</w>
l /
i ent</w>
hel ping</w>
ga ther</w>
es sions</w>
dro ps</w>
compris es</w>
b om
M )</w>
Em ploy
; .</w>
4 1</w>
(1 0)</w>
( where</w>
% 1
prolong ation</w>
po ol</w>
physici ans</w>
or y,</w>
lov es</w>
house holds</w>
extr acted</w>
ear th,</w>
diagno sed</w>
cli ents</w>
Rec ord
H al
D em
Centr e</w>
CART ON</w>
% ;</w>
" I</w>
whil e.</w>
v ac
tri be</w>
th -
stup id</w>
si a,</w>
ser s</w>
require ments;</w>
prou d</w>
prescrib ing</w>
opini on,</w>
metr e</w>
it ant</w>
insuffici ency</w>
identifi ed.</w>
fulfill ed.</w>
expo sure,</w>
er s)</w>
en rolled</w>
carcin ogenic</w>
bre l</w>
bi of
Y et</w>
V ari
They 'll</w>
Sub -
C ir
“ ‘
w n</w>
v s.</w>
tubercul osis</w>
trans mis
tari ff</w>
some thing?</w>
serv ed</w>
p ent
mem bran
hand s,</w>
f et
e ase</w>
develop mental</w>
auth or</w>
at ad
any l</w>
ac company</w>
In de
Comm on:</w>
8 7</w>
1 3,</w>
( %)</w>
ve -
val ve</w>
stead y-state</w>
need les</w>
ne arly</w>
mid azol
explo itation</w>
ele br
constitu ent</w>
canc er,</w>
c ing</w>
ady cardi
Wast e</w>
N 1</w>
M any</w>
G ross</w>
(a ).</w>
( at</w>
yl ated</w>
struc tured</w>
l au
est ers</w>
dis clos
degre es</w>
connec tions</w>
candid ates</w>
c are.</w>
bagg age</w>
b y.</w>
b A1
W ind
U h,</w>
P H
M ove</w>
D /
B AT
0 ).</w>
w are
urg ency</w>
prov ed</w>
ph er
op hy
on ate</w>
oc e
mat ch</w>
los s.</w>
it rac
ing /
hy persensi
fail s</w>
dre am</w>
defin ing</w>
clos er</w>
be et</w>
acaf tor</w>
SU B
Jes us,</w>
IN FORM
Compli ance</w>
91/ 49
7 3</w>
2 1.
us ed;</w>
obstac les</w>
n ation</w>
long .</w>
him self.</w>
emb ed
coun ter</w>
cho ice.</w>
brea king</w>
Sup port</w>
Li pro
Ital y</w>
Col on
C O</w>
Ab out</w>
2010 .</w>
’ .</w>
vit ro
sup plements</w>
rel ations</w>
merg er</w>
investig ate</w>
inhi bits</w>
fatten ing</w>
es ign</w>
e igh
anc ies</w>
ab out?</w>
B ur
(1 0</w>
sof ar</w>
sodi um,</w>
pl ug
ozol omide</w>
mo fe
innov ative</w>
follow s</w>
d ye</w>
consider ations</w>
ch er
b ed.</w>
am or
Implement ing</w>
4 7</w>
w ire</w>
w in</w>
sulphonyl urea</w>
scrutin y</w>
re alis
pum ps</w>
polic y,</w>
par ty
loc k
ish ment</w>
institu tional</w>
in no
id ed</w>
fl ocks</w>
dis infec
ch ic
ch apter</w>
am ins</w>
al er
Z Y
Tran sport</w>
T im
Jac ob
Every thing</w>
Er ror</w>
En brel</w>
Acta vis</w>
7 ).</w>
2, 5</w>
u n</w>
temperat ure.</w>
tac hy
ren ,</w>
ref used</w>
pro xim
institu tion,</w>
ig ence</w>
gram s</w>
excep tions</w>
ev ents.</w>
est er</w>
electr on
dist ant</w>
corticosteroid s</w>
add er</w>
ac knowledg
ac ent</w>
T ry</w>
PCB s</w>
M es
M .A.
D ar
C os
C U
top ical</w>
thick ness</w>
t s
subm itting</w>
sh ift</w>
practic able</w>
mark ,</w>
it ted,</w>
intr ac
him :</w>
friend ,</w>
fact ors,</w>
confir matory</w>
arriv al</w>
What ever</w>
Wel come</w>
Respon se</w>
00 /
z .</w>
sup pose</w>
stor y.</w>
r af
preserv ed</w>
pip es</w>
n -
fertilis ers</w>
famil y,</w>
fail ing</w>
canc er.</w>
amlodip ine</w>
ab or
T M
Sk in</w>
S o
Jac ob</w>
Egyp t,</w>
Doc etaxel</w>
Author ity)</w>
- -
y ester
valu es.</w>
sor e</w>
s cop
resol ve</w>
power ful</w>
pharmac ist.</w>
ow er</w>
k l
it ly</w>
f ell
equip ment;</w>
en ables</w>
embry os</w>
ea red</w>
drin k.</w>
diox in-like</w>
competi tiveness</w>
blur red</w>
act ,</w>
Stat utory</w>
S ave</w>
P ass
thing 's</w>
sub stitution</w>
su peri
sti r
rati op
ratiop harm</w>
quali fy</w>
monit ore
metal lic</w>
direc tives</w>
differen ti
dail y)</w>
boo k.</w>
b und
authoris ation.</w>
af ore
Th ink</w>
B -
Attrib utes</w>
66/ 40
16 0</w>
10 %</w>
(j )</w>
whe ez
uma b.</w>
single- dose</w>
ris ks.</w>
rang es</w>
pl ain</w>
lit y.</w>
k W
ju ven
head ache</w>
gl ut
flu o
er !</w>
en closed</w>
com ing.</w>
N evertheless,</w>
Manufacture rs</w>
Exam ples</w>
( W
' em</w>
yl -
mid st</w>
lif ts</w>
lif ting</w>
li ked</w>
k le</w>
issu ers</w>
incid ent</w>
in direc
forward ed</w>
fibr ill
compar ing</w>
c ine</w>
air -
adj acent</w>
Hum ira</w>
200 9.</w>
operat or,</w>
ol im
infec tions.</w>
exc ell
em plo
asset s.</w>
arrhyth mi
a us
Un ivers
IS T</w>
E qu
Det ails</w>
Con sum
Cer tain</w>
4 6</w>
we 'd</w>
w inter
satis fying</w>
mod ul
mo m</w>
lat est,</w>
ili ation</w>
hydrochlorothiaz ide</w>
er ial</w>
ect ual</w>
depart ment</w>
clo ts</w>
as sh
af er
Per haps</w>
Fil ter</w>
B at
Acc ession</w>
( option
tub es</w>
subsidi arity</w>
po sts</w>
out put
it one
intraven ously</w>
gluc uron
glass )</w>
g e,</w>
fabric s</w>
dis covered</w>
copi es/
bo ard.</w>
arm ed</w>
Solom on</w>
Mil ky</w>
1 1.</w>
(2 -
work s.</w>
si ves</w>
process ing,</w>
or ;</w>
met :</w>
law y
hol id
f ent
exerc ising</w>
e ment;</w>
des i
circul ating</w>
ang el</w>
according ly</w>
Ru per
In stitute</w>
Gunn ar</w>
Exc use</w>
E ASA</w>
D M
A mon
24 -
1 2.5</w>
( 5</w>
temperat ures</w>
ta ught</w>
regi mens</w>
plan es</w>
infra red</w>
incre mental</w>
hav e.</w>
ha ve
dysp no
del ay,</w>
comple mentary</w>
antivir al</w>
Un it</w>
Sorr y,</w>
S AF
L ast</w>
Inst all
EN T</w>
5 7</w>
/ she</w>
weak ness,</w>
toler ated</w>
sub paragraphs</w>
prote in
pac lit
ox ifene</w>
methotrex ate</w>
level ;</w>
fati gue,</w>
father 's</w>
c able</w>
b on</w>
au to
an ase</w>
a ...</w>
Wat ch</w>
S ay</w>
Rev .</w>
N ext</w>
L ong
F ,</w>
Dav id,</w>
D er
2010 ,</w>
- specific</w>
y x</w>
wa ke</w>
sion al</w>
seiz ures</w>
saf ely</w>
ro- ro</w>
our se</w>
month ,</w>
gly col
firm ly</w>
con cre
complain t</w>
compil ed</w>
chem ically</w>
ch air</w>
bri ef
ation ),</w>
Lipro log</w>
INFORM ATION</w>
H ER
Are a</w>
A mend
weak ness</w>
tl ing</w>
s overeign</w>
row s</w>
ras h
pri est
poly propylene</w>
par a</w>
p in</w>
o ter
neutr al
manag ers</w>
jurisdic tion</w>
includ ed.</w>
gend er</w>
dab r
condition s;</w>
as par
al s;</w>
a i</w>
Maj or</w>
It 'll</w>
G ra
E .
Cz ech</w>
Cl assi
CON T
A no
(1) (a)</w>
v e.</w>
squ are</w>
seafare rs</w>
sa x
s cler
s cat
provisi ons.</w>
p unc
ow e</w>
ok ay,</w>
occur s,</w>
mul tic
meaning ful</w>
las er</w>
decisi on,</w>
condi tional</w>
any way.</w>
agre ement.</w>
ag it
acqu ire</w>
PRE Z
John son</w>
Invest ment</w>
Hum alog</w>
B es
AS S
AP PROV
sul fur
st eam</w>
repe al
produc t;</w>
prior ities</w>
hom e
fu n</w>
f ellow</w>
ag o,</w>
aer os
You 'd</w>
Where as:</w>
M ach
IS S
How 's</w>
Di ff
Bi o
A X
(b ).</w>
work ers,</w>
smo king</w>
saf e.</w>
ps r</w>
oes oph
mu sic</w>
mir r
measure ,</w>
h uge</w>
depres s
bro m
amino transferase</w>
aff ix
acid osis</w>
ab ,</w>
a bel</w>
Sal monella</w>
S hel
Pre ven
O la
M am
F CL
ES S
B E</w>
vin ey
sh ir
recom mend</w>
own ed</w>
noti fier</w>
monohydr ate</w>
is ;</w>
ga me.</w>
equ ally</w>
dr af
di methyl
destro y
del ay.</w>
d al
cycl e,</w>
arrang ed</w>
aliski ren</w>
ag ed,</w>
addres ses</w>
T ox
P ack
G ly
Actu ally,</w>
4. 2.
20 92/
(C AS</w>
ur in
t ext
st em</w>
mater nal</w>
deli ber
d op
car ded</w>
b icon
[1 ]</w>
V eri
T ro
M emb
L it
I sa
F ile</w>
199 4</w>
sum m
siz e,</w>
on i
in er
experienc e,</w>
es c
en sure
cr ack
clust er</w>
capsul es.</w>
as c
air por
Ola f</w>
IN C
IM I</w>
How ever</w>
G i
Dep ending</w>
D .
C li
(2 );</w>
w ay?</w>
us )</w>
trig g
t /
shap ed</w>
re st.</w>
nur se.</w>
lor atad
iv ud
il ine</w>
ground ,</w>
gi ant</w>
effectiv e,</w>
de -
cong reg
cis platin</w>
ataz anavir</w>
adv ice.</w>
T ru
Sub part</w>
PC D
M AN
Gal ile
Fin land</w>
Char li
5 ,
( type</w>
your s.</w>
us es.</w>
tion -
terat ogenic</w>
purch ases</w>
ph ases</w>
ist ing</w>
h edge</w>
gre y</w>
fe ature</w>
fast .</w>
counter party</w>
cellul ose,</w>
c ock
bre ed
ati s</w>
ad es</w>
ad apter</w>
Th us,</w>
Riv astigmine</w>
H bA1
strong ly</w>
ri ding</w>
pra ise</w>
pl ing</w>
neph ro
mat ter,</w>
includ ing:</w>
in sofar</w>
happen ed.</w>
f on
es sion,</w>
digox in</w>
d )</w>
as sume</w>
aggreg ated</w>
W il
V el
Some one</w>
4. 1.
(0. 9%)</w>
( other</w>
vis its</w>
undertak ings.</w>
un expected</w>
tion ).</w>
subsidi aries</w>
recover able</w>
prec ious</w>
ob struc
n 't.</w>
log o</w>
knowledg e,</w>
in organic</w>
fur nit
first -
ev olution</w>
enc e;</w>
en vel
desc end
c ity.</w>
ann ually</w>
Re port</w>
QT c</w>
8 8</w>
0 6</w>
z oledronic</w>
vide o</w>
tobacc o</w>
susp ici
stit ut
se al
s ong
s and
righte ous</w>
ow ed</w>
ococc al</w>
n ity</w>
materi als.</w>
m mol</w>
is om
end o-1,
eas ier</w>
d ress</w>
conc ession</w>
cal ci
ar my</w>
acc ession</w>
ac compl
F i
Cont ent</w>
5 3
4 ;</w>
(5 ).</w>
“ You</w>
wor n</w>
wall s</w>
s lip
prof ession</w>
polys orbate</w>
nit rate</w>
nar row</w>
monitor ing,</w>
injec tor</w>
haemorrh age</w>
gl ov
ex ic
double- blind</w>
discre tion</w>
c elebr
P ,</w>
M ethyl
He ad
H on
Fr anc
Ear th</w>
E le
Did n't</w>
C at
Bel gi
7 3/
4 /EEC</w>
transpor tation</w>
ti um</w>
stat ements.</w>
se ating</w>
say s:</w>
reserv o
reflec ting</w>
public ,</w>
pleas e?</w>
p and
hypoten sion,</w>
e. ”</w>
d y.</w>
constit uting</w>
an other.</w>
aliv e.</w>
al ity.</w>
US E</w>
Ne w
N R
N E
Environ mental</w>
ECT ION</w>
C ard</w>
17 .
tre s
satur ated</w>
r ation
r ace</w>
out comes</w>
ol ine</w>
off ers</w>
oc k.</w>
lik es</w>
em o
dos ing.</w>
distinc t</w>
dec imal</w>
car s</w>
attemp t</w>
appe aring</w>
ap art</w>
anc ing</w>
P S
Op inion</w>
F ather</w>
Con centr
(d ),</w>
" The</w>
whe at</w>
we an
ver ifying</w>
trad e,</w>
sen ior</w>
packag ing,</w>
operat or.</w>
old -
net work.</w>
fu el
corne al</w>
concer ted</w>
cam pa
bur ned</w>
V -
Ol anzapine</w>
H all
A z
16 ,</w>
to il
sp in
sev enth</w>
serv er</w>
re aches</w>
re ach
programm es.</w>
i es;</w>
dimen sion</w>
deleg ation</w>
cros sing</w>
controll ed,</w>
benefici aries</w>
atmosph ere
ass et.</w>
adul ts,</w>
ad h
Sh all</w>
P resident</w>
Cro ati
1 18
ti ble</w>
streng then</w>
record ed.</w>
ol ive</w>
oc or
observ ed,</w>
need le.</w>
los ing</w>
k g
introduc ing</w>
h ire</w>
e es</w>
dep th</w>
defin it
cr y</w>
conflic ts</w>
cam p
bri ef</w>
bacter ia</w>
ap rep
antibio tics</w>
am id
absor p
V T
N either</w>
Lim ited</w>
Icel and</w>
91/ 67
water way</w>
ship ping</w>
se ed
rang e.</w>
prepar ation,</w>
pos ac
ol d,</w>
mar ry</w>
is m,</w>
effec ted</w>
cro ch
cr af
complex ity</w>
ch ari
c ig
bo y
ag lu
accident ally</w>
X X
St ep</w>
Hos pira</w>
HP V</w>
4. 8</w>
( AT
y me</w>
wh at,</w>
ure ;</w>
struc tur
say ?</w>
par t.</w>
ing s;</w>
haemorrh age,</w>
ev ent,</w>
embed ded</w>
dispos able</w>
cl ass.</w>
c al</w>
bes ide</w>
U l
Op ti
J ack</w>
Hy po
EX P.</w>
D S</w>
As say</w>
5 1</w>
( Table</w>
w inter</w>
w er</w>
trav ell
tim ate</w>
special ist</w>
regist ers</w>
phas e.</w>
op aque</w>
n g/
ini um</w>
fre ight</w>
em phas
dist ress</w>
circu it</w>
charg e,</w>
car bo
at e).</w>
again ?</w>
ag e;</w>
Pre vention</w>
Pa ediatric</w>
In divid
II ;</w>
I H
AS T
AD E</w>
( K
w ard.</w>
up -to-
tw o.</w>
thromboembol ic</w>
stri p</w>
st ones</w>
sh ared</w>
re med
re dem
lam ps,</w>
k er.</w>
instruc tions.</w>
i od
gener ic</w>
form ity</w>
fil ters</w>
farm ed</w>
diox ins</w>
collec tion,</w>
TS E</w>
St art</w>
N i
M id
M exic
F iel
Bor tezomib</w>
Av oid</w>
A tri
weap ons</w>
wash ed</w>
valu es,</w>
st ellar</w>
pow er.</w>
orig in.</w>
on autical</w>
m asses</w>
lo ose</w>
la you
l av
ini b.</w>
inhal ed</w>
ig at
gener alised</w>
g ate</w>
ext ending</w>
ex .</w>
dis per
dil ute</w>
descrip tions</w>
def ence</w>
def ects</w>
ag en</w>
T as
S pan
Paragrap hs</w>
C el
we al
tro ugh</w>
tr um
stud ents</w>
resear ch
ra ising</w>
opo i
om .</w>
n ig
it -
in soluble</w>
he ts</w>
gluc os
gen ,</w>
end ed.</w>
else where</w>
d as
col on
boo ks</w>
b ow</w>
ar ab
appe tit
an ten
ad y</w>
M O
CY P</w>
Ac tive</w>
1 20
- wide</w>
vis ually</w>
v ice</w>
understand .</w>
thereof ;</w>
secur ity,</w>
refract ory</w>
rab bit
pul p</w>
per me
o )</w>
malign ant</w>
loo k,</w>
it self.</w>
involv ed.</w>
intell ectual</w>
institu tion
he par
go l</w>
fun .</w>
enc es,</w>
edg es</w>
dog s.</w>
coron ary</w>
b ing</w>
altern ate</w>
ab out,</w>
Spi rit</w>
Pharmac okine
Loc al</w>
H as</w>
E th
B Y</w>
ys is.</w>
wind ow.</w>
t ation.</w>
sofosbu vir</w>
ship ment</w>
sel v
person n
ophil ia</w>
ocy te</w>
oc ation</w>
nigh t
l em
in adequate</w>
fel low
fas hi
fac ing</w>
comm odi
cir rh
character s</w>
cere als</w>
bound ary</w>
bleed ing,</w>
back ?</w>
avir/ ritonavir</w>
ar ly,</w>
analy se</w>
Spiro max</w>
Ne o
N one</w>
B ack</w>
tri al,</w>
represent ation</w>
pr an
ord ered</w>
on- the-
ob arbit
menopa usal</w>
m ount</w>
import ation</w>
head ings</w>
fish ,</w>
dom ain</w>
discomfor t</w>
clou ds</w>
chick ens</w>
bro thers</w>
an other,</w>
P aul</w>
G ,</w>
Associ ation</w>
w ound
unit s.</w>
tri p</w>
te eth</w>
tam per
sur ge
psychi atric</w>
opo e
m m,</w>
fil tration</w>
es cal
elev ation</w>
di e,</w>
dar un
bow el</w>
b ure
author ity;</w>
anti psycho
Wh at,</w>
T N
O UT
John ’s</w>
Ca ref
86/ 36
0 9.
un controlled</w>
sw allowed</w>
sp read
some thing,</w>
smar t</w>
sm ote</w>
sh ed</w>
seg ment</w>
paragrap h
ox ides</w>
o par
maj or
lip id</w>
lic k</w>
instru ments.</w>
hav e,</w>
fav or
en cl
ed ),</w>
d airy</w>
d a</w>
conduc ted.</w>
col lo
but ,</w>
bival ve</w>
at e-
ar gu
am ong
P il
H -
F ore
5 8
tru e.</w>
trans- European</w>
tachy cardi
spec tive</w>
s wa
ru it</w>
puri fied</w>
precau tionary</w>
ot on
om al</w>
og u
nu ts</w>
eli hood</w>
econom ically</w>
dis cover
colour s</w>
circumst ances.</w>
b ic
ati ve
alumin i
RE Y
Ph ot
P ress</w>
Commun ities.</w>
Av ail
A A</w>
98/ 8/EC</w>
200 3,</w>
( g
stit utes</w>
speci men</w>
process es,</w>
p ock
neuro pathy</w>
hun gr
determin es</w>
chass is</w>
br adycardi
ann u
T en
Statis tics</w>
REY AT
M echan
B ill
1 B
- 2</w>
visi bility</w>
us tic
tru th.</w>
sp inal</w>
radi us</w>
pass age</w>
otyp es</w>
oste opor
luc ky</w>
it zer
it :</w>
fati gue</w>
ex ports</w>
disturb ances</w>
cyl inder</w>
cris is</w>
clo thing</w>
ard ing</w>
alg ia,</w>
T ou
Some times</w>
M odi
Every body</w>
Eur o</w>
Chri st,</w>
CYP2D 6</w>
AB L
A sh
up s</w>
sh ot
second s.</w>
se a
remedi al</w>
pen sion
o a</w>
liquid ity</w>
lique ur</w>
is er</w>
in o</w>
grap h</w>
eith er:</w>
e ut
cros s
cri ed</w>
con v
chang es,</w>
arm ,</w>
Syn dro
P re-
NS AID
NG C</w>
G )</w>
Dul oxetine</w>
8 3/
1408/ 71</w>
us ;</w>
thrombocytopen ia</w>
t ang
produc es</w>
pres sed</w>
people )</w>
pen s</w>
offic es</w>
m as
inv ite</w>
inv asive</w>
interrup ted</w>
inf li
hybri d</w>
hon ey</w>
geograph ic</w>
ey e.</w>
evir apine</w>
et ra</w>
environ ment;</w>
e. "</w>
delet e</w>
ag rel
acetyl salicylic</w>
L ,</w>
FCL .
v ital</w>
su it</w>
rang ing</w>
pow der.</w>
inf eri
he /she</w>
formul ae</w>
dog .</w>
dies el</w>
bu ried</w>
bet a</w>
among st</w>
alan ine</w>
Whe ther</w>
Tem ozolomide</w>
Engl ish</w>
De part
Cl ose</w>
C hi
89/ 10
( vi
tre es</w>
s ession</w>
ril pivir
recycl ed</w>
re jection</w>
ligh t
k el</w>
hid den</w>
g est
expec ted.</w>
deploy ment</w>
deb ossed</w>
car d.</w>
b ile</w>
anti- inflammatory</w>
Sw itzer
S oci
In d
Hydro chlor
5 ),</w>
% s</w>
‘ 1.</w>
z ol
ul c
sudden ly</w>
s artan</w>
ren dered</w>
pro pri
point s.</w>
in ess,</w>
il legal</w>
form ance</w>
extrap ol
discontinu ed.</w>
con fusion</w>
cog ener
bot tle.</w>
as le
UR E</w>
R os
R V
Parkinson ’s</w>
J ere
I tem</w>
9 8
7 /EEC</w>
( +
vit amins</w>
veterin ari
tomor row</w>
tal k.</w>
sur fact
s "</w>
repor ts,</w>
re stor
posi t</w>
ph one.</w>
patient s)</w>
p om
ov al</w>
offer ings</w>
mg/kg/ day</w>
it 'll</w>
investig ating</w>
impa ir</w>
g all
fing er</w>
dis colour
decision- making</w>
constip ation,</w>
as best
Wh enever</w>
Preg n
Pos sible</w>
PV C/
P riv
O ther
M en
Guid ance</w>
Dec re
Complet e</w>
B acillus</w>
200 8.</w>
“ This</w>
word s,</w>
type- approval,</w>
transplan tation</w>
suc ro
membr ane</w>
loc king</w>
f y,</w>
dest ined</w>
are d.</w>
Z al
T ES
Observ atory</w>
N ations</w>
In ser
EM S</w>
Cont inu
Ber n
Agr icul
9 ).</w>
yea h.</w>
wel come</w>
ut ely</w>
tic .</w>
there in</w>
stand ard.</w>
sourc es,</w>
other s,</w>
ord er,</w>
me ters</w>
it able</w>
h e,</w>
draw ings</w>
detec table</w>
des k
de struc
contr ary</w>
cash- generating</w>
b ast
archit ec
ap olog
V II,</w>
Medi an</w>
H A</w>
CO .
word .</w>
wid ely</w>
ud e.</w>
ter ?</w>
sugg ested</w>
prob able</w>
lact ating</w>
keep s</w>
ing ),</w>
h ...</w>
go ?</w>
experienc ing</w>
en atide</w>
determin ed.</w>
cyt otoxic</w>
cy an
consum ers,</w>
calibr ated</w>
H S
Amon g</w>
9 9</w>
20 20</w>
uc in
though .</w>
scho ol
righ ts.</w>
prophy laxis</w>
oph thal
id ity</w>
happen .</w>
g/ d
feed er</w>
fa int
encour aging</w>
cr acked</w>
box .</w>
aut onom
ag ent.</w>
ag enc
[ 3
V EG
R EC
N RT
6. 1.</w>
5 /EC</w>
tur ns</w>
seri ously</w>
s ly</w>
ref usal</w>
ous ness,</w>
jec ts</w>
human s,</w>
gain s</w>
fin alised</w>
el ig
docu ment,</w>
distingu ish</w>
disord ers,</w>
discus sed</w>
dec ides</w>
citiz en
certain ly</w>
ag on</w>
Produc tion</w>
La w</w>
K et
ER S</w>
Counc il.</w>
) /
) ).</w>
( Part-
( CO
% 2</w>
your selves</w>
tariff s</w>
st uck</w>
sal v
sacrific e</w>
s crip
ro ad,</w>
pres sing</w>
posi tioned</w>
poly m
olog ous</w>
neuro logical</w>
micro crystalline</w>
mea sur
man ip
lens es</w>
ing ).</w>
in ;</w>
ill ing</w>
identifi es</w>
hyp oc
fl u</w>
de fl
compar ability</w>
coff ee</w>
ativ es.</w>
al so,</w>
Tra ining</w>
Sta r</w>
O D</w>
Memb ers</w>
Eph ra
Committe e.</w>
Commis sions</w>
C lear
AN C
< 0.00
70/15 6
6 3
17 ,</w>
tiv ity,</w>
there !</w>
than ks</w>
tak e.</w>
swe ar</w>
sci ence</w>
sampl e,</w>
ro of</w>
ret ari
requ is
phosph at
oz one</w>
ograp hs</w>
m yst
list ,</w>
ke y.</w>
g est</w>
form ation,</w>
fl ash
extr acts</w>
diseas es,</w>
ator y,</w>
Symptom s</w>
N ice</w>
N ame
Ky oto</w>
Cap tain</w>
AT ION
5. 2</w>
5 3</w>
00 ,</w>
w ishes</w>
trastuz umab</w>
tr acts</w>
to ...</w>
strateg ies</w>
s cared</w>
prop yl</w>
pron oun
pre sumed</w>
oppos ite</w>
objectiv es,</w>
lymph oma</w>
iv ol
in qu
expir ation</w>
el ed</w>
ec od
control s,</w>
breath ing,</w>
av es</w>
author iti
as eptic</w>
ar ial</w>
al ?</w>
P T
Fed eral</w>
F IR
Ano ther</w>
8 6</w>
50 %</w>
00 1</w>
sw allow</w>
slud ges</w>
refl ected</w>
osp as
organ ise</w>
n ice.</w>
mark er</w>
lif ted</w>
lear ned</w>
ia ),</w>
for got</w>
ecod esign</w>
doxorub icin</w>
craz y.</w>
contain s:</w>
ch el
bag s</w>
annex ed</w>
an ?</w>
aff ix</w>
ad visory</w>
accred ited</w>
P rac
Mar itime</w>
Labor atory</w>
L ight</w>
Justi ce</w>
G ases</w>
Altern atively,</w>
6 4</w>
200 7.</w>
(1 1)</w>
struc ture.</w>
spon taneous</w>
so ever</w>
sens ation</w>
sector .</w>
satis fied.</w>
resul t,</w>
refl ects</w>
pe di
ogen ous</w>
od il
liter ature</w>
l ot.</w>
king 's</w>
ho c</w>
fore ver.</w>
ef .</w>
cl eared</w>
bro ther,</w>
br and</w>
at tain
arter y</w>
an al</w>
advanta ges</w>
accur ately</w>
W illi
U p</w>
S I
L iver</w>
D E
CC P</w>
C hol
- ing</w>
wit ness</w>
tr a</w>
set ,</w>
pro be</w>
priv acy</w>
par ts,</w>
oul d.</w>
is ...</w>
happ y.</w>
feasi bility</w>
econom y</w>
ci di
V ER
Sub topic</w>
S I</w>
M ess
G ard
E duc
Di ag
Criteri a</w>
C anc
201 6</w>
(i ),</w>
(A UC
undertak ing.</w>
thre w</w>
sti ff
speci fies</w>
sp ap
ro d</w>
ri a</w>
rec k
pow er,</w>
person s.</w>
mag nit
load s</w>
lik elihood</w>
levod opa</w>
laun ch</w>
it ap
ill a</w>
homogen eous</w>
fire ,</w>
f an</w>
em ia</w>
ell ular</w>
di d,</w>
consider able</w>
consequ ently</w>
concentr ation,</w>
compres sion</w>
competi tion,</w>
accel eration</w>
RE D</w>
4 (1)</w>
200 4,</w>
1 10</w>
( creatinine</w>
y es/
vent ure</w>
trad er</w>
trac eability</w>
stra di
situ ation,</w>
rec ourse</w>
re store</w>
prov en</w>
product- type</w>
pris on
polic ies,</w>
physi ological</w>
ph thal
ord in
on i</w>
lymp h</w>
jo y</w>
id e/
ex pos
emis sions,</w>
de posit</w>
contain er.</w>
comm is
aw ay
attach ment</w>
Ne bul
N U
L ith
Here ,</w>
Guid elines</w>
30 -
syn erg
st en
sec rec
quar ter</w>
medic in
me ...</w>
mal function</w>
im umab</w>
erad ication</w>
de em</w>
capac ity,</w>
at o
at e:</w>
ag lin
ag ement</w>
VI S</w>
H T
G NS
En ter
A m</w>
5 8</w>
target ed</w>
shoul d
qual ifying</w>
popul ation,</w>
phen omen
our .</w>
oc r
nec ro
mic ron
intr av
im ple</w>
he ?</w>
ferti lity.</w>
establish ment,</w>
es tion,</w>
dis closures</w>
ation ?</w>
T on
St .</w>
P ull</w>
HbA1 c</w>
H i,</w>
G rand
Fol low</w>
Cooper ation</w>
9 7
tw o,</w>
specific ations,</w>
phen obarbit
nom encl
lik e.</w>
k iss</w>
furn ace</w>
explic itly</w>
disturb ance</w>
din ner</w>
describ ing</w>
cl am
attest ation</w>
are s</w>
approv ed.</w>
all -
activ ely</w>
acr yl
Wor k</w>
Re stric
Imm uno
D ig
70/524 /EEC</w>
(‘ the</w>
wh o,</w>
war r
wa it
var n
thin k.</w>
ta bility</w>
st ayed</w>
sp r
sit agliptin</w>
sign at
respon ding</w>
otox ic
organis ation,</w>
my cophenolate</w>
il it
g es
fro m,</w>
fre e
for gotten</w>
ep razole</w>
discomfor t,</w>
controll er</w>
comfor t</w>
ch oc
car go
P aul
M ov
M ix</w>
Ir on</w>
In jec
Ch il
1 :
( 20
zoo technical</w>
up-to- date</w>
tr ame
se a,</w>
registr ation,</w>
re conc
princip ally</w>
pric ing</w>
pl ag
perform ance.</w>
ov al
or y.</w>
oll en</w>
methodolog ies</w>
itone al</w>
gran ted.</w>
dos e)</w>
bel ts</w>
b ath
appreci ate</w>
ag e)</w>
aem ia.</w>
P at
M ,</w>
It ali
Dist rib
Al so,</w>
Afric an</w>
5 4</w>
v ig
ton gu
toge ther
subcutan eously</w>
lung s</w>
instru ment.</w>
inh erent</w>
indic es</w>
imp urities</w>
hi p</w>
compart ments</w>
atmosph eric</w>
appoint ment</w>
Simil arly,</w>
ST E
S har
H and
A tl
201 1.</w>
10 ,000</w>
trans lation</w>
star ted.</w>
sk ill</w>
sac het</w>
run way</w>
perfor ated</w>
path ogen
ly ;</w>
it self,</w>
ist ,</w>
flex ibility</w>
financ ed</w>
et an
ent s:</w>
ent ;</w>
ed ...</w>
be ar
after no
TH ER</w>
T O
Sap t</w>
P N
Or al</w>
Ex po
C M
6 2</w>
( Annex</w>
star s.</w>
som ni
ple :</w>
phosphor us</w>
pen sions</w>
p y</w>
oper ates</w>
ocyt es</w>
me al.</w>
head ed</w>
exp ire</w>
ep h</w>
endor se
do or,</w>
di ed.</w>
child ’s</w>
bat tle</w>
an aesthes
am ic</w>
G il
D V
Cap ital</w>
A Z</w>
(c )
y ol
wa ived</w>
so on.</w>
s is,</w>
respon se,</w>
resear ch,</w>
phas e,</w>
ol y
myel oma</w>
ly ophil
isol ates</w>
involv ed,</w>
grav ity</w>
flam mable</w>
commun ity</w>
bot tl
bo ard,</w>
antagon ists</w>
all ed</w>
V EL
OUT ER</w>
Measure ment</w>
Joshu a</w>
5 /EEC</w>
0 7</w>
( IN
where :</w>
we b</w>
w ishing</w>
ther ing</w>
sion )</w>
sh if
rumin ants</w>
random ized</w>
prob ability</w>
mL/ min
k ni
juven ile</w>
infu sion,</w>
has n't</w>
fulfill ing</w>
ev acu
d ated</w>
commerci ally</w>
P OR
Mainten ance</w>
B ol
which :</w>
us !</w>
trans l
tion /
thro at,</w>
suspec t</w>
suppl ying</w>
selec ting</w>
rul e,</w>
ret ard
reas on,</w>
reac tion.</w>
re vol
preserv ation</w>
o stat
noti fications</w>
moun tain</w>
me )</w>
lab el.</w>
industr y,</w>
gas .</w>
ex -
end er</w>
dos ed</w>
defini tive</w>
conf id
ass et,</w>
V /
Not e:</w>
Mod ule</w>
L ED</w>
G ar
F O
Applic ants</w>
A si
6 6</w>
20 .</w>
1 (1)</w>
0. 1</w>
vic tim
ti me?</w>
territor ial</w>
ro tation</w>
re pli
ph on
pain ful</w>
out lined</w>
im atinib</w>
haemodi alysis</w>
eng age</w>
ele ments:</w>
def ec
be at
be ?</w>
as ide</w>
al ign</w>
aer onautical</w>
ab und
S a
Ecol abel</w>
Develop ment</w>
(E17 2)</w>
view ,</w>
ur ine,</w>
tod ay,</w>
to ys</w>
sulph uric</w>
stim ulation</w>
spea king</w>
safegu ards</w>
quanti fication</w>
pul led</w>
perm ission</w>
out door</w>
os .</w>
o x</w>
n ick
mill ig
me tro
long ,</w>
km/ h</w>
de ar</w>
c ous
benzo ate</w>
an i
al ive</w>
aff ili
ab use</w>
M .</w>
Jos eph</w>
A ),</w>
201 3,</w>
0. 3</w>
wast e.</w>
urtic aria,</w>
t adalafil</w>
stat us,</w>
stand ardi
sim vastatin</w>
se at
practic es,</w>
objectiv e,</w>
k ;</w>
evalu ated.</w>
com a</w>
catal y
cap ecitabine</w>
ax les</w>
ator s.</w>
Posi tive</w>
P B
Gen u
C AT
Alumin ium</w>
200 5.</w>
vehicle ;</w>
valu ed</w>
ter i
su b</w>
ren tal</w>
rec re
pre sid
pre serve</w>
por table</w>
os ine</w>
oder ma</w>
meta st
len alidomide</w>
job ,</w>
hon ey
holder s,</w>
heav en,</w>
explo sives</w>
ed /
distill ate</w>
cough ,</w>
contrib u
consist ently</w>
breast- feed</w>
bl ack
as then
ammon ia</w>
administ ered.</w>
ab u
R are</w>
Proced ure</w>
Meth ods</w>
K j
Jerusal em.</w>
G as</w>
F und</w>
Every one</w>
Can not</w>
9 3
6 ),</w>
wonder ful</w>
sp as
sen sor
ri m
pos it
pic ked</w>
o tide</w>
muc h,</w>
me try</w>
mark ings</w>
lin ing</w>
in correct</w>
hedg ing</w>
fe ed,</w>
famili ar</w>
f ound.</w>
dang er
dab igat
challeng e</w>
bos entan</w>
block ers</w>
associ ate</w>
T V</w>
S uc
Pow er</w>
Per formance</w>
I F</w>
H EX
ES S</w>
D om
Bas ic</w>
A id</w>
201 1,</w>
wis e.</w>
wh o
vir /
vi br
up dat
un iver
th in</w>
spon sor</w>
sol ve</w>
sh ot.</w>
sh ell</w>
sa quin
s y.</w>
re plac
pow der,</w>
on- board</w>
occas ion</w>
introduc tory</w>
eith er.</w>
d ual</w>
contracep tives</w>
ba thro
ati o</w>
altern atives</w>
alph a</w>
ag ent,</w>
advis able</w>
W ell</w>
Se par
P erc
Govern ment</w>
Docu ment</w>
Cy pr
Community 's</w>
Cal culation</w>
' t,</w>
trad ed</w>
tic asone</w>
ti sed</w>
ster one</w>
po is
pl enty</w>
n aire</w>
man ner,</w>
lad y</w>
jo ints</w>
in o
exha ust
en de
employ ment,</w>
definit ely</w>
conjunc tiv
ch ance.</w>
blu et
authoris ed.</w>
alcohol ,</w>
Res id
Pl an</w>
F ree</w>
F light</w>
D y
D G
Cre dit</w>
C AR
B us
Atri pl
200 3.</w>
u ximab</w>
st age,</w>
sax agliptin</w>
re ared</w>
r alt
princi ple,</w>
pleas e,</w>
ness es</w>
n y,</w>
mir ror</w>
mg/ d
man nit
k ets</w>
in di
id e)</w>
fil tr
dis charges</w>
de al.</w>
con genital</w>
compon ents.</w>
chang e,</w>
c en
ar thro
aerob ic</w>
T ION</w>
T ER</w>
R ules</w>
Preven ar</w>
P K</w>
H E
A :</w>
2377/ 90</w>
00 0
y ing.</w>
vess el
ul a</w>
stear ate</w>
rig id</w>
res sion</w>
real ize</w>
rat s.</w>
r ice</w>
psori asis</w>
opoi etic</w>
oph en
k g)</w>
is ation,</w>
hyper glycaem
ha b
enterpris es,</w>
e );</w>
distribu tion,</w>
dissol ve</w>
disci ples</w>
con su
command er</w>
boo ster</w>
as ing</w>
am er</w>
T ex
Rud olf</w>
Pl us</w>
I AL</w>
F our</w>
Bulg aria</w>
2. 3.
( m
wh is
ul timate</w>
tex tiles</w>
stimul ating</w>
st aying</w>
sleep .</w>
sc rap</w>
recogn ises</w>
re tri
prin c
preven ted</w>
pre val
os k
n ap
man u</w>
ma il
le y,</w>
le ather</w>
lat er
instru ment,</w>
fulfil ment</w>
flu ids</w>
facil ities,</w>
examin ing</w>
emtric itab
duc t</w>
down !</w>
cere al</w>
cam era</w>
breath ,</w>
bol us</w>
ation s)</w>
at rial</w>
as vir</w>
anc est
T rac
Peg as
L a</w>
Chap ters</w>
9 4</w>
wo od,</w>
there in.</w>
secon d.</w>
proced ural</w>
pa int
mofe til</w>
mand ate</w>
loc ally</w>
inhibit ors.</w>
incorpor ation</w>
forc e,</w>
erc ept</w>
er ated</w>
educ ation,</w>
cul tures</w>
concentr ation.</w>
clust ers</w>
characteris tic
biof u
big u
ban ks</w>
atmosph ere</w>
affor d</w>
a !</w>
UN /EC
S ide</w>
Inser t</w>
H u
D ou
D ad,</w>
Con nec
201 4.</w>
2 1,</w>
15 0
x yl
ward s.</w>
un common</w>
type- approved</w>
trans national</w>
ti es;</w>
thrombo tic</w>
t ear
surg ery,</w>
stimul ate</w>
se ud
sche me.</w>
moun ting</w>
memb ers,</w>
man i
lubr ic
ivol umab</w>
id s,</w>
erythem a</w>
don or</w>
cr ust
arrang ements,</w>
ab and
TR AN
Swed en</w>
S end</w>
Lev ites</w>
Fact or</w>
21 A.
(N =
(F igure</w>
your self,</w>
though ts</w>
surg ery.</w>
st y
se en.</w>
ro ad.</w>
righ th
recipi ents</w>
qu ick</w>
practic able,</w>
neutroph il</w>
n ed.</w>
mill ilit
leav e.</w>
k ul
immunosuppres sive</w>
immunoglobul in</w>
fut ure.</w>
fix ed-
fact ory</w>
f od
exc it
diver sity</w>
develop s</w>
d am</w>
contex t,</w>
bub bles</w>
bl ast</w>
benefici ary</w>
bene ficial</w>
approv ing</w>
anti hypertensive</w>
addres s,</w>
Plas ma</w>
Par t
M an</w>
GNS S</w>
F L
D R
8 ;</w>
vess els,</w>
un necessary</w>
trav elling</w>
system s;</w>
provision ally</w>
par as
p e</w>
organis m</w>
ma ize</w>
lin es,</w>
intr a
in compatible</w>
hy promell
fe wer</w>
fast ing</w>
f lip
distribut ors</w>
deteri or
collabor ation</w>
cl ast
chlor inated</w>
chemo therapy.</w>
aircraf t.</w>
O ver</w>
K ey</w>
H R
F ind</w>
Direc t</w>
.e. ,</w>
tre x
tabl e:</w>
struc k</w>
so ...</w>
shar p</w>
rul ed</w>
room ,</w>
py ri
particl e</w>
multi t
man -
k g,</w>
iv ir</w>
him self,</w>
fast er</w>
ent ly.</w>
depres sion,</w>
correspon d
cor rup
clot ting</w>
chol in
aster n</w>
assembl ed</w>
all el
addres sing</w>
They 've</w>
Pro vision</w>
Pers ons</w>
Lev etiracetam</w>
II -
I R</w>
AS T</w>
90/ 4
3 (2)</w>
( See</w>
train ing.</w>
succ essive</w>
stat e,</w>
rati os</w>
por tions</w>
pain t</w>
op en.</w>
neutr al</w>
merc y</w>
man !</w>
limit ed.</w>
inter n
ini qu
gr ace</w>
fl ag
fe et.</w>
expor ted</w>
enem ies</w>
complain ts</w>
compl ement</w>
bot tom
b ind</w>
b are</w>
aripip razole</w>
adjust ing</w>
S R
Russi an</w>
PREZ ISTA</w>
PF S</w>
Can a
AL T
200 4.</w>
1 3.
- containing</w>
zidov udine</w>
z e
vis ited</w>
ter restrial</w>
sustain ability</w>
sp p.</w>
s ing.</w>
s .;</w>
run s</w>
new spap
mut atis</w>
mut and
l ing.</w>
kin ase</w>
her pes</w>
fru its</w>
fl ock</w>
el ap
declar ations</w>
d or
ain ,</w>
Yor k</w>
W ay</w>
Th er
Mem antine</w>
Lord ’s</w>
I ?</w>
G ud
EE E</w>
2004/ 39
1 (a)</w>
um /
ul t
tion s:</w>
ta z
remed y</w>
r ð
pattern s</w>
p ali
ol i
methyl -
lip s,</w>
install ation,</w>
fund ed</w>
f ought</w>
expres sly</w>
etc. ).</w>
employ ers</w>
coupl ed</w>
compu ter
c y,</w>
c iv
bra kes</w>
bl adder</w>
as pir
appetit e,</w>
an aemia,</w>
al y
Some body</w>
P lat
Med ical</w>
Lit tle</w>
Heal th
( an</w>
year s;</w>
ter al</w>
suspen sion.</w>
ship 's</w>
rejec ted</w>
re pl
pharmac ovigilance</w>
penal ty</w>
os in
om ,</w>
munic ip
magnit ude</w>
lam p
internation ally</w>
in side.</w>
g ods</w>
fluo resc
fe els</w>
examin ation,</w>
electr ic
document ary</w>
disp utes</w>
defici enc
dabr afenib</w>
